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Abstract

Designing Allosteric Inhibitors of Thrombin

By Preetpal Singh Sidhu

A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy
at Virginia Commonwealth University

Virginia Commonwealth University, 2011

Director: Dr. Umesh R. Desai
Professor, Department of Medicinal Chemistry

Thrombin is a key enzyme of the coagulation cascade exhibiting important roles in both procoagulation and anti-coagulation processes. Most clinically used anticoagulant drugs, including polymeric
heparin, warfarin, hirudin, argatroban and the recently approved dabigatran, aim to reduce thrombin
activity. There are several binding domains on thrombin including the active site, anion-binding exosites I
and II, and the sodium binding site. We hypothesized that thrombin may be better regulated through an
allosteric process mediated by small molecules binding to either exosite I or II. An appropriately designed
allosteric regulator that reduces the procoagulant signal in a finely tuned manner may maintain a delicate
balance between procoagulant and anticoagulant signals in blood resulting reduced bleeding
complications.

xvii

In this work, we synthesized and studied a library of potent, small, aromatic molecules as allosteric
inhibitors of thrombin. Of the 28 potential inhibitors, 11 molecules inhibited thrombin with reasonable
potency. Structure activity relationship studies showed that sulfation at the 5-position of the benzofuran
scaffold was essential for targeting thrombin. Michaelis-Menten kinetic studies indicated a noncompetitive, allosteric mechanism of inhibition. Site-directed mutagenesis, competitive binding and
molecular modeling studies led to the identification of the most plausible binding pose for a potent
sulfated dimer. To further improve the potency, a small library of sulfated benzofuran trimers was
synthesized and studied for thrombin inhibition. Further, to find new scaffold to inhibit thrombin
allosterically, docking-based virtual screening approach was used. All these molecules were found to be
moderately potent thrombin inhibitors and can serve as lead to develop allosteric inhibitor.
Overall, this work presents the first small, synthetic, sulfated aromatic molecules as potent
allosteric modulators of thrombin. Finally, this work also highlights the opportunity of exploring
allosteric modulators of other coagulation enzymes, e.g., factors Xa, IXa and XIa, based on the sulfated
benzofuran scaffold.

Chapter 1 Introduction

1.1 Background
Cardiovascular diseases have been responsible for the highest number of deaths
worldwide counting up to 17.1 million people. It is estimated that the mortality may reach 23.6
million by the end of 2030.1-3 Venous thrombocytopenia (including deep vein thrombosis and
pulmonary embolism) is a serious and fatal condition. It causes significant mortality and
morbidity in modern society that imposes a major burden on healthcare.1, 4 Approximately one in
every 1000 individuals are diagnosed with this condition annually. These numbers may actually
be much higher due to unreported cases because of the asymptomatic nature of the ailment.5
Other examples of clotting disorders include acute myocardial infarction, unstable angina,
disseminated intravascular coagulation, cerebrovascular thrombosis and atrial fibrillation.
Complications resulting from mechanical heart values and surgery are also related. The risk of
developing thrombotic disorder is higher in cancer patients.6 Besides the enormous interest and
research in advancing treatment of thrombotic disorders, safety still remains a major concern.
The primary reason for excessive bleeding associated with thrombotic therapy lies in the
complexity of hemostatic system and the high sequence homology in proteases involved in the
coagulation target.1,
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The primary targets for thrombotic treatment are thrombin and factor
1

Xa.8 Modern therapy has significantly reduced the side effects of traditional therapy, but is still
associated with side effects like compromised immune responses, liver toxicity and requires
regular blood monitoring. Consequently, there is significant medicinal potential for the design
and synthesis of novel anticoagulant agents that are potent and selective with minimal side
effects.2, 4
1.2 Blood Coagulation Cascade
Hemostasis is a spontaneous process that arrests the blood flow to prevent the blood loss
in the event of damage to the vascular wall.9 Blood coagulation can be defined as the body’s
defense mechanism against blood loss and microbial infiltration upon injury.10 It is a complex
interplay involving various plasma proteins, the cell membrane, tissue factors, platelets and
inorganic ions such as calcium and sodium.11 The hemostatic system is comprised of three
mechanisms: the platelet-dependent mechanism, coagulation and fibrinolysis, which are also
termed as primary, secondary and tertiary hemostasis, respectively. The mechanism of
coagulation is highly conserved throughout the animal kingdom.12, 13
Coagulation begins instantly after an injury to the vascular wall that exposes the
transmembrane tissue factor. This is a vascular trigger required to initiate coagulation of blood
flow. Exposure of the blood to this tissue factor and endothelial cells initiates the changes in the
platelet and other proteases required for the generation of a clot. Platelets are thus immediately
activated upon exposure to tissue factor and begin to form a plug at the site of the vascular
injury.14 Simultaneously, the secondary hemostasis mechanism is activated leading to a cascade
of events for the formation of fibrin, the primary component of a blood clot.15

2

1.2.1 Primary Hemostasis Mechanism
The primary hemostasis mechanism (platelet activation) leads to the exposure of
collagens on the surface of endothelial cells.16 Platelets adhere to the exposed collagen through
the von Willebrand Factor (vWF), which acts as a bridge between a glycoprotein complex on the
surface of platelets and collagen fibrils.17 The vWF also binds to factor VIII and is required for
its survival while circulating in the blood. Upon binding to collagen, platelets release the
contents of their granules, which in turn attract more platelets for aggregation.18 The activation of
platelets is also mediated by thrombin binding to specific receptors on the surface of the
platelets. Thrombin is important for initiating the signal transduction cascade. Activation of
platelets finally leads to formation of a platelet plug.19

1.2.2 Secondary Hemostasis Mechanism
The secondary hemostasis mechanism is divided into two pathways: intrinsic and
extrinsic (Figure 1).20 The intrinsic pathway (also known as the contact activation pathway) is
thought to be less significant for blood coagulation than the extrinsic pathway under normal
physiological conditions.15 However, in disease states, such as hyperlipidemic conditions or
bacterial infection, the intrinsic clotting cascade initiates the clot formation. In the state of
vascular injury, the extrinsic pathway is mainly responsible for the clot formation. Both
pathways merge at the point of conversion of inactive factor X to its active form factor Xa into a
common pathway leading to generation of thrombin.10
The intrinsic pathway is comprised of the clotting factors (VIII, IX, X, XI, and XII),
proteins including prekallikrein (PK) and high-molecular-weight kininogen (HK), along with
3

calcium ions and phospholipids.21 The intrinsic pathway begins when PK, HK, factor XI and
factor XII are exposed to a negatively charged surface such as that of phospholipids, lipoproteins
or a bacterial outer membrane. This is known as the “contact phase”.22 The accumulation of
contact phase components results in conversion of PK to kallikrein, which in turn leads to
activation of factor XII to factor XIIa. Upon activation, factor XIIa activates another inactive
zymogen factor XI to form factor XIa. Factor XIIa further converts PK to kallikrein through a
positive feedback mechanism. In the presence of Ca2+, factor XIa activates factor IX to form
factor IXa. Active factor IXa cleaves factor X at an internal Arg-Ile bond, leading to its
activation and forming factor Xa. The assembly of factors VIIIa, IXa and X (inactive form of
factor Xa) and Ca2+ create the intrinsic tenase complex on the surface of activated platelets. This
tenase complex is required for activation of factor Xa.13, 15, 23 Factor VIIIa acts as receptor for
factors IXa and X.21 Thrombin regulates the formation of the tenase complex by playing a dual
role via regulating the activation (at low concentration) and inhibition (at high concentration) of
factor VIIIa.24 The extrinsic pathway (also known as the tissue factor pathway) is initiated at the
site of injury in response to exposure of tissue factor to the blood. Tissue factor is a cofactor in
the factor VIIa-catalyzed activation of factor X. The exposed tissue factor binds to activated
factors VIIa and X to form the extrinsic tenase.14 The activation of factor VII is regulated by
action of thrombin and factor Xa. The activation of factor VII by factor Xa generates the
connection between the intrinsic and extrinsic pathways (Figure 1).25, 12, 17
The common point in both pathways is the activation of factor X to factor Xa. In the
common pathway, factor Xa activates prothrombin (factor II) to thrombin (factor IIa). This
occurs on the surface of activated platelets and requires formation of a prothrombinase
complex. It is comprised of platelets, phospholipids, Ca2+, factors Va and Xa, and prothrombin.26
4

Factor V plays the role of cofactor in the formation of the prothrombinase complex, similar to
the role of factor VIII in intrinsic tenase complex. Similar to the intrinsic pathway, activation of
factor Va is regulated by thrombin in a concentration-dependent manner.27 Thus, thrombin
regulates its own production by regulating the activation of factor VIIIa and Va. Once thrombin
is activated, it converts the inactive fibrinogen into an active form by release of two
polypeptides. This thrombin-mediated release of the fibrinopeptides then generates fibrin
monomers, which spontaneously aggregate in a regular array to form a weak fibrin clot. The
weak clot is strengthened by the formation of cross-linked covalent bonds between the fibrin
monomers by factor XIIIa,28 which is activated by the action of thrombin.29
1.2.3 Tertiary Hemostasis Mechanism
The tertiary hemostasis mechanism, also known as fibrinolysis, is the degradation of a
blood clot.28 Plasmin is a serine protease that circulates in the blood in its inactive form,
plasminogen. Plasmin degrades the cross-linked fibrin resulting in dissolution of the clot. The
inactive plasminogen binds to both fibrinogen and fibrin, thereby being incorporated into a
clot.30 Tissue plasminogen activator (tPA) and urokinase are serine proteases that convert
plasminogen to plasmin. Plasmin digests the fibrin to a soluble degradation product to which
neither plasmin nor plasminogen can bind. Once the plasminogen and plasmin are released from
clot, the free circulating plasmin in the blood is rapidly inactivated by α2-antiplasmin.31

5

Figure 1. Blood coagulation cascade. The intrinsic and extrinsic pathway merges into a common
pathway leading to the formation of a fibrin clot. The red arrows represent the regulation of
coagulation by thrombin at various levels.

1.3 Regulation of Coagulation
Several endogenous proteins regulate the coagulation mechanism to prevent the condition
of hyper-coagulation
coagulation by inhibiting various proteases involve
involved
d in the coagulation process. They
also limit the size of the clot formed at the site of injury.
Tissue factor pathway inhibitor (TPFI)
(TPFI): TPFI modulates the formation of the extrinsic tenase
complex. It mediates the feedback inhibition of the tissue factor
factor-factor
factor VIIa complex, resulting in
decreased activation of both factor
actors IX and X.12 A small amount of factor Xa is required for
6

TFPI to achieve inhibition of factor VIIa-tissue factor complex. Heparin increases activity of
TFPI by 2-4 folds by bringing TFPI and the TF-FVIIa complex closer and hence increasing their
interaction. Heparin is also known to increase the release of endothelial stores of TFPI.10, 13, 32
Protein C: Protein C is a vitamin-K dependent inhibitor of the procoagulant system involved in
inactivating factors Va and VIIIa. The binding to the thrombin-thrombomodulin complex
activates protein C. By inactivating factors Va and VIIa, protein C significantly decreases the
thrombin generation, thereby dampening the cascade.33, 34
Antithrombin III: Antithrombin III (AT) directly binds and inactivates thrombin and several
serine proteases such as factors IXa, Xa, and XIa.35 The reaction between the serine proteases
and AT is relatively slow, but is catalyzed in the presence of heparin. In the presence of heparin
or similar sulfated glycosaminoglycans, the reaction between AT and serine proteases is virtually
instantaneous, resulting in the immediate arrest of fibrin formation.36

1.4 Anticoagulants Therapy and Targets
Over last five decades, anticoagulant therapy relied mainly on the use of traditional
anticoagulants such as heparin and warfarin. The available drugs can be broadly categorized into
anticoagulant and antithrombotic, depending on their effects to prolong plasma-based assays.
Anticoagulant drugs exert their effect solely by inhibiting the coagulation cascade and hence
prolonging the clotting time as indicated in prothrombin (PT) and activated partial
thromboplastin time (APTT) assays. In contrast, antithrombotic drugs exert anticoagulation by
other mechanisms, apart from any direct effect on the coagulation cascade.37 Recent advances in
the development of direct inhibitors of thrombin and factor Xa have resulted in more specific
7

agents with better pharmacokinetic and pharmacodynamic profiles. Currently, there are three
major classes of anticoagulants available in the United States. These are the vitamin-K
antagonists, indirect and direct thrombin and factor Xa inhibitors.38
Vitamin-K antagonists: Warfarin was the only oral anticoagulant used over the last 50 years until
the discovery of direct inhibitors of thrombin and factor Xa (Figure 2). Warfarin exerts its
anticoagulant effects by inhibiting the hepatic synthesis of vitamin-K dependent coagulation
factors II, VII, IX and X and anticoagulant proteins C and S. Warfarin not only decreases the
synthesis of these coagulation factors, but also reduces their biological activity by inhibiting their
activation.39 Warfarin has no effect on circulating coagulation factors, therefore attainment of
full antithrombotic effects is delayed depending on the half-lives of the coagulation factors.
Warfarin displays an initial transient phase of procoagulation due to the shorter half-life and fast
clearance of its anticoagulant protein C.40 It has a slow onset of action and needs frequent
monitoring of its anticoagulant effects, resulting in increased cost and discomfort to patients.
Beside these side effects, warfarin has a narrow therapeutic window due to undesired drug-drug
and drug-food interactions. This is even more complicated by significant patient-to-patient
variations.41
Heparins: Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are used in
the clinics as primary anticoagulant therapy. Despite their numerous side effects, they are still
considered as first line anticoagulants.38 Heparin is a heterogeneous mixture of polysaccharides
chains of molecular weight ranging from 5,000-30,000 Daltons (Figure 3). LMWHs are
synthesized by chemical or enzymatic cleavage of UFH to reduce the average molecular weight
to 5000 Daltons.42 Heparin exerts its biological effect by forming a ternary complex with
thrombin and antithrombin.
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Figure 2. Structure of warfarin, a vitamin-K antagonist.
Heparin binds to antithrombin through a specific pentasaccharide unit causing a major
conformational change in antithrombin that accelerates its activity to inhibit factor Xa, thrombin
and factor XIa.43 The heparin molecule with the pentasaccharide unit (Figure 3) and an
additional 13 saccharide units are able to inhibit thrombin by the bridging mechanism.38 LMWHs
having shorter chain lengths are not able to inhibit thrombin as well, but are able to induce a
major conformational chain in antithrombin that is required to inhibit factor Xa.44 The
advantages of LMWHs that helped it to replace the clinical usage of UFH is that of longer halflife, allowing the once-daily dosing regimen and its more predictable ADME properties,
eliminating the need of regular laboratory monitoring. It also has a lesser risk of
thrombocytopenia due to reduced binding to platelet factor 4 (PF4).45, 46 The synthetic compound
fondaparinux has advantage over LMWHs because it is homogeneous in nature. It is thus safer
and carries lower risk of thrombocytopenia than LMWHs and UFH.47 Although enormous
progress has being made in heparin-based drugs, this class of anticoagulant still has much room
for improvement. Heparin and LMWHs are not available orally and require parenteral
administration. Heparin also induces thrombocytopenia by binding to PF4. The immune system
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produces antibodies for the heparin-PF4 complex, which leads to reduced platelet count.48
Fondaparinux is an indirect inhibitor of factor Xa. It is unable to inhibit thrombin due to its
shorter chain length. The major drawback of fondaparinux is unavailability of an antidote to
neutralize excessive bleeding.49-51

Figure 3. Structure of heparin with various labeled sugar units.
Direct Thrombin Inhibitor (DTI): Hirudin is a peptide-based natural inhibitor of thrombin
obtained from the medicinal leech, hiruda medicinalis. It is a 65 amino acid long peptide
(molecular weight 7000 Daltons), stabilized in three different structural forms by disulfide
bridges.52 Unlike the heparins, it is a direct inhibitor of thrombin.52 It irreversibly inhibits
thrombin by binding at two of its sites, thus it is classified as a bivalent DTI.53 Hirudin has other
advantages over the heparins by inhibiting both free and clot-bound thrombin.54 Hirudin shows
no interaction with plasma proteins and has predictable dose response.55 Bivalirudin is
dodecapeptide from the carboxy-terminal region of hirudin and bridged with an active site10

specific tetrapeptide (D-Phe-Pro-Arg-Pro) by four glycine residues (Figure 4). Like hirudin, it is
also a divalent DTI, but only produces transient inhibition of thrombin due to its shorter half-life
(Figure 4).56 Currently, it is used as alternative to heparin for angioplasty and unstable angina.57
On the other hand, hirudin and hirudin-based anticoagulants suffer from serious drawbacks
leading to discontinuation of hirudin from clinical use. Hirudin has a strong dependence of the
pharmacokinetics of renal function, resulting in difficulties in dosing for elderly patients.
Increased risk of bleeding and lack of an antidote worsen the safety profile. In addition, its nonhuman source and polypeptide nature can lead to serious immune reactions. However,
immunogenicity is reduced in bivalirudin and argatroban (a direct active site inhibitor of
thrombin).52

Figure 4. The mechanism of action of DTIs lepirudin, bivalirudin and argatroban. This figure is
adapted from Greincher et al.52
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Active site inhibitors of thrombin: The design and development of active site inhibitors of
thrombin is driven by three major factors: 1) the increasing incidence of immune response
against heparin and its analogs, 2) their inhibition of only free thrombin and 3) the non-specific
interaction of heparin with other plasma proteins.58 Argatroban was the first univalent active site
DTI (Figure 4). It is small synthetic molecule derived from L-Arginine and is a competitive and
reversible inhibitor.57 Melagatran and ximelagatran (prodrug of melagatran) are peptide-based
active site DTIs, which significantly eliminated the need of regular laboratory monitoring of
anticoagulation level. The clinical success of these inhibitors led the trail for discovery of various
other active site DTIs, which are currently under clinical investigation.59, 60
Aptamers: Aptamers are single stranded nucleotides that bind to molecular targets and inhibit
their function by physically blocking their interaction with ligands and substrates. The aptamers
specific for exosite II (a positively charged patch on the thrombin surface) were successfully
designed and tested in vitro for competition with exosite II ligands.61 Toggle-25 is a selective
exosite II aptamer that specifically competes with glycosaminogylcan (GAGs) for binding with
thrombin. It helps the thrombin to escape inactivation by antithrombin, thus leading to a higher
concentration of active thrombin in circulation. It is also known to interfere with binding to the
platelets.62 HD22 is another aptamer for thrombin that specifically inhibits the activation of
platelets by thrombin.63 It is also possible to design aptamers that specifically inhibit the
activation of factors VIII and V by thrombin, which could lead to blockage of the positive
feedback loop.64 Exosite II aptamers could also serve as potential antidotes for exosite II based
allosteric inhibitors, such as UFH and LMWHs, to reduce the effect of drug overdose.
Selective indirect factor Xa inhibitors: Fondaparinux is the first known selective anticoagulant
designed to inhibit a single protease. It is synthetically derived with a highly specific
12

pentasaccharide unit of heparin, as required for antithrombin activation. The anticoagulant effect
is achieved by high-affinity binding and activation of antithrombin, which further selectively
inhibits factor Xa. Fondaparinux accelerates by 300-fold inactivation of factor Xa by
antithrombin.65 It has a predictable ADME profile and better safety profile than its parent UFH.
Owing to its synthetic source and homogeneous nature, there has been reduced incidence of
immunogenicity and thrombocytopenia. Idraparinux is a hypermethylated pentasaccharide unit
with a very long half-life for once-weekly dosage. It has a 30-fold higher binding affinity for
antithrombin and similar clinical properties as fondaparinux.66, 67
Direct factor Xa inhibitors: The successful design of argatroban opened new pathways for design
of active site inhibitors of factor Xa. Razaxaban was developed by Bristol-Myers-Squibb as the
first direct active site inhibitor of factor Xa to reach higher-stage clinical studies (Figure 5).
Razaxaban studies were, however, discontinued due to the development of its congener
Apixaban. Apixaban has a more favorable safety profile than Razaxaban and a better ADME
profile. Rivaroxaban is another small molecule inhibitor targeting the active site of factor Xa
developed by Bayer Health Care (Figure 5). It is currently used for prevention and treatment of
thrombosis, marketed under the name of “Xarelto” in the United States. In addition, there are
many more active site inhibitors of factor Xa currently under clinical trials.20, 68
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Figure 5. Structures of direct factor Xa inhibitors. A) razaxaban, B) apixaban and C)
rivaroxaban.
Factors XIa and IXa active site inhibitors: The development of active site inhibitors targeting
factors IXa and XIa is in the early stages. Initial results show promising advantages in terms of
the role this class of inhibitors may play.69
TF/Factor VIIa inhibitors: The TF/Factor VIIa complex plays an integral part in initiating the
extrinsic pathway for blood coagulation. By activating factor XIa, it also initiates the intrinsic
pathway.70 The function of TF/FVIIa can be blocked by many different approaches: 1) designing
antibodies to prevent the complex formation; 2) designing active site inhibitors of factor VIIa; 3)
designing exosite inhibitors that prevent binding of TF with factor VIIa; and 4) synthesizing the
recombinant protein of naturally occurring inhibitors of the TF/Factor VIIa complex.69, 71 The
naturally occurring nematode anticoagulant proteins (NAPs) are known to inhibit formation of
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the TF/Factor VIIa complex.72 The recombinant TFPI also inhibits the activation of factor Xa by
the TF/factor VIIa complex.73

1.5 Limitations of Current Therapy
Both heparin and warfarin have been used successfully in the clinics as primary
anticoagulant therapy for more than 50 years. Being highly effective, they are associated with
numerous side effects and safety issues that make regular blood monitoring obligatory. The
interaction of heparin and warfarin with numerous targets leads to side effects, and hence new
strategies are required to develop anticoagulants with high degrees of specificity for single
targets.74 Recently developed anticoagulants like direct thrombin and factor Xa inhibitors are
relatively safe as compared to heparin and warfarin. The most important advantage of direct
inhibitors is that they can inhibit both free and clot bound thrombin. Thrombin gets entrapped in
the growing clot and is responsible for clot maturation. Inhibition of clot-bound proteases is an
advantage of direct inhibitors over traditional anticoagulants. Clot-bound thrombin is
inaccessible to heparin or other AT-dependent drugs.39 However, the direct inhibitors suffer from
side effects such as liver toxicity and lack of available antidotes. Other available anticoagulants
such as hirudin, thrombin antibodies and natural products are not orally available and thus have
short durations of action. Thus, they require frequent dosing and are associated with higher
cost.75
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1.6 Thrombin: Its Structure and Role
Thrombin is derived from its inactive zymogen prothrombin which is a 70,000 Daltons
glycoprotein synthesized in the liver. The inactive prothrombin is converted to its active
thrombin form by the prothrombinase complex, consisting of factors Xa and Va, anionic
phospholipids and Ca2+.24,

76

Factor Xa cleaves prothrombin at Arg320 to generate the

meizothrombin and subsequently cleaves meizothrombin to generate active thrombin. The
activated thrombin has a very short half-life of few minutes due to its inactivation by
antithrombin present in plasma. Thrombin is activated upon cleavage of the Arg15-Ile16 bond,
generating a new N-terminus end. This new N-terminus end, containing Ile16-Val17 residues,
inserts into the main body and forms a salt bridge with carboxylate group of residue Asp194.
This inward rotation of the side chain causes the outward rotation of the preceding loop causing
the opening of the specificity pocket knows as “S1”.77-79
Thrombin consists of two polypeptide chains: a 36 amino acid light chain and a 259
residue heavy chain linked by a disulfide bridge. The heavy chain consists of all the functional
epitopes of thrombin.80, 81 Thrombin molecules have a typical serine protease fold, containing
two six-stranded β-barrels packed asymmetrically forming the catalytic triad of His57, Asp102
and Ser195. The 60-loop structures form the upper lid of the active site, restricting the access of
solvent to His57 and Ser195. Asp102 anchors His57 in the correct orientation for proton transfer
from Ser195. The orientation of the catalytic triad polarizes the side chain of Ser195 for
nucleophilic attack on the carbonyl carbon in the scissile bond of the substrate molecules.23, 82 In
the transition state, the carbon atom attains tetrahedral geometry, which is stabilized by hydrogen
bonding between the charged oxygen atom of the scissile bond and the amide hydrogen of
Gly193 and Ser195, forming the “oxyanion” hole. The substrate is acylated by the Oγ atom of
16

Ser195 by transferring the proton to His57 and by losing its C-terminal end (Figure 7). The water
molecule catalyses the deacetylation process by releasing the carboxylic acid and the N-terminal
end of the substrate. A particularly striking feature of the thrombin molecule is its uneven
distribution of charge over its surface causing patches of both positive and negative charges.83-86

Figure 6. Thrombin plays a central role in blood coagulation regulating its own production by
positive and negative feedback loops. Broken red arrows represent the inhibition of thrombin
activity, red arrows represent the negative feedback regulation of thrombin to regulate its own
production and green arrows represent the positive feedback regulation of thrombin to increase
its production.
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1.6.1 Active Site
The active site residues are located inside the narrow cleft formed between the two barrels. The
active site is divided into various sub-pockets. To the left of the active site resides the S1
specificity site, a narrow deep pocket containing the acidic Asp189 at the bottom.87 This pocket
is guarded by uncompensated charge of Glu192 residue at the entrance, which plays a significant
role in the specificity of thrombin in selecting substrates andinhibitors.88 The apolar binding
region on the top of the S1 pocket is further divided into two sub-pockets: S2 and S4. These are
hydrophobic pockets and also contribute to the specificity of thrombin. The access of substrate
and inhibitors to these pockets is limited by the “60-loop”. The S1’ pocket lies on the right side
of the catalytic triad. It is limited in size and can only accommodate small polar residues. The
natural substrate of thrombin holds the following criteria: medium to bulky hydrophobic P4
residue, proline at the P2 site, positively charged (especially Arg) at the S1 site, serine at P1’, a
hydrophobic residue at P2’ and a basic residue at P3’.89-91 There are exceptions for this scheme,
but suboptimal substrates utilize additional binding sites on thrombin to compensate for the lost
binding energy.88
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Figure 7. Chemical mechanism of catalysis for serine proteases.

1.6.2 Exosite I
Exosite I is a highly anionic notched surface depression located to the right side of the
active site formed by the 70-80 loops. This region is similar to the calcium binding site of trypsin
where the required Ca2+ is replaced by the insertion of the side chain of Lys70. In the center of
the highly positive electrostatic potential formed by Arg63, Arg73, Arg75 and Arg77 lies the
hydrophobic region formed by the side chains of Tyr76 and Ile82. Structural and functional data
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suggest that exosite I is involved in the binding of thrombin with fibrinogen.92, 93 The α- and βchain fragments of fibrinogen bind at exosite I to provide the additional binding energy required
to overcome the suboptimal substrate residues at the cleavage site.94, 95 Thrombomodulin binds at
exosite I and allosterically induces changes in the active site to reverse the role of thrombin from
a procoagulant to potent anticoagulant.96 The natural inhibitors, such as hirugen, rhodniin,
ornithodorin and triabin, also induce allosteric changes in the catalytic triad.97 The nature of
interactions for these inhibitors with exosite I varies from ionic to hydrophobic in nature.
Thrombin also utilizes exosite I residues to interact with the protease-activated receptor-1
(PAR1).98 PAR1 is a thrombin receptor found on the surface of platelets that mediates the action
of thrombin in activation of platelets. The specific thrombin inhibitors such as heparin cofactor-II
and antithrombin-III utilize the exosite I to interact with thrombin in the blood. It is known that
the binding on exosite I communicates changes to the catalytic site and is thus involved in
allosteric modulation of thrombin.99, 100 The importance of exosite I is demonstrated by the fact
that the β- and γ- forms of thrombin, which lack the region of exosite I fail to cleave fibrinogen
but retain the catalytic activity at the active site.99, 101

1.6.3 Exosite II
The extreme cluster of positive charge located to the left of the active site is called the
anionic exosite II (also known as the heparin-binding site). This is formed primarily by Arg89,
Arg98, Arg245, Lys248 and Lys252. Basic arginine residues surround the small hydrophobic
Leu234 residue.92,

102, 103

Exosite II is known for its interaction with polyanionic ligands like

heparin and other GAGs that are required for forming the ternary complex for inhibition of

20

thrombin by antithrombin. The binding at exosite II allosterically modulates the catalytic site of
thrombin by disturbing the position of the Asp102 residue. In addition to its role in GAGs
binding, exosite II is also involved in activation of factors V and VIII. The thrombin inhibitor
haemadin derived from leech utilizes exosite II for binding with thrombin.94, 95

1.6.4 Role of the Light Chain
The boomerang-like thrombin light-chain is formed in a multiple turn conformation. The
light- and heavy-chains are linked mainly by salt bridges (Figure 8). However, the light-chain is
devoid of any known epitope for substrate recognition.104 Due to lack of any catalytic or
regulatory function, the light-chain of thrombin has received very little attention and almost can
be considered as an “appendage” of thrombin. Various studies have concluded that the bovine
thrombin with an omitted light-chain retains most of its catalytic functions. On the contrary,
phenotypes with mutations in residues of the light-chain are associated with moderate to severe
bleeding. The best explanation for this discrepancy may be the involvement of the light-chain in
the activation of prothrombin. The importance of the side light-chain is shown by the single
mutation of Lys9, which not only affects the activation of thrombin, but also impairs the catalytic
activity of thrombin for the chromogenic substrate, fibrinogen, PAR1 and protein C.105 It is rich
in acidic residues engaged in intra- and intercellular interactions. The major function of the lightchain is in its stabilization of the heavy-chain through various ionic interactions that neutralize
the basic residues on the heavy-chain.106, 107
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Figure 8. Graphical model of thrombin created by Sybyl8.1 showing the interaction of chain-A
(shown in space filled model) with chain-B (shown as molcad surface).
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Figure 9. Graphical model of human thrombin generated by Sybyl8.1 shows the location of
active site,
e, sodium binding site, exosite I and II. The model is generated from crystal structure
co-ordinates
ordinates obtained PDB (ID: 3EQ0).

1.6.5 Sodium Binding Site
odium binding site is located in the center of the 220
220-loop, 15-20
20 Å away from the
The sodium
catalytic triad and 5 Å away from Asp189 in the S1 pocket.108 This site is highly solvent exposed
and communicates with the catalytic triad through a network of eleven water molecules. It is
located in a cylindrical cavity formed by three antiparallel β-strands.
strands. Tyr225 is the most crucial
residue controlling sodium binding in thrombin and is conserved in other serine proteases. The
three ion pairs formed by Arg221a
Arg221a-Glu146, Lys224-Glu217
Glu217 and Asp221 and Asp222 bidentate
ion pair with Arg187 render stability to this site
site.. The bound sodium ion is octahedrally
coordinated by two backbone O atoms from Arg221a and Lys224 and four buried
burie water
molecules anchored by the side chains of Asp189 and Asp221 and the backbones of Gly223 and
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Tyr184a. Asp189 anchors the orientation of one of the four water molecules ligating sodium ion
and thus provides an important link between the sodium site and the P1 residue of the substrate
(Figure 10).109, 110

Figure 10. Model of the molecular environment of the Na+ binding site of thrombin showing the
residues of the allosteric core (purple). The bound Na+ is shown in blue with its coordinating
water molecules (purple balls). H-bonds are depicted as broken lines. The residues affecting the
Na+ affinity >3-fold (green) or <3-fold (cyan).111

Thrombin displays a striking feature in its ability to get activated by interaction with
sodium in a specific and allosteric manner.112 Sodium binding converts thrombin from the low
24

activity slow state to the high activity fast state.24 This also has a significant effect on thrombin’s
interaction with procoagulant (fibrinogen), prothrombotic (PAR) and anticoagulant (protein C)
substrates.85,

113

The Kd of sodium binding is 110 mM at 37 °C and the physiological

concentration of sodium is 140 mM.109 The procoagulant and anticoagulant activities of
thrombin correspond to the slow and fast forms, respectively. Hence, any factor that disturbs the
sodium binding increases the anticoagulant effect of thrombin leading to prolonged clotting time
and reduced platelet activation.76
The structures of E (slow form) and E:Na (fast form) are very similar with limited
structural changes being required to explain the complexity of the full range of allosteric
transitions. The few major structural differences between from slow and fast forms are the
favorable orientation of Asp189 in the specificity pocket, which explains the improvement in kM
and the position of Ser195, which explains the improvement in catalytic efficiency (Kcat). The
most significant structural change is the long-range communication between the sodium binding
site and the active site. In the fast form, the network of H-bonds in eleven water molecules
allosterically communicate information from the sodium binding site, whereas in the slow form
only seven water molecules form this network, thus significantly altering the connectivity.114
The perturbation of the primary specificity pocket is evident in the slow to fast transition
of thrombin. In the fast form, orientation of Asp189 is optimal for interaction with the basic P1
residue of the substrate. In the slow form, the carboxylate group of Asp189 rotates 30° from its
optimal position and this disturbs the interaction with the basic P1 residue of the substrate. The
conformation of Glu192 changes in this transition from fast to slow form. In the slow form, the
side chain of Glu192 moves away from active site region and thus minimizes the clash between
the acidic residues of P3 and P3’ of protein C. The orientation of Glu192 compensates the
25

deleterious changes in Asp189 and Ser195. This results in a conformation that retains the activity
toward protein C, and explains the anticoagulant nature of the slow form of thrombin. The
rotation of the hydrophilic side chain of catalytic Ser195 by 35° breaks the critical H-bond with
the catalytic His57, which is crucial for catalysis (Figure 11).24, 76

Figure 11. Model of the structural changes induced by the slow → fast transition of thrombin
depicted by the structures of F (free fast form, gold) and S (free slow form, red).111
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The physiological importance of sodium binding is demonstrated by bleeding phenotypes
such as prothrombin Frankfurt,115 Salakta116 and Greenville.117 Mutations in these phenotypes
significantly compromise sodium binding to thrombin. Conditions such as hypernatremia (high
sodium conc.) and hyponatremia (low sodium conc.) are associated with thrombosis and
bleeding, respectively.

1.6.7 Platelet Activation and Role of Thrombin
Human platelets circulate in the blood in dormant state and their premature activation is
prevented by the presence of the endothelial monolayer, prostaglandin and nitric oxide, which
limits the local accumulation of platelet agonists.118 Platelets start activating once these barriers
are overcome in response to local trauma or rupture of the atherosclerotic plaque.83 Thrombin
plays an essential role in activating platelets to form the platelet plug, similar to the formation of
the fibrin clot. When thrombin is added to human platelets in vitro, it causes the platelets to
change shape, stick to each other, and secrete their content of stored granules.119, 120
Thrombin displays many structurally distinct features that help it to interact specifically
with different ligands, proteins, receptors and substrates to modulate the various procoagulant
and anticoagulant functions responsible for maintaining the fine regulation of hemostasis.121 The
procoagulant role of thrombin is mediated by cleavage of seven transmembrane thrombin
receptors that, in turn, activate the platelets. Humans have two prototypes of protease-activated
receptors (PAR): PAR1and PAR4, of which PAR1 is thought to be more important.120
PAR1 is characterized as a seven transmembrane domain G-protein-coupled receptor
activated by specific cleavage of its N-terminal domain by thrombin. Thrombin cleaves at
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Arg41-Ser42 exposing a new N-terminus that acts as a tethered ligand by binding to the
intramolecular body of the receptor and leading to activation of platelets.98 PAR1 has “tow”
domains that interact with thrombin. Mutant studies showed that the receptors cleavage
recognition site and hirudin-like acidic domain are critical for interaction of the receptor with
thrombin. The hirudin-like acidic domain interacts with the anionic exosite I and is responsible
for overcoming the unfavorable interaction at the cleavage recognition site.122 The hirudin-like
domain of PAR1 has a similar proportion of acidic and hydrophobic residues to other exosite I
ligands of thrombin such as fibrinogen, hirudin and thrombomodulin. Mutant studies showed that
these residues are important for receptor activation and, thus, electrostatic and hydrophobic
interactions play an important role in PAR1 activation by thrombin.123, 124 Synthetic ligands that
mimic the newly exposed tethered ligand of PAR1 and PAR4 act as agonists for the receptor and
hence can be used as pharmacological tools to study the role of these receptors in various
cells.125, 126

1.7 Therapeutic Uses of Thrombin
Since 1930, there has been extensive work on the use of thrombin as a topical agent for
the treatment of surface bleeding.127 While there is sparsely published literature on the use of
thrombin as topical hemostatic agent, it is used extensively in surgery. Thrombin is frequently
used as adjuvant therapy to stop the residual bleeding in cardiothoracic and cardiovascular
surgery. Thrombin was also used for treatment of burns but now it has been replaced by
epinephrine.128
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The extensive use of thrombin is supported by the minimal risk to system damage due to
higher thrombin levels. The reason for such a low risk may be due to the low level of thrombin
and its application to confined space. It is also known that thrombin is well contained within
fibrin clots and that leaked thrombin is rapidly inactivated by antithrombin and other serpins in
systemic circulation. This is further supported by the fact that most of the global parameters such
as pro-thrombin time, thrombin time and partial thromboplastin time remain unchanged after
topical use of thrombin.34 Bovine thrombin had been extensively used as topical hemostatic
agent for a number of years without any reported incidences of adverse effects.129 In the last few
years, some serious immunological adverse effects were reported, such as the development of
antibodies to bovine thrombin or factor V.129 Bovine thrombin is available as topical preparation
is the most common source of thrombin for therapeutic use. Human thrombin is obtained by use
of recombinant DNA technology for therapeutic use. It is available as a lyophilized powder,
spray kit and as a syringe spray kit.
Production of native human thrombin is done in a multi-step process involving the
separation of crude prothrombin from plasma using the alcohol fractionation process of Cohn.129
Prothrombin is absorbed on an insoluble barium salt and subsequently eluted with sodium citrate.
In an alternative method, prothrombin is absorbed on the anion-exchanger DEAE-agarose and
subsequently eluted. The crude prothrombin is obtained as a mixture of factors VII, IX and X.
Prothrombin is activated by adding crude tissue factor, which initiates the activation cascade
leading to generation of thrombin. Activated thrombin is purified using a cation-exchange
chromatography method.129
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1.8 Other Components of Coagulation System
1.8.1 Factors VII/VIIa
Factor VIIa along with the tissue factor (TF) initiates the extrinsic pathway upon injury to
the vascular wall. The TF/Factor VIIa complex activates factor X to initiate the clotting
process.130 In addition, this complex also activates factor IX and initiates the intrinsic pathway.131
The majority of factor VII is present in inactive zymogen, along with traces of the activated
form.132 Factor VIIa consists of two chains: the heavy chain and the light chain covalently linked
by disulfide bridges. The light chain of factor VIIa contains the 10 γ-carboxyglutamic acids
residues and two growth factor homology domains, whereas the heavy chain contains the
catalytic region.133 The activation of factor VII is also catalyzed by factors XIIa,134 IXa, Xa135
and thrombin136 suggesting the importance of its production in physiology.
Factor VII is activated upon the cleavage of the peptide bond between Arg15 and Ile16,
thus generating new N-terminal residue Ile16.137 After cleavage, Ile16 buries its side chain in a
hydrophobic region and forms a salt bridge between its α-amino nitrogen atom and Asp194. The
formation of this salt bridge orients the neighboring Ser195 residue of the catalytic triad
optimally for proteolytic cleavage. Along with Ser195, three adjacent loops undergo
conformational changes to construct the substrate-binding region. Beside cleavage by proteases,
activation of factor VII also requires the binding of the TF. The function of TF is partly to
protect the chemical modification of the α-amino nitrogen atom of Ile16.138 Thus, factor VII
exists in equilibrium between its partially and fully active forms. TF binds specifically to the
active form of factor VIIa.138 TF is expressed in the vascular smooth muscle cells, pericytes and
fibroblasts in vessel walls. The binding of factor VII to TF is mediated by calcium ion at the Gla-
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containing region. Factor VIIa has three allosteric sites: the TF binding region, the active site
binding region and the macromolecular binding exosite.139 The binding of TF allosterically
enhances both proteolytic and amidolytic activities of factor VIIa.140

1.8.2 Factors IX/IXa
Factor IX, with a molecular weight of 54,000 Daltons, is a vitamin-K dependent single
chain glycoprotein of 415 amino acid residues. Factor IX consists of a Gla-containing region and
two epidermal growth factor-like regions. The Gla-region consists of 12 γ-carboxy glutamyl
residues and functions as a calcium binding region. It also serves as a site for interaction with
phospholipid monolayers.141 Gla is formed by the post-transitional modification of a glutamic
residue by enzyme γ-glutamyl carboxylase.142 The two epidermal growth factor-like domains
serve as binding sites with various cell receptors.143 Factor IX is activated by factor XIa in the
presence of calcium ion that, upon activation, binds to the surface of endothelial cells.144 This is
the first calcium dependent reaction in the intrinsic pathway. Activation of factor IX does not
require the presence of phospholipids. Factor IX can also be activated by the factor VIIa-TF
complex.131 This reaction bridges the intrinsic and extrinsic pathways. Factor IX is activated
upon cleavage at two sites: Arg145-Ala146 and Arg180-Val181. There is no cofactor required
for activation of factor IX.145 The cleavage at these sites generates two polypeptide chains: the
light and heavy chains, which are linked covalently by a disulfide bridge. The carboxy-terminal
heavy chain contains the catalytic triad formed by Ser365, His221 and Asp269. The structures of
both metal-bound and metal-free factor IX have been solved by NMR spectroscopy. The
structure of the metal-free form is slightly disordered, whereas the calcium ion bound form is
well ordered, containing all the domains.
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The vascular surface provides the site for achieving high local concentration of factor IXa
to activate the factor X. Factor IXa along with calcium and modified factor VIII activate factor
X.146 Patients deficient in factor IX suffer from the bleeding disorder hemophilia B.
Recombinant factor IX is widely used worldwide for treatment of hemophilia A and B.146

1.8.3 Factors XI/XIa
Factor XI is 160,000 Daltons dimeric protein of two identical 607 amino acid chains
containing subunits linked by a disulfide bond.147 It consists of four apple-like domains and a Cterminal trypsin-like catalytic domain.148 It circulates in blood complexed of with high molecular
weight kininogen.149 Blood also contains a monomeric homolog of factor XI, prekallikrein.
Factor XI zymogen is activated in the blood to form factor XIa and the process is mediated by
activators such as thrombin, factor XIIa and XIa (auto activation), by cleaving the Arg369-Ile370
bond.150 Thrombin activates factor XI in the presence of charged surfaces such as dextran sulfate
or heparin.151 The exosite I of thrombin interact with the A1 domain of factor XI, with residues
like Glu66, Lys83, and Gln84. These residues are located in close proximity to the activation
loop that contains the Arg369-Ile370 cleavage site.152
It was postulated earlier that factor XI was involved in fibrin generation, 152 but later it
was observed that the patients with factor XII deficiency do not have an excessive bleeding
tendency. Thus, there are alternative pathways that can activate factor XI. Recently, factor XIa
has been considered as a part of the positive feedback loop to sustain the process of thrombin
generation.152 Activated factor XIa is regulated in blood by plasma serpins such as antithrombin,
the C1-inhibitor, protease nexin 1, and protein Z-dependent protease inhibitors.148 Heparin
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enhances the serpin-mediated inactivation by binding on the A3 domain and the catalytic domain
through a template mechanism.153
The four apple-like domains (A1-A4) of factor XIa are similar to those of other vitaminK dependent proteases. Each apple domain is comprised of 7 β-strands that fold into curved
antiparallel sheets that frame into an α-helix.154 Two disulfide bonds lock the helix onto the
central β4 and β5 strands, and the third one connects the N- and C-terminals. The two loops, β4β5 and β5-β6 generate a small pocket on the other side of the α-helix.155 The dimeric units are
attached to each other through the A4 domain, with an interface area of 886 Å.154 The β-sheets of
the two units pack against each other, and Cys321 forms an interchain disulfide bond.156

1.8.4 Factors XII/XIIa
Factor XII is a glycoprotein with a single polypeptide chain composed of 596 amino acid
residues, with a molecular weight ranging from 76,000 to 80,000 Daltons.157 It is also called the
“Hageman” factor. Inactive zymogen factor XII is activated in the presence of negatively
charged surfaces by kallikrein, factor XIa and plasmin. Factor XII auto-activates in presence of
negatively charged surfaces such as glass, kaolin, ellagic acid, sulfatide micelle, polyethylene,
silicon rubber, cartilage, skin, fatty acids, endotoxins, heparins, phospholipids and many more.158
The fact that factor XII can be auto-activated in the presence of negatively charged surfaces
makes it medically important for clinical plasma assays (activated partial thromboplastin time) to
well predict the bleeding risk.159 Activation, either by auto-activation or plasma kallikrein,
results in formation of a heavy chain (MW 52,000) and a light chain (MW 28,000) that are
covalently linked by a disulfide bridge. The light chain contains the catalytic triad formed by
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Ser544, His393 and Asp442, which are responsible for the proteolytic function of the enzyme.
After the initial cleavage, a second slower cleavage occurs at the heavy chain thus retaining the
activity of the enzyme and resulting in two forms of activated factor XII enzymes in the blood
circulation.160
Once activated, factor XIIa activates factor XI, which is associated with the high
molecular weight kininogen and prekallikrein. Beside this, factor XIIa is also involved in the
activation of C1 of the complement system, activation of factor VII and down regulation of
monocyte receptors of IgG.161 The activity of factor XIIa is inhibited in the blood by a plasma
protease inhibitor and the C1 inhibitor. The presence of activating surfaces such as kaolin,
dextran sulfate and sulfatides can protect the deactivation of factor XIIa.162 It has been shown
that the presence of factor XII influences the size of thrombus growth and thus makes it an
important pharmacological target.163 Besides its involvement in blood coagulation, factor XII is
also known to play a role as a growth factor. It is important for tissue repair after thrombosis or
inflammation.164

1.8.5 Thrombomodulin and Protein-C
Thrombomodulin (TM) is a glycosylated type-I transmembrane protein of 75 Daltons
with no intrinsic enzymatic activity.165 TM is present in endothelial cells and in capillary rich
endothelial cell surfaces.166 The presence of multiple disulfide bonds ensures TM stability under
extreme pH conditions. The mature TM contains six epidermal growth factor (EGF) likedomains.167 Domains 4, 5 and 6 are involved in thrombin binding and protein C activation
(Figure 12).168 In addition, these domains are also responsible for signaling posttranslational
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modifications. Thrombin forms a 1:1 complex with TM with a Kd of 0.5 nM.
nM This complex
activates protein C with a KM of 0.5 µM on the endothelial cell surface.165 Almost all of the
thrombin is removed from circulati
circulation,
on, as it passes through the vascular bed, by a high
concentration of TM, leading to inactivation of thrombin by converting its procoagulant role to
anticoagulant. Thrombomodulin is regulated by internalization of the molecule with a
concomitant loss of capability for activating protein C.169, 170

Figure 12. Structure of thrombomodulin showing the domains involved in thrombin binding and
protein C activation.
Protein C is a vitamin K
K-dependent serine protease that upon activation down-regulates
down
the clotting cascade. Protein C is activated by the thrombin-thrombomodulin
thrombomodulin complex
compl by
cleaving a 12 residue peptide in the activation loop.171,

172

In vivo,, activation of protein C by

thrombin occurs on endothelial cell surfaces in the presence of the cofactor thrombomodulin and
a calcium ion.173 Thrombomodulin accelerates the activity of thrombin toward protein C by
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1000-fold in the presence of calcium ion.78 The presence of endothelial protein C receptor
(EPCR) further enhances the reaction by another 10-fold.174 Protein C can also be activated by
factor Xa and plasmin.175 Activated protein C (APC) circulates in the blood as a light and heavy
chain molecule covalently linked by a single disulfide bond.176 The N-terminal light chain of
APC contains the non-catalytic Gla domain and two epidermal growth factor domains. The Gla
domain mediates calcium dependent interaction with protein S on its negatively charged
surface.177 Protein S is a vitamin K-dependent plasma cofactor of protein C that amplifies the
anticoagulant function of protein C. The C-terminal heavy chain contains the catalytic site. APC
is inactivated in the blood circulation by α1-antitrypsin, α2-antiplasmin and α2-macroglodulin.178
The APC anticoagulant pathway is also regulated by protein S activity and inhibition of the
thrombin-TM complex by antithrombin.172,177
Upon binding to TM, thrombin switches its function from procoagulant to anticoagulant
by increasing its specificity to cleave protein C to form APC (Figure 13). The binding of TM
induces allosteric changes in the active site of thrombin to alleviate the activating function
towards the procoagulant proteases, fibrinogen, PAR-1, and cofactors V and VIII.173 Besides
activating protein C, TM-thrombin complex also activates the thrombin activatable fibrinolysis
inhibitor (TAFI).179 Hirudin competes with TM for binding with thrombin and thus inhibits the
activation of protein C. Thrombin bound to TM is inhibited more rapidly by antithrombin and
protein C inhibitor, with a half-life of approximately 2 seconds.180
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Figure 13. Graphical model of interaction of thrombin
thrombin-thrombomodulin
thrombomodulin complex and activation
of protein C.
Upon activation, APC dissociate
dissociates from the thrombin-TM-EPCR
EPCR complex and binds to
protein S.181 Protein S has strong affinity for the surfaces of the negatively
negative charged
phospholipids. The APC, in complex with protein S
S, interacts with phospholipids or with the
platelet-bound
bound activated factors Va and VIIIa.182 APC mediates the anticoagulant function by
proteolytically degrading
ing the procoagulant cofactors factors Va and VIIIa, which are essential for
activation of thrombin by factor Xa in both the extrinsic and intrinsic pathways.172,

183

The

inactivation
ivation of these cofactors down
down-regulates the production of thrombin. The
he inactivation
inactivati of
factor Va by APC requires cleavages at Arg306 and Arg506 in sequential kinetic order, with
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initial rapid cleavage at Arg506 followed by slower cleavage at Arg306. The inactivation of
factor Va is accelerated by the presence of protein S.184 In the case of factor VIIIa, APC cleaves
the cofactor at Arg336 and Arg562. Cleavage at either of these sites leads to complete
inactivation of factors VIIIa, Va and VIIIa, in complex with factors Xa and IXa, are resistant to
inactivation by APC, but the presence of protein S inactivates the bound form of factor Va and
VIIIa.185,186 APC can also inactivate the native forms of factors V and VIII and prevent their
participation in the coagulation reaction. APC has a long half-life of 10 minutes in the blood
circulation, favoring the enzyme remaining in circulation for localization and degradation of
cofactors.187
The regulation of the TM level is clinically significant, as high levels lead to bleeding,
whereas low levels lead to thrombosis. The qualitative and quantitative deficiencies of protein C
and protein S and defective APC lead to significant risk of venous thromboembolism and
myocardial infarction.187 APC also exhibits cytoprotective, anti-inflammatory and profibrinolytic
properties.188, 189

1.9 Thrombin Engineering
Thrombin has two important but functionally opposite roles in the blood coagulation
system. The procoagulant role is initiated by conversion of fibrinogen into an insoluble fibrin
clot, followed by activation of platelets to platelet plugs and initiate wound repair.190 This action
is amplified by the activation of factor XIII that stabilizes the fibrin clot, activation of TAFI to
inhibit fibrinolysis and activation of factors V, VIII and XI in a positive feedback loop to
increase its own production. In its anticoagulant role, thrombin activates protein C upon binding
38

with TM. This action is amplified in the presence of endothelial cell receptors.76 Binding with
TM initiates allosteric changes in the active site of thrombin leading to an enhanced specificity
for protein C over fibrinogen and PAR1. Activated protein C inactivates the factors Va and VIIIa
in a negative feedback loop to decrease the thrombin generation (Figure 14). The role of
thrombin is further complicated by the allosteric effect of occupancy of sodium ions at the
sodium binding site. Sodium binding converts thrombin from the slow anticoagulant form to its
fast procoagulant form. Sodium binding is required for cleavage of fibrinogen, activation of
factors V, VIII and XI, and activation of PAR1.191 Sodium binding is the major force driving the
procoagulant role of thrombin. A sodium-free state converts thrombin into a slow form to
produce an anticoagulant role, by activation of protein C and reduction of the platelet activation.
Under physiological conditions, the balance between the procoagulant and anticoagulant roles of
thrombin is optimal. Any effect that destabilizes the sodium-binding site converts thrombin into
a potent anticoagulant. Several naturally occurring mutants of thrombin and physiological
conditions that disturb the sodium binding equilibrium are associated with severe bleeding.
There are some examples where multifunctional roles of thrombin were dissociated into
procoagulant and anticoagulant activities.106
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Figure 14. Schematic model of regulation of thrombin function by binding of sodium ion. “F”
represents the fast form of sodium with procoagulant function and “S” represents the slow form
of thrombin with anticoagulant function. 85
Mutation of the Arg75 residue to Glu in exosite I of thrombin retains fibrinogen clotting
activity but has only 7% protein C activity in the presence of TM. The mutation of Lys60 to Phe
leads to a 2-fold increase in activity for protein C but only retains 17% of the original activity for
fibrinogen. The most
ost pronounced anticoagulant effect is seen in mutation of Glu217 to Ala or
Lys, both of which completely abolishes the procoagulant activity of thrombin. The dissociation
of the thrombin functions in these mutations provides an important pharmacological tool to
regulate the activity of thrombin and for designing novel methods for treatment of various
clotting and bleeding disorders. The residues important for fibrinogen binding to thrombin are
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spread over the region of the exosite I, the 60-loop, the sodium binding site, and the active site.
In the case of protein C, the surface recognition is limited to the primary specificity pocket and
portions of the 60-loop. Thus, it is easy to identify the residues that are significant for fibrinogen
binding and to construct mutants with enhanced anticoagulant activity. A thrombin mutant with
lower proteolytic cleavage activity for fibrinogen but retaining activity for protein C can act as
an anticoagulant by generating APC in blood circulation. In one of the studies by Cera et al.,192
the double mutant W215A/E217A (WE) was found to be a safe and potent anticoagulant in a
baboon model. At the dose of 0.011 mg/kg, it reduced the platelet thrombus accumulation by
80%. Subjects treated with WE showed no signs of hemorrhage or organ failure. There was no
procoagulant activity observed in plasma until the end of one week. At high doses, it exhausted
the cofactors for protein C activation before consuming the substrate reserve and the effect of
overdose is thus down regulated rapidly. Protein C activation by WE appeared to be safe when
compared with other methods of anticoagulation.192 In another study by Cera et al., the double
mutant R221aA/K224A completely abolished the sodium affinity by retaining the discrimination
among monovalent cations. The disturbance of two ions pairs formed by these residues elicited
drastic changes in structure such that fibrinogen specificity is completely lost but the specificity
for protein C is retained, making the thrombin act as an anticoagulant.113
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Chapter 2 Hypothesis

2.1 The Era of Small Molecule Inhibitors of Thrombin
Thrombin is an attractive target for designing anticoagulants owing to its most central
role in the coagulation cascade. “Direct” and “indirect” are the two most important approaches
used to target the inhibition of thrombin.69 Heparin, an indirect inhibitor of thrombin, mediates
its action through activation of antithrombin. Direct inhibitors mediate their action by binding
directly to the active site of thrombin.193 Hirudin was the first direct inhibitor of thrombin
reported in literature. Hirudin is the most potent inhibitor of thrombin, making it an essentially
irreversible inhibitor.52 Based on the hirudin structure, ximelagatron was the first orally available
direct thrombin inhibitor (DTI).75 Later, hundreds of small molecules were identified as active
site inhibitors of thrombin and factor Xa. Recently, a number of selective inhibitors of thrombin
and factor Xa have been identified by exploring the specificity site in the active site region.194
DTIs have certain advantages over indirect inhibitors. They have the potential to inhibit the
fibrin-bound thrombin whereas heparin fails to inhibit it. Secondly, small molecule inhibitors do
not elicit thrombocytopenia.195 Also, the direct inhibitors demonstrate a predictable dose
response, which translates into a reduced requirement for regular laboratory monitoring. They
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also demonstrate both larger therapeutic windows and rapid onset of action, yet they suffer from
certain disadvantages such as higher cost, patient compliance, hepatotoxicity and the need for
regular dosage adjustment.44

2.2 Inhibition of Thrombin Through Exosites
Thrombin can be also be targeted by the action of inhibitors at its two exosites.196 These
exosites can be used for designing allosteric inhibitors of thrombin. Besides acting as functional
epitopes for defining high specificity binding, the exosites can also allosterically modulate the
proteolytic activity of thrombin. It is known that thrombin has excellent communication between
its exosites and active site.76 The long range communication of the sodium binding site with the
active site through a network of eleven water molecules is the best known example of thrombin’s
allosteric modulation.109 The binding of thrombomodulin to exosite I of thrombin distorts the
active site in such a way that it changes the specificity from a procoagulant role to an
anticoagulant role. This proves that a communication pathway between exosite I and the catalytic
site.168 Sucrose octasulfate (SOS), which is considered to be a surrogate for heparin, binds at
exosite II. It is found that SOS weakly inhibits thrombin activity by an allosteric mechanism
mediated by binding to exosite II. Low molecular weight lignins (LMWLs) previously
synthesized in our group were found to be potent allosteric inhibitors of thrombin. This set of
examples encourages a new pathway for designing the inhibitors that mediate the allosteric
inhibition of thrombin by binding to one of the exosites.
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2.3 Advantages of Allosteric Over Direct Inhibitors
The major disadvantage of DTIs is that they can completely inhibit the catalytic activity
of thrombin. Besides inhibiting its procoagulant role, these inhibitors will also block the
anticoagulant function of thrombin by inhibiting activation of protein C. This can lead to
rebound hyper-coagulability.96 The active site DTIs are also known to have an antiplatelet effect
through reduced platelets activation. Furthermore, the clinical data on the longer use of DTIs
suggests a higher risk of fatal hepatotoxicity and other side effects. However, these effects are
asymptomatic and reversible on discontinuation of therapy. Severe hepatotoxicity led to
disapproval of ximelagatran by FDA followed by its withdrawal from the European market.197
Moreover, a suitable monitoring method for anticoagulant therapy using DTIs has not been well
established. The activated partial-thromboplastin time (APTT) assay suffers from poor linearity
and reproducibility. Recombinant hirudin and its analogs can be monitored with activated
partial-thromboplastin.44 Finally, the lack of an available antidote for reversing the effect of
overdosed active site directed DTIs further increases the risk associated with this therapy. The
requirement for an antidote is of extreme necessity in high bleeding risk patients.198
Beside these limitations, DTIs are also not optimal therapy for most of the thrombotic
disorders. None of the DTIs have shown better efficacy and safety profile than LMWHs for longterm treatment of acute coronary syndrome. DTIs are also less effective than LMWHs for
treatment of thromboprophylaxis after orthopedic surgery. Altogether, lower efficiency, poor
safety profile, hepatotoxicity and the lack of an antidote drives research toward the path of
allosterically inhibiting the thrombin for anticoagulant therapy.199
It is easy to attain selectivity for a single protease in allosteric design of inhibitors. The
active sites are mostly conserved in proteases in the coagulation cascade, thus making it difficult
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for selective inhibition. Selectivity for a single protease will be translated into lesser side effects
and lower risk of excessive bleeding. The partial inhibition of thrombin to maintain the balance
between anticoagulation and coagulation can be easily achieved by allosteric inhibitors. One of
the major advantages of allosteric inhibitors is the relatively easy design of antidotes for reversal
of the effects of accidental over-dosing.

2.4 Rationale for Design of Benzofuran scaffold
To design functional mimics of heparin that are orally available and safe, our laboratory
previously designed sulfated LMWLs, which are synthetic versions of naturally occurring
lignins. 200, 201 The synthesis involved enzymatic oxidative coupling of commercially available 4hydroxycinnamic acids, caffeic acid, sinapic acid and ferulic acid using horseradish peroxidase.
The oligomeric intermediates were sulfated to give three sulfated LMWLs, named CDSO3,
SDSO3 and FDSO3, having interesting anticoagulant profiles and modes of action.202
Sulfated LMWLs are oligomeric and polyanionic in nature. Similar to heparin, they are
polydisperse and heterogeneous in nature. Beside these similarities with heparin, the mechanism
of inhibition of thrombin is significantly different from heparin.202 This is owing to the nature of
scaffold being less anionic and more hydrophobic as compared to heparin. The saccharide
scaffold chain in heparin is replaced by an aromatic scaffold chain in sulfated LMWLs.
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Figure 15. Structure and scheme of synthesis of LMWLs displaying the various linkage
formations leading to pool of different structures

Sulfated LMWLs are a heterogeneous mixture arising from multiple inter-monomeric
unit linkages (β-5, β-β, β-O-4, and 5-5).200, 202, 203 This mixture is further complicated by variable
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chain lengths and patterns of sulfation. The presence of multiple chiral centers further adds to the
heterogeneity of the mixture. A simple calculation gives 262,144 distinct structures in the
decamer-length unit.200,

203

The average molecular weight of CDSO3 (the most interesting

LMWL) was found to be 3320, with a range of chain lengths between 5 and 13 monomeric units.
CDSO3 contains an average of 0.4 sulfate groups/unit as compare to 0.7 sulfate groups/unit on
heparin.200 The substrate hydrolysis assay of CDSO3 for thrombin in the presence and absence of
antithrombin suggested that CDSO3 inhibits thrombin by the direct mechanism.202 Unlike
heparin, CDSO3 does not require the presence of antithrombin to inhibit the activity of
thrombin.202 Based on these studies, it was found that CDSO3 is a potent direct inhibitor of
thrombin. In a Michaelis-Menten kinetics analysis, it was found that the KM of substrate
hydrolysis by thrombin was not affected by the presence of CDSO3. At the same time, VMax was
significantly reduced. This result suggested that CDSO3 does not compete with the substrate for
binding.201 Competitive binding studies with known ligands for exosite I and II indicated strong
competition with UFH and H8. Based on these biochemical studies, it was concluded that
CDSO3 is a non-competitive, direct thrombin inhibitor. Interestingly, human plasma and blood
studies indicated that CDSO3 possessed anticoagulant potency similar to clinically approved
LMWHs.201, 202
The major concerns with LMWLs are their poly-dispersity and heterogeneity in structure.
This can result in batch-to-batch variation in structural population, thus affecting the potency of
the mixture. The presence of structures with different binding features can also bind at various
non-target sites leading to severe side effects. The lack of structural information of such a
heterogeneous mixture presents a hurdle for rational design of newer molecules to improve
potency and ADME profiles.
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To design homogeneous structures with potent anticoagulant activity based on the
sulfated LMWL scaffold, we envisioned sulfated LMWLs as aromatic units formed by various
random linkages of 4-hydroxy-cinnamic monomers. Literature suggests an abundance of β-5
linkages in natural lignins.204, 205 We initiated the design of new classes of anticoagulants based
on the β-5 linkage of sulfated LMWLs (Figure 16). The β-5 linked monomers of CDSO3 form a
dihydrobenzofuran moiety having carboxylate and sulfate groups at 3- and 7- positions,
respectively. It also has two stereo-centers at the 2- and 3- positions. Simplification of the above
structure, gave the benzofuran unit. After incorporating synthetic feasibility, we proposed 5, 6dihydroxy-benzofuran-3-carboxylate ester as the first designed, small molecule scaffold for
allosteric modulation of thrombin’s activity.

Figure 16. The development of design of benzofuran scaffold from the DHPs, showing various
inter-monomeric linkages present in sulfated lignin. The β-5 linkage forms the Dehydrobenzofuran ring, which is modified to benzofuran to remove the complexity of two chiral centers
and for ease of synthesis.
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Based on this hypothesis, a small library of sulfated benzofuran monomers were
synthesized and evaluated for thrombin inhibition. It was found that the selected sulfated
monomer inhibited thrombin with low potency but that Michaelis-Menten kinetic analysis
revealed that these molecules do not compete with spectrozyme-TH.205 Thus, based on these
findings, it can be concluded that, although inhibition potency of sulfated monomers is low, the
design of allosteric inhibition of thrombin is proven. This led us to further ask whether:
1) Can we design dimeric or higher oligomeric sulfated benzofurans to improve the
inhibition potency?
2) Can we still retain the allosteric mode of inhibition for higher oligomeric sulfated
benzofurans and explore the binding region?
3) Can in vitro potency of these inhibitors translated in higher systems?
4) Is it possible to propose newer scaffolds based as potential leads for allosteric inhibition
of thrombin?
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Chapter 3 Synthesis of Library of Sulfated Benzofuran Monomers and Dimers

3.1 Introduction
Thrombin is a key enzyme of the coagulation cascade, exhibiting important roles in both
pro-coagulation and anti-coagulation processes. Most clinically used anticoagulant drugs,
including polymeric heparin, warfarin, hirudin, argatroban and the recently approved dabigatran,
aim to reduce thrombin activity.197 Although these drugs have been successful in treating many
thrombotic disorders, anticoagulation therapy continues to suffer from bleeding risk, narrow
therapeutic index and other drug-specific adverse effects, which highlight the critical need to
develop agents with better therapeutic profiles.
Structurally, thrombin is a complex serine protease of the trypsin family that displays
multiple ligand-binding domains that modulate its activity and interactions with other molecules.
These domains include the active site, the anion-binding exosites I and II, and the sodium
binding site. The design of thrombin inhibitors has focused almost exclusively on blocking the
substrate’s access to the active site through a competitive process.197 This paradigm has resulted
in the design of thousands of molecules distributed across a large number of scaffolds.20, 80, 197, 206
Of these, a select group of scaffolds, including the pyrazoles, napthylamidines, indoles,
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biphenyls, and benzimidazoles, are preferred because of their high thrombin selectivity.
Fundamentally, these designed inhibitors attempt to mimic the D-Phe-Pro-Arg recognition
sequence through the incorporation of a guanidine or amidine moiety. Recently, however, newer
molecules have been designed with a P-1 halophenyl substituent so as to interact with Tyr228 in
the S1 pocket, which improves the poor oral bioavailability of most P-1 guanidine-based
inhibitors.197, 207, 208
An exciting alternative to competitive inhibition of thrombin is allosteric inhibition
through either exosite I or II. It is well established that binding of ligands in these exosites can
induce conformational changes in the active site of thrombin.79, 86, 209, 210 An example of this is
thrombomodulin, which interacts with exosite I so as to change the substrate specificity of
thrombin from fibrinogen to protein C.210 Likewise, hirugen binding in exosite I increases or
decreases the catalytic efficiency of thrombin, depending on the nature of the chromogenic
substrate.86,

209

Similarly, exosite I – active site allosteric coupling is also the reason why

peptides such as bothrojaracin inhibit thrombin.101, 102 Nevertheless, no small organic molecule
has been designed to date that utilizes exosite I to effect physiological thrombin inhibition.
Exosite II ligands include heparin, chondroitin sulfate, haemadin, and fibrinogen γ’.
These can be broadly classified as either highly anionic polysaccharides or traditional peptides.
Interaction of heparin with exosite II is known to induce greater reactivity with antithrombin and
recent work shows that formation of the antithrombin – thrombin complex disrupts exosite II.211
Also, exosite II – active site coupling is suggested by the change in fluorescence properties of
para-amino benzamidine, a non-covalent active site probe, upon heparin binding to exosite II.212
However, no exclusive II ligand has been found to date that reduces the catalytic efficiency of
thrombin.
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Allosteric regulation is a promising strategy for thrombin inhibition. Nature tends to
utilize allosterism to confer specificity of recognition and also to effect regulation. For thrombin,
the possibility of regulation, or controlled inhibition, is of considerable importance because
nearly all current anticoagulants are associated with risk of bleeding. An appropriately designed
allosteric regulator that does not fully nullify the procoagulant signal may maintain a finely tuned
balance between procoagulant and anticoagulant signal resulting in reduced bleeding
complications. In pursuit of such allosteric regulators, we had earlier designed sulfated low
molecular weight lignins (LMWLs) as functional mimetics of heparin targeted to exosite II-like
regions of coagulation enzymes, including thrombin.213, 214 Sulfated LMWLs, chemo-enzymatic
variants of the naturally available lignin (Fig. 1), were found to potently inhibit thrombin with an
IC50 of 18–34 nM under physiological conditions.213 More importantly, sulfated LMWLs also
inhibited blood clotting under ex vivo conditions with potency comparable to the LMW
heparins.215
Despite their excellent in vitro and ex vivo anticoagulant properties, sulfated LMWLs are
challenging because of their polydispersity and microheterogeneity, which parallel that observed
with the heparins. Sulfated LMWLs represent a large library of structures arising from multiple
inter-monomeric linkages, variable sulfation and chain length, and the presence of many chiral
centers.216 These variables introduce considerable structural diversity to these molecules, which
nevertheless bind to exosite II of thrombin and allosterically induce thrombin inhibition.213
Sulfated LMWLs represent the first examples of an exclusive exosite II-mediated inhibition of
the key coagulation protease.
In this and the next chapter, we present a study of 28 monomeric and dimeric sulfated
benzofurans, molecules derived from the sulfated LMWL structure, as inhibitors of thrombin.
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Enzyme inhibition studies show that the library of molecules displays a range of inhibition
potential, while Michaelis-Menten kinetic studies show the inhibition to arise from an allosteric
process. Collectively, this work establishes the potential of allosteric inhibition of thrombin
through the interesting and unusual features of sulfated benzofurans that direct the interaction
with thrombin.

3.2 Synthesis
3.2.1 Simple Synthesis Procedure of Highly Functionalized Benzofuran Unit
Our initial synthesis of ethyl 5,6-dihydroxy-2-methylbenzofuran-3-carboxylate on a 5gram scale using the method reported by Pei et al 217 produced the desired product only in yields
below 20% and required several rounds of chromatographic purification. In order to obtain
enough hydroxylated benzofuran as a building block for the thrombin inhibitors, various solvent
systems, base and reaction times as well as a simplified purification procedure were investigated.
It was found that solvent composition played a crucial role in defining the reactivity of
components. Detailed studies indicated that the amount of water played a crucial role in the
reaction (Table 1). Whereas 1:1 water – ethanol mixture was completely ineffective, a 3:1 was
found to be optimal in yielding the desired highly functionalized benzofuran. Likewise, neither
water alone nor ethanol alone yielded any product. The reason for this significant stringency
appears to be the insolubility of catechol and ethyl acetoacetate. Yet, other solvents such as
acetonitrile or DMF, in which both reactants are fully soluble, also failed to give any product.
Attempting to improve solubility by heating to 50 °C also failed as it resulted in tar, possibly due
to polymerization. Preventing this tar formation by removing atmospheric oxygen (flushing with
nitrogen) gave back the starting materials in nearly quantitative yields. The reaction requires
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atmospheric oxygen to promote oxidative addition and cyclization, although no experiments
were performed to assess the minimal level of atmospheric oxygen necessary to sustain the
reaction.
Table 1. The effect of different solvent composition on reaction yield. The following reaction
condition was used: catechol (20 mmol), ethyl acetoacetate (10 mmol), base (40 mmol), NaIO3
(10 mmol) at room temperature for 14 hours.
O

O

HO

HO

OEt
Base, NaOI3

HO

O

HO
O

Solvent
Water
Water: Ethanol (96:4)
Water: Ethanol (90:10)
Water: Ethanol (85:15)
Water: Ethanol (80:20)
Water: Ethanol (75:25)
Ethanol
Acetonitrile
Acetonitrile: Ethanol (80:20)
*
Water: Ethanol (75:25)
*
Water: Ethanol (75:25)

OEt

Yield
0
0
7%
10.5%
18%
25%
0
0
0
0 (Heating at 50 °C)
0 (under nitrogen)

To further improve the yield of the reaction, various bases with increasing pKa were
screened (Table 2). Bases such as triethylamine and DIPEA improved the yield to 40-50%, most
probably arising from better deprotonation of acidic hydrogen from ethyl actetoacetate. Yet,
stronger bases such as K-t-butoxide (pKa = 19) resulted in no products. Reaction time of 10-12
hours was also found to be critical (Table 2). Extending the reaction time beyond 12 hours led to
a significant decrease in yield probably because of oxidative degradation of the product.
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Finally, purification of the desired product could be achieved through direct precipitation
in ethyl acetate as the yield had increased to a sufficiently high level. Thus, an effective
procedure for the synthesis of highly funcationalized benzofuran was developed. In this process,
catechol (4.4 g), ethyl acetoacetate (5.6 g) and DIPEA (10.14 g) were added and stirred for 5
minutes to make a slurry. Ethanol (50 mL) and then water (150 mL) were added to the slurry,
stirred for 10 minutes followed by addition of sodium iodate (4 g). The reaction was allowed to
proceed unattended at room temperature for 10 hours, then quenched with ethyl acetate (400 mL)
and extracted with acidified brine followed by vacuum concentration. The desired product was
obtained with > 95% purity by direct precipitation from ethyl acetate.

Table 2. The effect of various bases and reaction time on percentage yield of 1a. The following
reaction condition were used: 1catechol (20 mmol), ethyl acetoacetate (20 mmol), NaIO3 (10
mmol), water: ethanol (3:1) at room temperature for 14 hours; 2DIPEA (40 mmol) was used as
the base.
Impact of different bases1

Impact of reaction time2

Base

%Yield

Time (Hours)

% Yield

Pyridine (2 equiv.)

25

8

15

Pyridine (1 equiv)

10

10

60

Triethylamine

40

12

50

DIPEA

50

14

40

0

24

20

+-

K O-tBu

To evaluate the feasibility of this synthetic procedure to other reactants, various
commercially available alkyl acetoacetates including methyl, ethyl, t-butyl, methoxy ethyl and
allyl ester were investigated at a 10 g scale. It was observed that yield improved with polarity of
the esters such as methoxyethyl ester and decreased with hydrophobic t-butyl ester (Table 3). On
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the other hand, the simple purification method of direct precipitation in ethyl acetate is
applicable to all of these esters. Thus, overall a significant advance could be achieved in the
application of this useful reaction to synthesis of a library of highly functionalized benzofurans.

Table 3. The effect of substitutions on the dicarbonyl compound. The following reaction
condition were used: catechol (20 mmol), ethyl acetoacetate (20 mmol), DIPEA (40 mmol),
NaIO3 (10 mmol), water: ethanol (3:1) at room temperature for 10 hour.

Compound

-R

% Yield

1a

-CH3

60 %

1b

-CH2CH3

60 %

1c

-C(CH3)3

40 %

1d

-CH2CH2OCH3

70 %

1e

-CH2CH=CH2

60 %
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b, c, d, e, f)
_

18

1a – 1e

_

a)

f)

5a – 5j

_

i, f)
_
_

9a,9b

6

2a – 2j

e, f)
b)
i, f)
g)

_

7
8a, 8b
3a – 3f

c, l, e, f)

c)

j, e, f)

_

_

10
j, e,

4a – 4f

k, e, f)

14
h, e, f)
_

d)
_

13

_

i, f)

17

11a – 11f
e, f)

_

_

16
_

19
12a – 12f
m)

_
_

_

15

Figure 17. Synthesis of a library of sulfated benzofurans as potential allosteric regulators of
thrombin. The library consists of 15 monomers (5a – 5j, 6, 7, 9a, 9b, and 10) and 13 dimers (12a
– 12f, 13 – 19). Reactions: a) Cs2CO3, alkyl or acyl halide , an. DMF; b) TBDMSCl, Imidazole,
57

_

DMF; c) NBS, CCl4; d) Cs2CO3, 2; DMF; e) KF, CH3COOH, DMF; f) Et3N:SO3, CH3CN:DMF
(4:1), MW; g) Me3Al, R-H, toluene; h) Cs2CO3, 1a, DMF; i) LAH, an. THF; j) Cs2CO3,
morpholine, DMF; k) Cs2CO3, 4a, DMF; l) Cs2CO3, DMF, desilylated 8a; m) alc. LiOH.

3.2.2 Synthesis of Benzofuran Monomer and Dimer Precursors
The detailed protocol for the synthesis of each benzofuran precursor is provided in the
Experimental Section (3.4). The overview of the highly branched synthesis scheme is described
in Figure 17. This highly branched synthesis scheme was required for the synthesis of a diverse
library in term of number and position of sulfate and variable substitutions at the 2-, 3- and 6positions.

3.2.3 Hydrolysis of Ethyl Ester
Initially, several attempts failed to hydrolyze the ethyl ester present at 3- and 3’- positions
of the sulfated benzofuran dimer. In addition to the abundance of literature on mild hydrolysis of
ester groups, the reaction required effort to optimize the conditions to hydrolysis ester in the
presence of labile sulfate groups (Table 4). The following conditions were tried:
To the solution of 12a in anhydrous DMSO was added K-t-butoxide (2 equiv) and a
catalytic amount of water. The reaction was stirred at room temperature for 12 hours. No product
was observed. The use of a different solvent system such as DMF also failed to give the desired
product. At low temperature, no product was observed and mostly starting material was retained.
At room temperature, the conditions were too harsh for the sulfate group. An enzymatic method
was used as an alternative approach for ester hydrolysis. Pig liver esterase was used in various
buffer systems. However, no product was observed even after prolonged reaction time. t-Butyl
ammonium hydroxide was also used to facilitate the hydrolysis of ester group. It also failed to
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give desired the product at room temperature. Under microwave radiations for 20 minutes at 80
°C, degradation of starting material was observed. High temperature conditions were not suitable
for the stability of the product. Other bases such as cesium carbonate and NaOH were used. The
solvent systems such as methanol, ethanol and water: methanol (1:1) failed to give desired
product.
There were several reports on the use of LiOH for hydrolysis of ethyl ester. Initially, it
failed to give the desired product in the acetonitrile:DMF (4:1) and THF:water (4:1) solvent
systems. The saturated solution of LiOH in methanol led to degradation of starting material.
Finally, 3 equivalents of LiOH in methanol at room temperature in 5 hours gave the desired
product in good yield.
Table 4. The reaction condition tried for hydrolysis of ethyl ester group of 12a
Base

Solvent

Condition

Result

K-t-butoxide

DMSO

Water (cat.)

Sulfate removal

K-t-butoxide

DMF

Water (cat.)

Sulfate removal

Pig Liver Esterase

Phosphate buffer

RT

No product

Bu4NOH

THF

RT and MW (80°C)

No product

Cesium Carbonate

Water/methanol

RT

No product

NaOH

Ethanol

RT

Sulfate removed

LiOH

ACN: DMF

RT

No Product

LiOH

THF: water

RT

Degradation

Sat. LiOH

Methanol

RT

Degradation

59

Reason: The major concern in this step was the stability of the sulfate group. It is known that
sulfate groups are not stable under strong basic conditions as well as under moderate acidic
conditions, limiting the use to stronger bases and higher temperatures. Secondly, both ester
groups were sterically hindered, which limits the access of bulkier bases. The steric issue was
further exacerbated by Π-stacking of aromatic rings. The planar nature of these molecules
increases the probability of Π-stacking and aggregation.
3.2.4 Reduction Benzofuran Dimer to Diversify the Number and Position of Sulfate Group
In order to observe the effect of sulfate group at the 3- position, we tried to convert ethyl
ester to hydroxyl and methyl hydroxyl group at this position. For the introduction of 3-hydroxy
and 3-methylhydroxy groups, the Baeyer-Villiger reaction and reduction of ester were tried.
Procedure for Baeyer-Villiger Reaction: To a solution of 3a (1 mmol) in dry methylene chloride
was added meta-chloroperoxy benzoic acid (mCBPA, 2 mmol) and a catalytic amount of ptoluene sulfonic acid. The reaction mixture was stirred for 12 hours at room temperature. The
product formation was monitored using thin layer chromatography and 1H-NMR on the crude as
well as after initial work up using brine and methylene chloride. The reaction failed to give the
desired product. To optimize the reaction conditions, the reaction was performed at 50 °C to
overcome the energy barrier, but still no product was observed. The reaction conditions were
further modified using different equivalents of mCBPA and by varying the amount of p-toluene
sulfonic acid. All the above reaction conditions failed to give the desired product.
Procedure for Reduction Using Lithium Aluminum Hydride: To a solution of 2a, 3a and 11areduced (1 mmol) in dry THF was added lithium aluminum hydride (2 mmol). The reaction
mixture was stirred at room temperature for 3 hours and then quenched by adding a small
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amount of water. The reaction product was extracted between brine and methylene chloride
layers. The organic layer was concentrated and purified by flash chromatography using a silica
gel column. The product formation was monitored using thin layer chromatography and H-NMR
of crude as well as the purified product. No product was observed. In order to check the
efficiency of the reducing agent, lithium borohydride was used, but still no product was
observed. It was concluded that the reducing agent was either not of sufficient activity or had
been deactivated by moisture. Further, an excess of LAH was used and thus was transferred
under nitrogen atmosphere to prevent the deactivation by air moisture. When a large excess of
LAH (5-8 equiv) was used, product was observed in 70% yield. Reaction was purified using
silica gel flash chromatography using ethyl acetate in hexanes (10-50%) as solvent.
The product obtained was sulfated using a microwave-based protocol. The triethyl amine
salts of sulfated 6, 7 and 16 were purified by flash chromatography using a silica gel column.
Ethyl acetate in hexanes (30%-80%) was used as solvent. It was observed that the product started
degrading after purification. Initially, it was believed that the acidic nature of silica might be
responsible for degradation as it is known that the sulfate group is unstable in acidic condition.
To overcome this, a neutral alumina column was used for purification, but still degradation was a
major issue. To check the stability of the product, a small 1H-NMR study was performed to
check the stability of the product in various solvents. The 1H-NMR for 7 was recorded in various
solvents over times of 10 minutes to few days. It was observed that the product was stable in
CH3CN even after 10 days. In methanol, extra peaks corresponding to degradation product
started appearing in the proton spectra over the period of 2 hours and complete degradation of
product was observed in 2 days. In methanol-water (1:1), prominent peaks of degraded product
were observed after both 10 minutes and 2 hours. In the case of water as solvent, degradation of
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product started immediately and significant excess peaks started appearing in proton spectra in
just 10 minutes. Furthermore, no peaks corresponding to 6 were observed after separation on a
cation-exchange column, which is consistent with instability of the product in water. Based on
these studies, it can be concluded that 6 is stable in polar aprotic solvents, but starts degrading in
protic solvents. The nature of protic solvents to stabilize ions and promote protonation, might be
the factor responsible for degradation. The position of the sulfate group and resonance effects
may lead to the removal of the 3- position sulfate group.
Reason: The reason for the instability of these molecules in aqueous solvents is not fully
understood. But based on 1H-NMR data, it can be postulated that the electronic effects of the
sulfate group as well as of the aromatic ring play a major role. The sulfate group is highly
electron withdrawing in nature causing electron “pull” from the aromatic unit, which is further
supported by the electron donating nature of the oxygen atom. This movement of electrons can
lead to removal of the sulfate group as well as the resonance of aromatic unit to hydroquinone.

3.3 Results and Discussion
3.3.1 Design of the Sulfated Benzofuran Scaffold
Sulfated LMWLs, which recognize exosite II of thrombin, are based on an aromatic
scaffold, a scaffold dramatically different from the highly anionic polysaccharide scaffold of
heparin.216 Nevertheless, sulfated LMWLs retain one characteristic of heparin – structural
complexity arising from the presence of multiple inter-monomeric linkages, such as β-5, β-β, βO4, and 5-5 (Figure 16). A simple calculation suggests that LMWL molecules as small as a
tetramer can exhibit nearly 1400 distinct structures even if sulfation and inter-residue linkage are
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the only variables considered. To uncover distinct structures that may be the seat of
anticoagulant activity, we visualized lignin structure as concatenated, aromatic units, instead of
repetitions of 4-hydroxy-cinnamic acid monomers joined together through different inter-residue
linkages. In this alternative analysis, oligomeric lignin can be considered as a combinatorial
library of dihydro-benzofuran, phenoxy-propanoic acid, biphenyl and fused furan monomers
(Figure 16). We reasoned that one or more of these aromatic units with appropriate sulfate
groups could be the seat of thrombin recognition and inhibition.
To begin assessing the contribution of these individual aromatic units, we focused on the
benzofuran unit, which is a common scaffold used in many synthetic studies. In a preliminary
investigation, we had prepared a library of sulfated and carboxylated benzofuran monomers, of
which a small group of molecules were found to inhibit thrombin, albeit with IC50 in the
millimolar range. Interestingly, mechanistic studies had suggested allosteric inhibition by these
molecules.218 This promise led us to explore a more diverse set of sulfated benzofuran monomers
and dimers as potential inhibitors of thrombin (Figure 17).

3.3.2 Overall Description of the Sulfated Benzofuran Library
The benzofuran unit of sulfated LMWLs contains substitutions at the 2, 3, 5- positions
(Fig. 17). Of these, the 2- and 5- positions are utilized for inter-monomeric linkage and the 3position may bear a carboxylate or an alkylsulfate group. Considering these variations, charged,
polar and hydrophobic substitutions were engineered on this scaffold to obtain a structurally
diverse library. Figure 17 describes the multi-modal approach developed to synthesize 15
sulfated monomers and 13 sulfated dimers. This library reflects significant variations in: 1) the
number of negatively charged groups (1 to 3 anions); 2) the position of anionic and polar
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substitutions from the terminal to the center of the scaffold; 3) the size and nature of hydrophobic
groups; and 4) inter-residue linkage geometry. A characteristic feature is that each member of the
library is nearly fully water soluble because of the presence of one or more sulfate groups,
despite the primarily hydrophobic benzofuran backbone. This combination of water solubility
and hydrophobicity has been known to introduce novel physicochemical characteristics in the
sulfated lignin-based scaffold, e.g., higher than expected partition coefficient,219 and greater
proportion of non-ionic forces in binding to proteins.220

3.3.3 Synthesis of Sulfated Benzofuran Monomers
The first step in the synthesis of the library was the generation of base structures, 5,6dihydroxy-benzofuran-3-carboxylic acid esters 1a – 1e (Figure 17), from catechol in one step
using oxidative Michael addition conditions following the report of Pei et al.217 The reaction was
strongly susceptible to substituent effects, which required extensive optimization of reaction
conditions, especially the organic base, reaction time and solvent. Eventually, products 1a – 1e
were obtained in reasonably good yields (50–65%). Monoalkylation or acylation of
dihydroxybenzofurans proceeded smoothly to selective 6-substituted derivatives 2a – 2j. That
the substitution occurred at the 6-position of the benzofuran ring was confirmed through two
dimensional nuclear Overhauser spectroscopy experiments (ROESY), which showed a
correlation between the protons of the 3-alkyl ester and 6-alkoxy groups (not shown). The
monomeric benzofurans 2a – 2j so synthesized in two steps formed one major group of
precursors for library construction. Another set of monomer precursors 3a – 3g and 4a – 4g were
synthesized from 2a – 2j through silyl protection and bromination, respectively (Figure 17).
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Mono-sulfated benzofurans 5a – 5j were prepared by direct sulfation of precursors 2a –
2j. Phenolic molecules are typically more challenging to sulfate than alcoholic molecules.221 We
had previously developed a microwave-based sulfation protocol for introducing multiple sulfate
groups in a crowded environment using the triethylamine-sulfur trioxide complex at 100 °C.218,
222

This method gave good yields of mono-sulfated benzofurans 5a – 5j in their ammonium salt

forms, which were exchanged for sodium using a Sephadex C-25 exchange column. To test
whether the number and location of sulfate groups on the benzofuran scaffold play a significant
role in recognizing thrombin, we also introduced a sulfate group at the 3- position. Thus,
benzofurans 2a and 3a were reduced with LAH and sulfated to yield 6 and 7, respectively.
However, both 6 and 7 were found to degrade within a couple of hours after dissolution in water
at room temperature. The reason for the reduced aqueous stability of these 3-methylene sulfated
benzofurans is not clear, although the dual combination of electron pull by sulfate groups and
electron push by ring oxygen may be cause of more rapid desulfation.
To assess the importance of the nature of the carbonyl group at the 3-position, silylprotected benzofuran ester 3 was directly converted to morpholinyl and 4-methylpiperidinyl
amides 8a and 8b, respectively. Desilylation and sulfation gave mono-sulfated benzofuran
amides 9a and 9b in excellent yields. Finally, 2-morpholino monomer 10 was prepared from 4a
to study the effect of varying the 2-substituent.
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3.3.4 Synthesis of Sulfated Benzofuran Dimers
The construction of the library of dimers relied on the nucleophilic displacement of the
allylic bromide at the 2- position by free phenolic group at the 5-position. The apparent
simplicity of this reaction and the availability of ten nucleophilic monomers 2a – 2j and seven
allylic bromides 4a – 4g enticed us to construct a combinatorial library (Figure 17). However,
the coupling was challenging on both synthesis and purification fronts. Steric crowding around
both the nucleophile and the electrophile resulted in less than optimal yields (<50%) of 11a –
11f. In addition, the synthesized dimers typically co-eluted with monomers in a wide range of
multi-solvent systems, thus creating significant purification issues. We suspected that co-elution
may be occurring because of Π-stacking at high concentrations. Thus, a higher yielding
dimerization reaction was desirable, which was made possible through implementation of
microwave coupling. Using this strategy silylated dimers 11a – 11f were synthesized in excellent
yields (>90%). These were then de-protected and sulfated to yield mono-sulfated benzofuran
dimers 12a – 12f. Likewise, mono-sulfated benzofuran dimers 13 and 14, which contain a
morpholine ring at 2- and 3- positions, respectively, were synthesized starting from monomers
4a and 8a, respectively, through a series of silyl protection, allylic bromination, deprotection,
nucleophilic coupling and sulfation steps (Figure 17).
To evaluate the role of multiple anionic groups on the small hydrophobic scaffold, 12a
was hydrolyzed in alcoholic LiOH223 to yield 15, a mono-sulfated, dicarboxylated dimer.
Likewise, 11a was reduced with LAH and sulfated to yield 16, which is a di-sulfated dimer, but
as with monomers 6, 7 and 16 was found to degrade rapidly in water. Finally, coupling of 4a
with 1a followed by desilylation and sulfation gave 17, which is also a di-sulfated dimer, but
with a structure completely different from 16. Likewise, another variant of di-sulfated dimer, i.e.,
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18, was synthesized by coupling 1a and 2a in five steps (Figure. 17). In combination, dimers 15
– 18 display anionic groups around three key positions (3, 5, and 6) of the benzofuran scaffold.
These contain either two or three negative charges, which approximate the number of charges
typically found on a heparin disaccharide.

3.4 Experimental Section
3.4.1 Chemicals, Reagents and Analytical Chemistry
Microwave-based sulfation reactions were performed using a CEM-Discover synthesizer
(Matthews, NC) in sealed reaction vessels (7 mL) at 50 W. The temperature of the reaction was
maintained at the desired setting using cooled nitrogen (45 psi) flow. Reagents and chemicals
used in reactions were purchased from either Sigma-Aldrich (Milwaukee, WI) or Fisher
(Pittsburgh, PA) and used as supplied. Analytical thin layer chromatography (TLC) was
performed using UNIPLATETM silica gel GHLF 250 µm pre-coated plates (ANALTECH,
Newark, DE) that were analyzed by fluorescence (254 nm).
Column chromatography was performed using a Teledyne ISCO (Lincoln, NE) Combi
flash RF system and disposable normal silica cartridges of 30 – 50 µm particle size, 230 – 400
mesh size and 60 Å pore size. Sodium exchange chromatography was performed using SP
Sephadex C-25 sodium cation exchange columns from GE Healthcare Life Sciences
(Piscataway, NJ). An approximately 100 mg sulfated sample was loaded onto 10 g of the cation
exchanger in a 10 × 460 mm column and eluted with either water or 20% EtOH/H2O at 0.5
mL/min. Anhydrous reactions were carried out under nitrogen atmosphere in glassware dried at
high temperature. Reagent solutions and solvents were handled under nitrogen atmosphere using
syringe techniques. The HPLC purification of sulfated benzofurans was carried out on a Jasco
chromatography system (Easton, MD) using a 250×10 mm Varian Dynamax Microsorb C4
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column. An acetonitrile – water gradient (5 to 100% acetonitrile in 20 min) at 3 mL/min was
used to purify the compounds on milligram scale. The eluents were detected at 300 nm.
1

H and

13

C NMR spectra were recorded at either 300 or 400 MHz (Varian Mercury or

Bruker UltrashieldTM Plus) in appropriate deuterated solvents including CDCl3, DMSO-d6,
CD3OD, acetone-d6, or D2O. All signals are reported in ppm with the internal chloroform,
DMSO, acetone, and D2O signals at 7.26, 2.50, 3.31, 2.05, and 4.79, respectively, as standards.
The data is reported as: chemical shifts (ppm), multiplicity (s = singlet, d = doublet, t = triplet, m
= multiplet), coupling constant(s) (Hz), and integration. Mass spectrometry was performed on all
synthesized molecules using a Micromass ZMD 4000 single quadrupole mass spectrometer with
ESI ionization probe operating in negative ion mode (Waters Corp., Milford, MA). The samples,
dissolved in acetonitrile containing formic acid (5% v/v), were infused at 10 µL/min. The source
block temperature and the probe temperature were typically held at 100 and 120

O

C,

respectively, while corona and cone voltages were selected through manual optimization. The
desolvation nitrogen flow was 500 L/hour. Mass spectra were acquired in the mass range from
110 to 1000 Daltons at 400 amu/sec.

3.4.2 Detailed Description of Syntheses
Syntheses of (1a ̶ e)

To a solution of catechol (20 mmol) in 75 mL of ethanol were added the ester of acetoacetate (20
mmol) and N, N-Diisopropylethylamine (40 mmol). The reaction mixture was stirred for 5 min.
To this mixture was added sodium iodate (20 mmol) and stirred vigorously for 5 min and then 25
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mL of water was added. The reaction mixture was stirred for 10 hours at room temperature and
quenched with 400 mL of ethyl acetate and extracted with 150 mL of brine and 30 mL of 0.5 N
HCl. The organic layer was dried over magnesium sulfate and concentrated. The product was
purified by passing through plug of silica (1 inch in height) using 2% methanol in methylene
chloride. The product was concentrated and dried under vacuum to provide yield of 40% (see
Appendix, Page 239-241 for NMR spectra).
1a: 1H NMR (Acetone-d6, 300 MHz) δ 1.36 (t, J=3 Hz, 3H), 2.63 (s, 3H), 4.31 (q, J=6 Hz, 2H),
6.95 (s, 1H), 7.37 (s, 1H).

13

C NMR (CDCl3) δ 14.79, 14.96, 60.54, 98.53, 106.62, 108.83,

117.56, 144.09, 144.92, 147.79, 161.79, 164.48.
1b: 1H NMR (CDCl3, 300 MHz) δ 2.65 (s, 3H), 3.97 (s, 3H), 6.99 (s, 1H), 7.43 (s, 1H).
1c: 1H NMR (CDCl3, 300 MHz) δ 1.60 (s, 9H), 2.63 (s, 3H), 6.96 (s, 1H), 7.39 (s, 1H).
1d: 1H NMR (CDCl3, 300 MHz) 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t, J=12 Hz, 2H), 4.46 (t, J=12
Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H).
1e: 1H NMR (CDCl3, 300 MHz) 2.71 (s, 3H), 4.85 (d, 2H), 5.22 (d, 1H), 5.36 (d, 2H), 6.00 (m,
1H), 6.91 (s, 1H), 7.46 (s, 1H).

Synthesis of (2a ̶ 2j)

To a solution of 1a ̶ 1e (1.44 mmol) in DMF (12 mL) were added cesium carbonate (0.72 mmol)
and acyl or alkyl halide (1.44 mmol) and stirred for 15 hours under an N2 atmosphere. The
reaction was quenched by adding 0.5 N HCl and extracted with ethyl acetate. The organic extract
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was dried over magnesium sulfate, concentrated and purified on silica gel (0-25% ethyl acetate
in hexanes) to give product in 53% yield (see Appendix, Page 242-247 for NMR spectra).
2a: 1H NMR (CDCl3, 300 MHz) δ 1.46 (t, J=6 Hz, 3H), 2.75 (s, 3H), 3.96 (s, 3H), 4.39 (q, J=6
Hz, 2H), 5.58 (s, 1H), 6.95 (s, 1H), 7.37 (s, 1H).

13

C NMR (CDCl3, 300 MHz) δ 14.60, 14.66,

56.54, 60.43, 94.33, 106.04, 109.23, 119.19, 143.37, 145.18, 147.86, 162.87, 164.88.
2b: 1H NMR (CDCl3, 300 MHz) δ 2.71 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 6.95 (s, 1H), 7.44 (s,
1H).
2c: 1H NMR (CDCl3, 300 MHz) δ 1.60 (s, 9H), 2.63 (s, 3H), 3.92 (s, 3H), 6.92 (s, 1H), 7.39 (s,
1H).
2d: 1H NMR (CDCl3, 300 MHz) δ 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t, J=12 Hz, 2H), 3.82 (s, 3H),
4.46 (t, J=12 Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H).
2e: 1H NMR (CDCl3, 400 MHz) δ 1.45 (s, 6H), 2.70 (s, 3H), 4.13 (d, 2H), 4.36 (d, 2H), 6.93 (s,
1H), 7.43 (s, 1H).

13

C NMR (CDCl3) δ 14.34, 14.43, 14.76, 31.42, 36.45, 60.15, 65.02, 76.69,

77.00, 77.32, 94.97, 105.73, 109.04, 118.95, 143.34, 144.13, 147.63, 162.50, 162.58, 164.63.
2f: 1H NMR (CDCl3, 300 MHz) δ 1.40 (d, J=1.5 Hz, 6H), 1.43 (t, J=1.8 Hz, 3H), 2.71 (s, 3H),
4.38 (t, J=1.8 Hz, 2H), 4.58 (m, 1H), 6.96 (s, 1H), 7.44 (s, 1H).
2g: 1H NMR (CDCl3, 400 MHz) δ 1.45 (t, J=18 Hz, 3H), 2.71 (s, 3H), 3.76 (s, 3H), 4.36 (q, J=
18 Hz, 2H), 5.53 (s, 2H), 7.05 (s, 1H), 7.54 (s, 1H).
2h: 1H NMR (CDCl3, 400 MHz) δ 1.40 (t, J=18 Hz, 3H), 2.71 (s, 3H), 3.74 (m, 8H), 4.38 (q,
J=18 Hz, 2H), 6.95 (s, 1H), 7.58 (s, 1H).
2i: 1H NMR (CDCl3, 400 MHz) δ 2.71 (s, 3H), 3.83 (s, 3H), 4.85 (d, 2H), 5.22 (d, 1H), 5.36 (d,
2H), 6.00 (m, 1H), 6.91 (s. 1H), 7.46 (s, 1H).
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2j: 1H NMR (CDCl3, 400 MHz) δ 1.38 (t, J=18 Hz, 3H), 2.67 (s, 3H), 3.78 (s, 3H), 4.33 (q, J=18
Hz, 2H), 5.02 (s, 2H), 6.89 (d, J=21 Hz, 2H), 6.98 (s, 1H), 7.32 (d, J=21 Hz, 2H), 7.41 (s, 1H).

Synthesis of (3a ̶ 3f)

To a solution of 2a ̶ 2f (3.63 mmol) in DMF (30 mL) was added imidazole (18.15 mmol) and
TBDMSCl (21.83 mmol) and the mixture was stirred. After 16 hours the reaction mixture was
quenched with water and extracted with diethyl ether. The organic layer was dried over
magnesium sulfate, concentrated and purified by flash chromatography on silica gel (0-15%
EtOAc in hexanes) to obtain product in 85-90 % (see Appendix, Page 250-254 for NMR
spectra).
3a: 1HNMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 1.46 (t, J=6 Hz, 3H), 2.69 (s, 3H),
3.87 (s, 3H), 4.39 (q, J=6 Hz, 2H), 7.05 (s, 1H) 7.41 (s, 1H). 13C NMR (CDCl3, 300 MHz) δ 4.5,
14.47, 18.73, 22.25, 25.96, 55.99, 61.00, 95.23, 111.31, 112.77, 118.07, 143.56, 149.97, 151.43,
157.60, 163.69.
3b: 1H NMR (CDCl3, 300 MHz) δ 1.16 (s, 6H), 1.02 (s, 9H), 2.70 (s, 3H), 3.83 (s, 3H), 3.91 (s,
3H), 6.93 (s, 1H), 7.37 (s, 1H).
3c: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.03 (s, 9H), 1.62 (s, 9H), 2.69 (s, 3H), 3.83 (s,
3H), 6.92 (s, 1H), 7.36 (s, 1H).
3d: 1H NMR (CDCl3, 300 MHz) 0.13 (s, 6H), 1.01 (s, 9H), 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t,
J=12 Hz, 2H), 3.82 (s, 3H), 4.46 (t, J=12 Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H).
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3e: 1H NMR (CDCl3, 400 MHz) δ 0.11 (s, 6H), 1.04 (s, 9H), 1.46 (s, 6H), 2.71 (s, 3H), 4.03 (d,
2H), 4.35 (d, 2H), 6.93 (s, 1H), 7.40 (s, 1H).
3f: 1H NMR (CDCl3, 400 MHz) δ 0.19 (s, 6H), 1.04 (s, 9H), 1.37 (d, 6H), 1.42 (t, 3H), 2.71 (s,
3H), 4.40 (d, 2H), 6.94 (s, 1H), 7.40 (s, 1H).

Synthesis of (4a ̶ 4f)

To the solution of 3a ̶ 3f (1 mmol) in THF (20 mL) was added NBS (1 mmol) and refluxed at 65
o

C under a halogen lamp for 1 hour. The reaction mixture was cooled and quenched with water

and extracted with hexanes. The organic layer was concentrated and product was obtained in 9095 % yield (see Appendix, Page 258-260 for NMR spectra).
4a: 1HNMR (CDCl3, 300 MHz) δ 0.17 ( s, 6H), 1.01 (s, 9H), 1.46 (t, J=6 Hz, 3H), 3.87 (s, 3H),
4.39 (q, J=6 Hz, 2H), 4.93 (s, 2H), 7.05 (s, 1H) 7.41 (s, 1H).
4b: 1H NMR (CDCl3, 300 MHz) δ 1.17 (s, 6H), 1.02 (s, 9H), 3.83 (s, 3H), 3.91 (s, 3H), 4.91 (s,
2H), 6.93 (s, 1H), 7.37 (s, 1H).
4c: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.01 (s, 9H), 1.65 (s, 9H), 3.85 (s, 3H), 4.93 (s,
2H), 6.96 (s, 1H), 7.40 (s, 1H).
4d: 1H NMR (CDCl3, 300 MHz) 0.17 (s, 6H), 1.02 (s, 9H), 3.45 (s, 3H), 3.76 (t, J=12 Hz, 2H),
3.86 (s, 3H), 4.50 (t, J=12 Hz, 2H), 4.96 (s, 2H), 6.98 (s, 1H), 7.45 (s, 1H).
4e: 1H NMR (CDCl3, 400 MHz) δ 0.11 (s, 6H), 1.04 (s, 9H), 1.46 (s, 6H), 4.03 (d, 2H), 4.35(d,
2H), 4.96 (s, 2H), 6.93 (s, 1H), 7.40 (s, 1H).
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4f: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 1.38 (d, 6H), 1.43 (t, 3H), 4.48 (d,
2H), 4.57 (s, 2H), 6.97 (s, 1H), 7.41 (s, 1H).

Synthesis of (11a ̶ 11f)

To the solution of 2a ̶ 2f (0.3 mmol) and 4a ̶ 4f (0.4 mmol) in ethyl acetate (4 mL) were added
cesium carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred
under nitrogen for 15 hours at room temperature. The reaction was quenched with methylene
chloride and extracted with brine. The organic layer was dried over magnesium sulfate and
concentrated. Purification was done by using flash chromatography on silica gel using (0-20) %
ethyl acetate in hexanes. The product was obtained in 60-65 % yield (see Appendix, Page 261265 for NMR spectra).
11a: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 1.46 (m, 6H), 2.71 (s, 3H), 3.87
(s, 3H), 3.91 (s, 3H), 4.39 (m, 4H), 5.60 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.42 (s, 1H), 7.55 (s,
1H). 13C NMR (CDCl3, 300 MHz) δ 4.55, 14.41, 14.73, 14.68, 18.92, 25.57, 55.77, 56.62, 60.62,
61.93, 64.47, 95.27, 98.31, 103.47, 109.31, 112.55, 112.73, 117.90, 119.98, 143.29, 146.34,
147.95, 148.08, 151.20, 150.69, 157.66, 162.67, 164.17, 164.83.
11b: 1H NMR (CDCl3, 300 MHz) δ 1.16 (s, 6H), 1.02 (s, 9H), 2.71 (s, 3H), 3.84 (s, 3H), 3.87 (s,
3H), 3.91 (s, 3H), 3.92 (s, 3H), 5.60 (s, 2H), 6.98 (s, 1H), 7.01 (s, 1H), 7.44 (s, 1H), 7.59 (s, 1H)
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11c: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.01 (s, 9H), 1.59 (s, 9H), 1.60 (s, 9H), 2.68 (s,
3H), 3.82 (s, 3H), 3.87 (s, 3H), 5.57 (s, 2H), 6.92 (s, 1H), 6.98 (s, 1H), 7.41 (s, 1H), 7.54 (s, 1H).
11d: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 2.71 (s, 3H), 3.43 (s, 3H), 3.71
(m, 4H), 3.83 (s, 3H), 3.86 (s, 3H), 4.45 (m, 2H), 5.59 (s, 2H), 6.97 (s, 1H), 7.00 (s, 1H), 7.47 (s,
1H), 7.64 (s, 1H).
11e: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.03 (s, 9H), 1.37 (s, 12H), 2.70 (s, 3H), 4.08
(d, 4H), 4.33 (d, 4H), 5.57 (s, 2H), 6.98 (d, 2H), 7.44 (s, 1H), 7.58 (s, 1H). 13C NMR (CDCl3) δ
4.71, 14.19, 14.36, 14.38, 14.68, 14.74, 18.46, 25.75, 60.10, 60.16, 60.46, 64.31, 64.62, 65.01,
76.68, 77.00, 77.20, 77.32, 94.96, 96.01, 96.82, 109.13, 109.26, 111.63, 112.57, 117.85, 118.55,
143.03, 146.17, 148.42, 149.33, 149.90, 149.98, 158.17, 162.49, 163.71, 164.46.
11f: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 1.34 (d, 12H), 1.43 (m, 6H), 2.70
(s, 3H), 4.35 (t, 4H), 4.48 (m, 2H), 5.54 (s, 2H), 6.98 (d, 2H), 7.44 (s, 1H), 7.58 (s, 1H).

13

C

NMR (CDCl3, 400 MHz) δ 4.59, 14.19, 14.38, 18.43, 21.01, 21.92, 21.98, 22.05, 25.78, 60.09,
60.36, 60.43, 64.75, 70.94, 72.65, 76.68, 77.00, 77.32, 98.11, 100.29, 109.13, 109.78, 111.54,
112.74, 118.05, 119.37, 143.96, 147.23, 147.51, 148.54, 149.29, 149.82, 158.39, 162.78, 163.69,
164.43.

Deprotected form of 11a ̶ 11f

To a solution of 11a ̶ 11f (0.3 mmol) in DMF (3 mL) were added KF (4 mmol) and glacial acetic
acid (10 µL). The reaction mixture was stirred for 5 hours. The reaction was quenched by
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methylene chloride and extracted with brine solution. The aqueous layer was again extracted
with a fresh batch of methylene chloride. The organic layer was combined and dried over
magnesium sulfate and concentrated in vacuum. The solid was precipitated using methanol to
obtain product in 90% yield (see Appendix, Page 270-274 for NMR spectra).
11a deprotected form: 1H NMR (CDCl3, 300 MHz) δ 1.46 (m, 6H), 2.71 (s, 3H), 3.80 (s, 3H),
3.85 (s, 3H), 4.39 (m, 4H), 5.35 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.42 (s, 1H), 7.55 (s, 1H).
11b deprotected form: 1H NMR (CDCl3, 300 MHz) δ 2.71 (s, 3H), 3.80 (s, 3H), 3.83 (s, 3H),
3.85 (s, 3H), 3.87 (s, 3H), 5.35 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.42 (s, 1H), 7.55 (s, 1H).
11c deprotected form: 1H NMR (CDCl3, 300 MHz) δ 1.57 (s, 9H), 1.59 (s, 9H), 2.68 (s, 3H),
3.84 (s, 3H), 3.93 (s, 3H), 5.57 (s, 2H), 6.95 (s, 1H), 7.05 (s, 1H), 7.46 (s, 1H), 7.58 (s, 1H).
11d deprotected form: 1H NMR (CDCl3, 300 MHz) δ 2.71 (s, 3H), 3.43 (s, 3H), 3.71 (m, 4H),
3.83 (s, 3H), 3.86 (s, 3H), 4.45 (m, 2H), 5.59 (s, 2H), 6.97 (s, 1H), 7.01 (s, 1H), 7.50 (s, 1H),
7.63 (s, 1H).
11e deprotected form: 1H NMR (CDCl3, 400 MHz) δ 1.45 (m, 12H), 2.69 (s, 3H), 4.10 (m, 4H),
4.35 (m, 4H), 5.58 (s, 2H), 6.97 (s, 1H), 6.99 (s, 1H), 7.49 (s, 1H), 7.56 (s, 1H).
11f deprotected form: 1H NMR (CDCl3, 400 MHz) δ 1.38 (d, 12H), 1.47 (m, 6H), 2.70 (s, 3H),
4.37 (t, 4H), 4.39 (t, 4H), 5.57 (s, 2H), 7.02 (d, 2H), 7.50 (s, 1H), 7.57 (s, 1H). 13C NMR (CDCl3,
400 MHz) δ 14.31, 14.37, 14.38, 21.99, 22.05, 60.11, 60.53, 64.64, 72.40, 72.71, 76.69, 77.01,
77.21, 77.32, 96.70, 100.36, 106.03, 109.12, 109.60, 111.67, 118.50, 119.39, 143.83, 144.45,
147.15, 147.46, 148.66, 149.25, 158.69, 162.79, 163.67, 164.43.

Sulfation of Appropriate Precursors to Yield Sulfated Benzofuran Monomers and Dimers
The synthesis of sulfated benzofurans was developed following our earlier report on the
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synthesis of sulfated flavonoids.222 Briefly, to a solution of unsulfated benzofuran monomer or
dimer (typically 50 mg) in acetonitrile: DMF (4:1, 0.45 mL) in a microwave tube were added
triethylamine (10 equiv) and trimethylamine-sulfur trioxide complex (15 equiv). The reaction
mixture was exposed to microwaves (50 W) for 40 min at 100 ºC followed by vacuum
concentration to remove all solvent. The solid so obtained was directly loaded on a Sephadex C25 cation exchange resin and eluted with water. Fractions containing the sulfated product were
lyophilized to obtain a solid residue, which was further purified on reverse-phase gradient HPLC
to remove residual unsulfated contaminants (see Appendix, Page 282-305 for NMR spectra and
Page 307-318 for Mass Spectra).
5a: 1H NMR (D2O, 400 MHz) δ 1.45 (t, J=6 Hz, 3H), 2.51 (s, 3H), 3.76 (s, 3H), 4.36 (q, J=6 Hz,
2H), 5.38 (s, 1H), 7.15 (s, 1H), 7.57 (s, 1H).
5b: 1H NMR (D2O, 400 MHz) δ 2.48 (s, 3H), 3.89 (s, 3H), 4.21 (s, 3H), 6.98 (s, 1H), 6.61 (s,
1H). ESI MS (-ve) m/z calcd. for C12H11O8SNa [(M-Na)-)] 315.02, found 315.01 (M-Na)-.
5c: 1H NMR (D2O, 400 MHz) δ 1.62 (s, 9H), 2.49 (s, 3H), 3.89 (s, 3H), 6.98 (s, 1H), 6.61 (s,
1H).

13

C NMR (D2O, 400 MHz) δ 13.40, 21.22, 61.33, 73.87, 99.93, 107.79, 114.00, 118.54,

139.23, 147.28, 150.45, 164.37, 165.49. ESI MS (-ve) m/z calcd for C13H17O8SNa [(M-Na)-)]
357.05, found 357.08 (M-Na)-.
5d: 1H NMR (D2O, 400 MHz) δ 2.48 (s, 3H), 3.21 (s, 3H), 3.62 (t, J=12 Hz, 2H), 3.72 (s, 3H),
4.26 (t, J=12 Hz, 2H), 6.91 (s, 1H), 7.59 (s, 1H). ESI MS (-ve) m/z calcd. for C13H13O9SNa [(MNa)-)] 345.02, found 345.01 (M-Na)-.
5e: 1H NMR (D2O, 400 MHz) δ 1.70 (m, 6H), 2.99 (s, 3H), 4.41 (q, J=17 Hz, 2H), 4.66 (q, J= 17
Hz, 2H), 7.55 (s, 1H), 8.21 (s, 1H).

13

C NMR (D2O, 400 MHz) δ 16.36, 16.39, 16.76, 63.15,
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67.53, 99.69, 110.66, 116.09, 119.96, 141.73, 146.05, 151.33, 152.58, 165.90, 167.00. ESI
HRMS (-ve) m/z calcd. for C14H16O8SNa [(M-Na)-)] 343.0512, found 343.0357 (M-Na)-.
5f: 1H NMR (D2O, 400 MHz) δ 1.37 (m, 9H), 2.36 (s, 3H), 4.23 (q, J=18 Hz, 2H), 4.54 (m, 1H),
6.96 (s, 1H), 7.60 (s, 1H).

13

C NMR (D2O) δ 13.40, 13.48, 21.22, 61.33, 73.87, 99.93, 107.79,

114.00, 118.54, 139.23, 147.28, 150.45, 164.37, 165.49. ESI HRMS (-ve) m/z calcd. for
C14H15O8SNa [(M-Na)-)] 357.0532, found 357.0600 (M-Na)-.
5g: 1H NMR (D2O, 400 MHz) δ 1.45 (t, J=18 Hz, 3H), 2.50 (s, 3H), 3.64 (s, 3H), 4.31 (q, J=18
Hz, 2H), 5.33 (s, 2H), 7.15 (s, 1H), 7.64 (s, 1H). ESI HRMS (-ve) m/z calcd. for C14H15O9SNa
[(M-Na)-)] 359.0420, found 359.0395 (M-Na)-.
5h: 1H NMR (D2O, 400 MHz) δ 1.39 (t, J=18 Hz, 3H), 2.57 (s, 3H), 3.87 (m, 8H), 4.29 (q, J=18
Hz, 2H), 7.45 (s, 1H), 7.57 (s, 1H).

13

C NMR (D2O, 400 MHz) δ 13.48, 13.72, 44.11, 44.94,

61.53, 61.58, 66.25, 105.77, 106.60, 108.11, 114.53, 123.18, 139.99, 140.26, 149.66, 154.36,
165.33, 166.19. ESI HRMS (-ve) m/z calcd for C17H18O10SNa [(M-Na)-)] 428.0332, found
428.0889 (M-Na)-.
5i: 1H NMR (D2O, 400 MHz) δ 2.51 (s, 3H), 3.63 (s, 3H), 4.65 (d, 2H), 5.02 (d, 1H), 5.16 (d,
2H), 5.91 (m, 1H), 6.81 (s. 1H), 7.56 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.40, 55.05, 61.19,
70.68, 97.79, 107.91, 113.75, 114.30, 118.36, 128.61, 128.99, 138.55, 148.09, 150.16, 158.52,
163.59, 165.06. ESI HRMS (+ve) m/z calcd. for C20H19O9SNa [(M+Na)+)] 481.0632, found
481.1400 (M+Na)+.
5j: 1H NMR (D2O, 400 MHz) δ 1.28 (t, J=18 Hz, 3H), 2.09 (s, 3H), 3.54 (s, 3H), 4.12 (q, J=18
Hz, 2H), 4.78 (s, 2H), 6.57 (s, 1H), 6.68 (d, J=21 Hz, 2H), 7.17 (d, J=21 Hz, 2H), 7.67 (s, 1H).
13

C NMR (D2O, 400 MHz) δ 13.40, 55.05, 61.19, 70.68, 97.79, 107.91, 113.75, 114.30, 118.36,
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128.61, 128.99, 138.55, 148.09, 150.16, 158.23, 163.59, 165.06. ESI MS (-ve) m/z calcd. for
C14H13O8SNa [(M-Na)-)] 325.03, found 325.04 (M-Na)-.
6: 1H NMR (CD3OD, 300 MHz) δ 2.61 (s, 3H), 3.86 (s, 3H), 6.88 (s, 2H), 7.15 (s, 1H), 7.86 (s,
1H).

13

C NMR (CD3OD, 300 MHz) δ 10.85, 55.78, 59.93, 95.76, 110.69, 112.67, 120.71,

138.55, 150.48, 151.65, 154.22.
7: 1H NMR (CD3OD, 300 MHz) δ 0.44 (s, 6H), 1.02 (s, 9H), 2.75 (s, 3H), 3.96 (s, 3H), 6.68 (s,
2H), 6.98 (s, 1H), 7.36 (s, 1H).

13

C NMR (CD3OD) δ 4.48, 12.29, 18.70, 26.02, 55.88, 56.04,

95.47, 109.94, 114.31, 120.84, 142.03, 149.32, 149.40, 151.81.
9a: 1H NMR (D2O, 400 MHz) δ 2.47 (s, 3H), 3.55-3.90 (m, 8H), 3.91 (s, 3H), 7.25 (s, 1H), 7.41
(s, 1H).

13

C NMR (D2O, 400 MHz) δ 12.48, 42.76, 47.82, 56.43, 66.41, 66.79, 96.68, 110.52,

112.70, 118.31, 137.35, 149.74, 151.36, 156.79, 166.23. ESI HRMS (-ve) m/z calcd. for
C15H16NO8SNa [(M-Na)-)] 370.0544, found 370.0652 (M-Na)-.
9b: 1H NMR (D2O, 400 MHz) δ 0.89 (d, J=17 Hz, 3H), 1.01 (m, 1H), 1.61-1.81 (m , 4H), 2.39
(s, 3H), 2.92 (m, 1H), 3.08 (m, 1H), 3.56 (m, 1H), 3.92 (s, 3H), 4.45 (m, 1H), 7.27 (s, 1H), 7.64
(s, 1H).

13

C NMR (D2O, 400 MHz) δ 12.47, 12.55, 14.88, 20.89, 30.17, 55.67, 56.59, 96.67,

111.46, 112.63, 118.67, 137.67, 149.82, 151.26, 155.45, 165.32. ESI HRMS (-ve) m/z calcd. for
C17H20NO7SNa [(M-Na)-)] 482.1022, found 382.0847 (M-Na)-.
10: 1H NMR (D2O, 400 MHz) δ 1.47 (t, J=18 Hz, 3H), 2.71 (m, 4H), 3.81 (m, 4H), 3.95 (s, 3H),
4.02 (s, 2H), 4.39 (q, J=18 Hz, 2H), 7.25 (s, 1H), 7.74 (s, 1H).

13

C NMR (D2O, 400 MHz) δ

13.45, 52.47, 52.64, 56.34, 61.82, 66.07, 96.24, 111.83, 114.82, 117.14, 137.95, 150.45, 151.64,
159.30, 164.77. ESI HRMS (-ve) m/z calcd. for C17H20NO9SNa [(M-Na)-)] 414.0933, found
414.0847 (M-Na)-.
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12a: 1H NMR (CD3OD, 300 MHz) δ 1.32 (t, J=6 Hz, 3H), 2.65 (s, 3H), 3.82 (s, 3H), 3.86 (s,
3H), 4.29 (q, J=6 Hz, 2H), 5.52 (s, 2H), 7.12 (s, 1H), 7.22 (s, 1H), 7.43 (s, 1H), 8.04 ( s, 1H). 13C
NMR (CD3OD) δ 13.12, 13.53, 13.54, 55.65, 60.20, 60.67, 63.93, 95.54, 95.63, 109.19, 112.32,
115.57, 117.40, 118.31, 139.89, 145.50, 149.74, 152.08, 152.20, 158.70, 162.67, 163.51, 164.48.
ESI HRMS (-ve) m/z calcd. for C26H25O13SNa [(M-Na)-)] 577.1011, found 577.1146 (M-Na)-.
12b: 1H NMR (CD3OD, 300 MHz) δ 2.67 (s, 3H), 3.83 (s, 3H), 3.84 (s, 3H), 3.85 (s, 3H), 3.86
(s, 3H), 5.55 (s, 2H), 7.13 (s, 1H), 7.24 (s, 1H), 7.47 (s, 1H), 8.03 (s, 1H). ESI HRMS (-ve) m/z
calcd. for C24H21O13SNa [(M-Na)-)] 549.0723, found 549.0795 (M-Na)-.
12c: 1H NMR (CD3OD, 300 MHz) δ 1.49 (s, 9H), 1.51 (s, 9H), 2.65 (s, 3H), 3.83 (s, 3H), 3.88
(s, 3H), 5.47 (s, 2H), 7.12 (s, 1H), 7.22 (s, 1H), 7.37 (s, 1H), 8.09 (s, 1H).

13

C NMR (CD3OD,

300 MHz) δ 13.09, 27.30, 27.45, 55.59, 55.66, 64.26, 81.00, 81.62, 95.44, 95.56, 109.89, 110.21,
113.55, 115.59, 117.70, 118.42, 139.79, 145.31, 149.83, 151.87, 152.05, 158.16, 162.26, 162.63,
163.80. ESI MS (-ve) m/z calcd. for C30H33O13SNa [(M-Na)-)] 633.16, found 633.19 (M-Na)-.
12d: 1H NMR (D2O, 400 MHz) δ 2.30 (s, 3H), 3.26 (s, 3H), 3.32 (s, 3H), 3.57 (m, 2H), 3.63 (m,
5H), 3.77 (s, 3H), 4.18 (m, 2H), 4.27 (m, 2H), 5.17 (s, 2H), 6.49 (s, 1H), 6.89 (s, 1H), 6.93 (s,
1H), 7.67 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.49, 55.40, 56.07, 58.13, 58.24, 62.74, 62.96,
63.79, 69.76, 69.89, 93.22, 95.76, 105.85, 107.40, 111.06, 114.98, 116.73, 117.17, 138.28,
144.55, 147.64, 148.10, 150.78, 151.62, 158.55, 162.96, 163.49, 164.40. ESI HRMS (-ve) m/z
calcd. for C28H29O115SNa [(M-Na)-)] 637.1223, found 637.1161 (M-Na)-.
12e: 1H NMR (D2O, 400 MHz) δ 1.14 (m, 12H), 2.32 (s, 3H), 3.72 (m, 4H), 4.06 (m, 4H), 5.15
(s, 2H), 6.51 9s, 1H), 6.71 9s, 1H), 6.98 (s, 1H), 7.56 (s, 1H). ESI HRMS (-ve) m/z calcd. for
C28H29O13SNa [(M-Na)-)] 605.1312, found 605.0708 (M-Na)-.
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12f: 1H NMR (D2O, 400 MHz) δ 1.07 (m, 18H), 2.27 (s, 3H), 3.99 (m, 4H), 4.20 (m, 2H), 5.05
(s, 2H), 6.64 (s, 1H), 6.67 (s, 1H), 6.99 (s, 1H), 7.81 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.29,
13.50, 13.69, 13.78, 20.94, 21.19, 21.40, 60.34, 61.09, 63.81, 71.86, 72.97, 98.90, 108.13,
111.04, 114.71, 117.74, 118.33, 139.92, 146.62, 146.72, 148.33, 148.60, 151.24, 158.69, 162.57,
163.34, 164.08. ESI HRMS (-ve) m/z calcd. for C30H33O13SNa [(M-Na)-)] 633.1236, found
633.1494 (M-Na)-.
13: 1H NMR (CD3OD, 400 MHz) δ 1.38 (m, 6H), 2.60 (m, 3H), 3.71 (m, 4H), 3.91 (s, 3H), 3.93
(s, 3H), 4.37 (m, 6H), 5.62 (s, 2H), 7.02 (s, 1H), 7.05 (s, 1H), 7.49 (s, 1H), 8.01 (s, 1H). ESI MS
(-ve) m/z calcd. for C30H32NO14SNa [(M-Na)-)] 659.14, found 659.15 (M-Na)-.
14: 1H NMR (D2O, 400 MHz) δ 2.40 (s, 3H), 3.24 (m, 8H), 3.67 (m, 8H), 3.81 (s, 3H), 3.92 (s,
3H), 5.30 (s, 2H), 6.85 (s, 1H), 7.14 (s, 1H), 7.33 (s.1H), 7.43 (s, 1H).

13

C NMR (D2O, 400

MHz) δ 12.36, 42.55, 56.00, 56.40, 63.52, 66.17, 66.36, 96.23, 96.73, 107.16, 110.44, 113.33,
115.29, 116.94, 117.92, 138.10, 143.04, 148.81, 149.45, 151.21, 151.81, 152.46, 156.38, 164.20,
165.93. ESI HRMS (-ve) m/z calcd. for C30H31N2O13SNa [(M-Na)-)] 659.1422, found 659.1531
(M-Na)-.
17: 1H NMR (D2O, 400 MHz) δ 1.23 (m, 6H), 2.36 (s, 3H), 3.70 (s, 3H), 4.18 (m, 4H), 5.23 (s,
2H), 6.96 (s, 1H), 7.03 (s, 1H), 7.53 (s, 1H), 7.62 (s, 1H).

13

C NMR (D2O, 400 MHz) δ 13.4,

13.51, 13.59, 56.30, 61.53, 62.08, 63.51, 96.28, 99.06, 108.05, 111.73, 114.48, 115.06, 117.13,
119.54, 138.31, 138.82, 147.96, 150.23, 150.94, 152.02, 158.07, 164.50, 164.87, 165.60. ESI
HRMS (-ve) m/z calcd. for C25H22O14S2Na [(M-Na)-)] 665.0121, found 665.0366 (M-Na)-.
18: 1H NMR (D2O, 400 MHz) δ 1.55 (t, J=18 Hz, 3H),1.59 (t, J=18 Hz, 3H), 2.41 (s, 3H), 3.81
(s, 3H), 4.18 (q, J=18 Hz, 2H), 4.23 (q, J=18 Hz, 2H), 5.18 (s, 2H), 6.71 (s, 1H), 6.89 (s, 1H),
7.65 (s, 1H), 7.91 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.47, 13.61, 13.63, 56.32, 61.53, 62.18,
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63.61, 96.28, 99.16, 108.01, 111.53, 114.48, 115.06, 117.13, 119.54, 138.31, 138.82, 147.96,
150.23, 150.84, 152.12, 158.17, 164.53, 164.77, 165.60. ESI HRMS (-ve) m/z calcd. for
C25H22O14S2Na [(M-Na)-)] 665.0121, found 665.0277 (M-Na)-.
19: 1H NMR (CDCl3, 300 MHz) δ 1.39 (m, 6H), 2.67 (s, 3H), 3.85 (s, 3H), 3.88 (s, 3H), 4.36 (m,
4H), 5.55 (s, 2H), 7.22 (s, 1H), 7.23 (s, 1H), 7.43 (s, 1H), 8.07 (s, 1H). 13C NMR (CD3OD, 400
MHz) δ 13.25, 13.38, 13.52, 55.66, 55.77, 60.25, 60.79, 63.16, 95.63, 99.17, 103.95, 108.76,
112.48, 115.58, 117.27, 120.11, 139.90, 146.40, 148.00, 148.45, 152.15, 152.23, 158.27, 163.04,
163.59, 164.61. ESI HRMS (-ve) m/z calcd. for C26H25O13SNa [(M-Na)-)] 577.1011, found
577.1100 (M-Na)-.

Synthesis of 15
To a solution of 12a (100 mg, 0.16 mmol) in 2 mL of methanol was added LiOH (20 mg, 0.8
mmol) and stirred for 5 h at RT. After completion, the reaction mixture was concentrated and
purified using HPLC (see Appendix, Page 301 for NMR spectra). 1H NMR (D2O, 400 MHz) δ
2.66 (s, 3H), 3.84 (s, 3H), 3.89 (s, 3H), 5.52 (s, 2H), 7.11 (s, 1H), 7.27 (s, 1H), 7.41 (s, 1H), 8.01
(s, 1H).

13

C NMR (CD3OD, 400 MHz) δ 13.43, 61.67, 63.73, 95.54, 95.63, 109.19, 112.32,

115.57, 117.40, 118.31, 139.89, 145.50, 149.74, 152.08, 152.20, 158.54, 162.57, 164.51, 165.48.
ESI HRMS (-ve) m/z calcd. for C17H20NO9SNa [(M-Na)-)] 521.0322, found 521.1496 (M-Na)-.

Synthesis of 6 from 2a
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To a solution of 2a (0.5 mmol) in toluene was added lithium aluminum hydride (2.5 mmol) and
stirred for 4 hours at RT. The reaction was quenched by adding water. The reaction mixture was
extracted with ethyl ether twice. The organic layer was concentrated under vacuum and purified
by flash chromatography using ethyl acetate in hexanes (0-40%). The reduced form of 2a was
sulfated by method described previously in this chapter (see Appendix, Page 250 for NMR
spectra).
2a-reduced: 1H NMR (CDCl3, 300 MHz) δ 2.75 (s, 3H), 3.96 (s, 3H), 5.58 (s, 2H), 6.98 (s, 1H),
7.36 (s, 1H).
6: 1H NMR (CD3OD, 300 MHz) δ 2.61 (s, 3H), 3.86 (s, 3H), 6.88 (s, 2H), 7.15 (s, 1H), 7.86 (s,
1H).

13

C NMR (CD3OD, 300 MHz) δ 10.85, 55.78, 59.93, 95.76, 110.69, 112.67, 120.71,

138.55, 150.48, 151.65, 154.22.

Synthesis of 7 from 3a

To a solution of 3a (0.5 mmol) in toluene was added lithium aluminum hydride (4 mmol) and
stirred for 4 hours at RT. The reaction was quenched by adding water. The reaction mixture was
extracted with ethyl ether twice. The organic layer was concentrated under vacuum and purified
by flash chromatography using ethyl acetate in hexanes (0-40%). The reduced form of 3a is
sulfated by method described previously in this chapter (see Appendix, Page 250 for NMR
spectra).
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3a-reduced: 1H NMR (CDCl3, 300 MHz) δ 0.44 (s, 6H), 1.02 (s, 9H), 2.75 (s, 3H), 3.96 (s, 3H),
5.58 (s, 2H), 6.98 (s, 1H), 7.36 (s, 1H). 13C NMR (CDCl3, 300 MHz) δ 4.48, 12.29, 18.70, 26.02,
55.88, 56.04, 95.47, 109.94, 114.31, 120.84, 142.03, 149.32, 149.40, 151.81.
7: 1H NMR (CD3OD, 300 MHz) δ 0.44 (s, 6H), 1.02 (s, 9H), 2.75 (s, 3H), 3.96 (s, 3H), 6.68 (s,
2H), 6.98 (s, 1H), 7.36 (s, 1H). 13C NMR (CD3OD, 300 MHz) δ 4.48, 12.29, 18.70, 26.02, 55.88,
56.04, 95.47, 109.94, 114.31, 120.84, 142.03, 149.32, 149.40, 151.81.

Synthesis of 10 from 4a

To the solution of 4a (0.3 mmol) in DMF was added Morpholine (0.4 mmol) and cesium
carbonate (0.4 mmol) and stirred for 8 hrs at RT. The reaction was quenched by adding
methylene chloride and extracted with brine. The organic layer was concentrated and purified by
flash chromatography using ethyl acetate in hexanes (0-40%). To the solution of intermediate 4a1 (0.3 mmol) in DMF (3 mL) were added KF (4 mmol) and acetic acid (10 µL). The reaction
mixture was stirred for 5 hours. The reaction was quenched by methylene chloride and extracted
with brine solution. The organic layer was combined and dried over magnesium sulfate and
concentrated. The solid was precipitated using methanol to obtain intermediate 4a-2 in 90%
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yield. Compound 10 was obtained by the sulfation reaction previously described (see Appendix,
Page 252 and 255 for NMR spectra)
4a-1: 1H NMR (CDCl3, 400 MHz) δ 1.44 (t, J=18 Hz, 4H), 2.63 (s, 4H), 3.74 (s, 4H), 4.11 (s,
2H), 4.39 (q, J=18 Hz, 3H), 7.02 (s, 1H), 7.48 (s, 1H).
4a-2: 1H NMR (CDCl3, 400 MHz) δ 1.45 (t, J=18 Hz, 3H), 2.67 (m, 4H), 3.76 (m, 4H), 3.94 (s,
3H), 4.15 (s, 2H), 4.40 (q, J=18 Hz, 3H), 7.03 (s, 1H), 7.48 (s, 1H).
10: 1H NMR (D2O, 400 MHz) δ 1.47 (t, J=18 Hz, 3H), 2.71 (m, 4H), 3.81 (m, 4H), 3.95 (s, 3H),
4.02 (s, 2H), 4.39 (q, J=18 Hz, 2H), 7.25 (s, 1H), 7.74 (s, 1H).

13

C NMR (D2O, 400 MHz) δ

13.45, 52.47, 52.64, 56.34, 61.82, 66.07, 96.24, 111.83, 114.82, 117.14, 137.95, 150.45, 151.64,
159.30, 164.77. ESI HRMS (-ve) m/z calcd. for C17H20NO9SNa [(M-Na)-)] 414.0933, found
414.0847 (M-Na)-.

Synthesis of 13 from 4a
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To a solution of 4a-2 (0.3 mmol) and 4a (0.4 mmol) in ethyl acetate (4 mL) were added cesium
carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred under
nitrogen for 15 hours at room temperature. The reaction was quenched with methylene chloride
and extracted with brine. The organic layer was dried over magnesium sulphate and
concentrated. Purification was done by using flash chromatography on silica gel using 0-70%
ethyl acetate in hexanes. The product 4a-3 was obtained in 60% yield. The deprotection step
followed by sulfation (performed as explained previously) yielded the product 13 (see Appendix,
Page 252 and 266 for NMR spectra).
4a-3: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.03 (s, 9H), 1.39 (m, 6H), 2.62 (m, 4H), 3.65
(m, 4H), 3.73 (s, 3H), 3.82 (s, 3H), 4.36 (m, 6H), 5.61 (s, 2H), 7.00 (s, 1H), 7.06 (s, 1H), 7.45 (s,
1H), 7.62 (s, 1H).
4a-3 (deprotected form): 1H NMR (CDCl3, 400 MHz) δ 1.38 (m, 6H), 2.60 (m, 3H), 3.71 (m,
4H), 3.91 (s, 3H), 3.93 (s, 3H), 4.37 (m, 6H), 5.62 (s, 2H), 7.02 (s, 1H), 7.05 (s, 1H), 7.49 (s,
1H), 7.59 (s, 1H).
13: 1H NMR (CD3OD, 400 MHz) δ 1.38 (m, 6H), 2.60 (m, 3H), 3.71 (m, 4H), 3.91 (s, 3H), 3.93
(s, 3H), 4.37 (m, 6H), 5.62 (s, 2H), 7.02 (s, 1H), 7.05 (s, 1H), 7.49 (s, 1H), 8.01 (s, 1H). ESI MS
(-ve) m/z calcd. for C30H32NO14SNa [(M-Na)-)] 659.14, found 659.15 (M-Na)-.
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Synthesis of 16 from 11a

To a solution of 11a (200 mg, 0.32 mmol) in 10 mL of dry THF was added LiAlH4 (65 mg, 1.6
mmol) and stirred for 6 hours under nitrogen. After completion, the reaction was quenched by
adding 30 mL of water and extracted with 100 mL of ethyl ether twice. The organic layer was
concentrated down and purified with flash chromatography using ethyl acetate in hexanes (050%). The reduced form of 11a was sulfated using the general sulfation procedure explained
previously (see Appendix, Page 270 for NMR spectra).
11a-reduced: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 2.71 (s, 3H), 3.87 (s,
3H), 3.91 (s, 3H), 5.51 (s, 2H), 5.55 (s, 2H), 5.60 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H,), 7.42 (s, 1H),
7.55 (s, 1H).
16. 1H NMR (CD3OD, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 2.71 (s, 3H), 3.87 (s, 3H), 3.91 (s,
3H), 5.51 (s, 2H), 6.65 (s, 2H), 6.69 (s, 2H), 7.01 (s, 1H), 7.04 (s, 1H), 7.37 (s, 1H), 7.45 (s, 1H).
13

C NMR (CDCl3, 300 MHz) δ 4.47, 12.31, 18.70, 26.00, 55.45, 55.81, 55.94, 56.58, 94.60,

95.48, 103.35, 114.35, 118.34, 120.39, 121.24, 142.32, 142.65, 144.82, 148.21, 149.73, 152.05.
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Synthesis of 17 from 4a and 1a

To a solution of 1a (0.3 mmol) and 4a (0.4 mmol) in ethyl acetate (4 mL) were added cesium
carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred under
nitrogen for 15 hours at room temperature. The reaction was quenched with methylene chloride
and extracted with brine. The organic layer was dried over magnesium sulfate and concentrated
in vacuo. Purification was done by using flash chromatography on silica gel using (0-70) % ethyl
acetate in hexanes. The product 4a-4 was obtained in 60% yield. The deprotection step followed
by the sulfation step (performed as explained previously) yielded the product 17 (see Appendix,
Page 264 and 275 for NMR spectra).
4a-4: 1H NMR (CDCl3, 400 MHz) δ 0.03 (s, 6H), 0.04 (s, 6H), 0.96 (s, 9H), 0.97 (s, 9H), 1.36
(m, 6H), 2.72 (s, 3H), 3.81 (s, 3H), 4.15 (m, 4H), 5.34 (s, 2H), 6.78 (s, 1H), 6.80 (s, 1H), 7.22 (s,
1H), 7.37 (s, 1H).
Deprotected 4a-4: 1H NMR (CDCl3, 400 MHz) δ 1.36 (m, 6H), 2.70 (s, 3H), 3.86 (s, 3H), 4.35
(m, 4H), 5.54 (s, 2H), 6.98 (s, 1H), 7.00 (s, 1H), 7.42 (s, 1H), 7.57 (s, 1H).
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17: 1H NMR (D2O, 400 MHz) δ 1.23 (m, 6H), 2.36 (s, 3H), 3.70 (s, 3H), 4.18 (m, 4H), 5.23 (s,
2H), 6.96 (s, 1H), 7.03 (s, 1H), 7.53 (s, 1H), 7.62 (s, 1H).

13

C NMR (D2O, 400 MHz) δ 13.4,

13.51, 13.59, 56.30, 61.53, 62.08, 63.51, 96.28, 99.06, 108.05, 111.73, 114.48, 115.06, 117.13,
119.54, 138.31, 138.82, 147.96, 150.23, 150.94, 152.02, 158.07, 164.50, 164.87, 165.60. ESI
HRMS (-ve) m/z calcd. for C25H22O14S2Na [(M-Na)-)] 665.0121, found 665.0366 (M-Na)-.

Synthesis of 8a & 8b from 3a

To a solution of trimethyl aluminum (1.5 mmol) in THF was added Morpholine or 4-methyl
Piperidine (1.5 mmol). The solution was stirred for 1 hour at RT. The solution of 3a (1 mmol) in
THF was added to drop wise to the above solution over the time of 30 mins. The reaction
mixture was stirred at 70 oC for 24 hours. The reaction was quenched by adding ethyl acetate and
extracted with brine. The organic layer was concentrated and purified by flash chromatography
using ethyl acetate and hexanes (0-70 %) (See Appendix, Page 256 for NMR spectra).
8a: 1H NMR (CDCl3, 400 MHz) δ 0.13 (s, 6H), 1.00 (s, 9H), 2.48 (s, 3H), 3.64 (m, 8H), 3.78 (s,
3H), 6.84 (s.1H), 6.93 (s, 1H).
8b: 1H NMR (CDCl3, 400 MHz) δ 0.11 (s, 6H), 0.97 (d, J=18 Hz, 3H), 0.98 (s, 9H), 1.65 (m,
4H), 2.44 (s, 3H), 2.88 (m, 2H), 2.98 (m, 2H), 3.80 (s, 3H), 6.86 (s, 1H), 6.93 (s, 1H).
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Synthesis of 9a and 9b

The deprotection step followed by the sulfation step (performed as explained previously) yielded
the product 9a and 9b (see Appendix, Page 248 for NMR spectra).
8a-1: 1H NMR (CDCl3, 400 MHz) δ 2.48 (s, 3H), 3.69 (m, 8H), 3.91 (s, 3H), 6.91 (s, 1H), 6.94
(s, 1H).
8b-1: 1H NMR (CDCl3, 400 MHz) δ 0.97 (d, J=18 Hz, 3H), 1.67 (m, 4H), 2.46 (s, 3H), 2.88 (m,
2H), 2.98 (m, 2H), 3.80 (s, 3H), 6.86 (s, 1H), 6.93 (s, 1H).
9a: 1H NMR (D2O, 400 MHz) δ 2.47 (S, 3H), 3.55-3.90 (m, 8H), 3.91 (s, 3H), 7.25 (s, 1H), 7.41
(s, 1H).

13

C NMR (D2O, 400 MHz) δ 12.48, 42.76, 47.82, 56.43, 66.41, 66.79, 96.68, 110.52,

112.70, 118.31, 137.35, 149.74, 151.36, 156.79, 166.23. ESI HRMS (-ve) m/z calcd. for
C15H16NO8SNa [(M-Na)-)] 370.0544, found 370.0652 (M-Na)-.
9b: 1H NMR (D2O, 400 MHz) δ 0.89 (d, J=17 Hz, 3H), 1.01 (m, 1H), 1.61-1.81 (m , 4H), 2.39
(s, 3H), 2.92 (m, 1H), 3.08 (m, 1H), 3.56 (m, 1H), 3.92 (s, 3H), 4.45 (m, 1H), 7.27 (s, 1H), 7.64
(s, 1H).

13

C NMR (D2O, 400 MHz) δ 12.47, 12.55, 14.88, 20.89, 30.17, 55.67, 56.59, 96.67,

111.46, 112.63, 118.67, 137.67, 149.82, 151.26, 155.45, 165.32. ESI HRMS (-ve) m/z calcd. for
C17H20NO7SNa [(M-Na)-)] 482.1022, found 382.0847 (M-Na)-.
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Synthesis of 14 from 8a

To a solution of 8a (1 mmol) in THF (20 mL) was added NBS (1 mmol) and the mixture was
refluxed at 65 oC under a halogen lamp for 1 hour. The reaction mixture was cooled and
extracted using hexanes and water. The organic layer was concentrated and product 8a-Br was
obtained in 90% yield.
To a solution of 8a-1 (0.3 mmol) and 8a-Br (0.4 mmol) in ethyl acetate (4 mL) were added
cesium carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred
under nitrogen for 15 hours at room temperature. The reaction was quenched with methylene
chloride and extracted with brine. The organic layer was dried over magnesium sulphate and
concentrated in vacuo. Purification was done by using flash chromatography on silica gel using
(0-70) % ethyl acetate in hexanes. The product 4a-4 was obtained in 60% yield. The deprotection
step followed by the sulfation step (performed as explained previously) yielded the product 14
(see Appendix, Page 268 and 276 for NMR spectra).
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8a-Br: 1H NMR (CDCl3, 400 MHz) δ 0.14 (s, 6H), 1.01 (s, 9H), 3.72 (m, 8H), 3.85 (s, 3H), 4.69
(s, 2H), 6.85 (s, 1H), 6.99 (s, 1H).
8a-2:1H NMR (CDCl3, 400 MHz) δ 0.14 (s, 6H), 1.01 (s, 9H), 2.49 (s, 3H), 3.74 (m, 16H), 3.85
(s, 3H), 3.87 (s, 3H), 5.24 (s, 2H), 6.90 (s, 1H), 7.00 (s, 1H), 7.02 (s.1H), 7.11 (s, 1H).
8a-2 (deprotected form): 1H NMR (CDCl3, 400 MHz) δ 2.48 (s, 3H), 3.74 (m, 16H), 3.87 (s,
3H), 3.96 (s, 3H), 5.25 (s, 2H), 6.99 (s, 1H), 7.04 (s, 1H), 7.09 (s.1H), 7.12 (s, 1H).
14: 1H NMR (D2O, 400 MHz) δ 2.40 (s, 3H), 3.24 (m, 8H), 3.67 (m, 8H), 3.81 (s, 3H), 3.92 (s,
3H), 5.30 (s, 2H), 6.85 (s, 1H), 7.14 (s, 1H), 7.33 (s,1H), 7.43 (s, 1H). 13C NMR (D2O) δ 12.36,
42.55, 56.00, 56.40, 63.52, 66.17, 66.36, 96.23, 96.73, 107.16, 110.44, 113.33, 115.29, 116.94,
117.92, 138.10, 143.04, 148.81, 149.45, 151.21, 151.81, 152.46, 156.38, 164.20, 165.93. ESI
HRMS (-ve) m/z calcd. for C30H31N2O13SNa [(M-Na)-)] 659.1422, found 659.1531 (M-Na)-.

Synthesis of 18 from 1a

The protection of the free phenolic groups of 1a with TBDMSCl (as per procedure for synthesis
of 3a ̶ 3f) followed by the introduction of the bromo group (as per procedure for synthesis of 4a ̶
4f) leads to synthesis of intermediate 1a-2. Coupling intermediate 1a-2 with 2a using the
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procedure described above (synthesis of 5a ̶ 5f) leads to formation of intermediate 1a-3. The
deprotection step followed by the sulfation step (performed as explained previously) yielded the
product 18 (see Appendix, Page 256, 260, 266 and 280 for NMR spectra).
1a-1: 1H NMR (CDCl3, 400 MHz) δ 0.12 (s, 12H), 1.05 (s, 18H), 1.37 (t, J=18 Hz, 3H), 2.71 (s,
3H), 4.40 (q, J=18 Hz, 2H), 6.95 (s, 1H), 7.30 (s, 1H).
1a-2: 1H NMR (CDCl3, 400 MHz) δ 0.10 (s, 12H), 1.05 (s, 18H), 1.34 (t, J=18 Hz, 3H), 4.21 (q,
J=18 Hz, 2H), 6.99 (s, 1H), 7.23 (s, 1H).
1a-3: 1H NMR (CDCl3, 400 MHz) δ 0.04 (s, 6H), 0.09 (s, 6H), 1.01 (s, 9H), 1.05 (s, 9H), 1.43
(m, 6H), 2.62 (s, 3H), 3.81 (s, 3H), 4.15 (m, 4H), 5.34 (s, 2H), 6.88 (s, 1H), 6.96 (s, 1H), 7.22 (s,
1H), 7.37 (s, 1H).
1a-3 (deprotected form): 1H NMR (CDCl3, 400 MHz) δ 1.35 (m, 6H), 2.71 (s, 3H), 3.84 (s,
3H), 4.37 (m, 4H), 5.52 (s, 2H), 6.98 (s, 1H), 7.12 (s, 1H), 7.35 (s, 1H), 7.47 (s, 1H).
18: 1H NMR (D2O, 400 MHz) δ 1.55 (t, J=18 Hz, 3H),1.59 (t, J=18 Hz, 3H), 2.41 (s, 3H), 3.81
(s, 3H), 4.18 (q, J=18 Hz, 2H), 4.23 (q, J=18 Hz, 2H), 5.18 (s, 2H), 6.71 (s, 1H), 6.89 (s, 1H),
7.65 (s, 1H), 7.91 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.47, 13.61, 13.63, 56.32, 61.53, 62.18,
63.61, 96.28, 99.16, 108.01, 111.53, 114.48, 115.06, 117.13, 119.54, 138.31, 138.82, 147.96,
150.23, 150.84, 152.12, 158.17, 164.53, 164.77, 165.60. ESI HRMS (-ve) m/z calcd. for
C25H22O14S2Na [(M-Na)-)] 665.0121, found 665.0277 (M-Na)-.
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Synthesis of 19

To a solution of 2a’ (0.3 mmol) and 4a (0.4 mmol) in ethyl acetate (4 mL) were added cesium
carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred under
nitrogen for 15 hours at room temperature. The reaction was quenched with methylene chloride
and extracted with brine. The organic layer was dried over magnesium sulphate and concentrated
in vacuo. Purification was done by using flash chromatography on silica gel using 0-70% ethyl
acetate in hexanes. The product 2a’-1 was obtained in 60% yield. The deprotection step followed
by the sulfation step (performed as explained previously) yielded the product 19 (see Appendix,
Page 270 and 277 for NMR spectra).
2a’: 1H NMR (CDCl3, 300 MHz) δ 1.48 (t, J=6 Hz, 3H), 2.75 (s, 3H), 3.94 (s, 3H), 4.40 (q, J=6
Hz, 2H, CH2), 7.03 (s, 1H), 7.43 (s, 1H).
2a’-1: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.01 (s, 9H), 1.41 (m, 6H), 2.70 (s, 3H), 3.83
(s, 3H), 3.92 (s, 3H), 4.39 (m, 4H), 5.60 (s, 2H), 6.99 (s, 1H), 7.21 (s, 1H), 7.43 (s, 1H), 7.44 (s,
1H).13C NMR (CDCl3) δ 4.50, 14.46, 14.63, 14.78, 18.72, 25.97, 55.97, 56.62, 60.42, 60.93,
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63.47, 95.47, 98.39, 103.77, 109.21, 112.25, 112.73, 117.90, 119.98, 143.29, 146.34, 147.95,
148.08, 150.20, 150.99, 157.66, 162.77, 164.07, 164.79.
2a’-1 (deprotected form): 1H NMR (CDCl3, 300 MHz) δ 1.43 (t, J=6 Hz, 6H), 2.72 (s, 3H),
3.92 (s, 6H), 4.39 (m, 4H), 5.60 (s, 2H), 7.00 (s, 1H), 7.19 (s, 1H), 7.41 (s, 1H), 7.44 (s, 1H). 13C
NMR (CDCl3) δ 14.57, 14.63, 14.77, 56.52, 56.65, 60.42, 61.01, 63.57, 94.71, 98.55, 103.83,
106.24, 109.21, 112.35, 118.39, 120.08, 143.81, 146.34, 147.95, 148.12, 149.07, 157.99, 162.82,
164.06, 164.80.
19: 1H NMR (CDCl3, 300 MHz) δ 1.39 (m, 6H), 2.67 (s, 3H), 3.85 (s, 3H), 3.88 (s, 3H), 4.36 (m,
4H), 5.55 (s, 2H), 7.22 (s, 1H), 7.23 (s, 1H), 7.43 (s, 1H), 8.07 (s, 1H). 13C NMR (CD3OD, 300
MHz) δ 13.25, 13.38, 13.52, 55.66, 55.77, 60.25, 60.79, 63.16, 95.63, 99.17, 103.95, 108.76,
112.48, 115.58, 117.27, 120.11, 139.90, 146.40, 148.00, 148.45, 152.15, 152.23, 158.27, 163.04,
163.59, 164.61. ESI HRMS (-ve) m/z calcd. for C26H25O13SNa [(M-Na)-)] 577.1011, found
577.1100 (M-Na)-.

3.4.3 Determination of Purity by HPLC Method:
HPLC purification was carried out on a Jasco chromatography system using a Varian Dynamax
microsorb C4 column of size 250*10 mm. The mobile phase consisted of acetonitrile – water
mixture run at a constant flow rate of 3 mL/min. Absorbance was recorded by a Jasco MD-2010
plus UV-VIS detector at 300 nm. The following HPLC method was used:
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Table 5. Method used for purity determination
Time

Solvent A (water)

Solvent B (Acetonitrile)

0

95%

5%

5

95%

5%

15

50%

50%

20

0%

100%

25

0%

100%

30

95%

5%

95

Table 6. Purity of compounds synthesized
Compound
5a
5b
5c
5d
5e
5f
5g
5h
5i
5j
9a
9b
10e
12a
12b
12c
12d
12e
12f
13
14
15
17
18
19

Retention time (mins)
16.21
15.38
16.64
14.69
15.85
16.32
12.23
11.60
16.31
16.04
11.22
11.72
13.34
12.72
12.01
13.37
11.20
12.97
13.50
10.34
11.1
8.01
8.34
8.61
12.65
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% purity
98.12
98.09
98.56
96.56
98.34
97.87
78.11
76.85
95.15
98.08
98.27
97.59
98.52
99.01
96.64
96.22
95.37
99.05
97.52
98.43
98.15
99.13
97.59
98.36
98.27

Chapter 4 Identification of a Novel Binding Site for Allosteric Regulation of Thrombin

4.1 Introduction
In this work, we present the enzyme inhibition and Michaelis-Menten kinetic studies for
the library of sulfated benzofuran monomers and dimers, synthesized as described in an earlier
chapter, that display a range of inhibition potentials and an allosteric mechanism of inhibition. In
this study, we also propose a binding site for sulfated benzofuran dimers (SBDs) based on
detailed biochemical studies on the interaction of one of the potent SBDs with thrombin
combined with molecular modeling techniques. This will encourage for further rational structurebased drug design. Our work reveals that the SBD interacts with exosite II of thrombin, but in a
manner dramatically different from all previously known exosite II ligands, including full-length
heparin, heparin octasaccharide, sucrose octasulfate, γ’-fibrinogen peptide, and sulfated LMWLs.
The identification of a new site of binding on thrombin together with the molecular size, the
novelty of inhibitor structures, the nature of their inhibition and allosteric modulation of
thrombin, may lead to a powerful alternative to the competitive inhibitors approved to date. This
work puts forward a distinct direction in the terms of the site of binding and thrombin inhibitor
structures that will re-direct the search for allosteric modulators of coagulation enzymes,
especially thrombin.
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4.2 Results
4.2.1 Thrombin Inhibition Potential of Designed Sulfated Benzofuran Monomers and
Dimer
Inhibition of thrombin by the designed benzofurans (in Chapter 3) was measured through
Spectrozyme TH hydrolysis assay, as described earlier.213, 214 This assay relies on the decrease in
the initial rate of substrate hydrolysis in the presence of the sulfated benzofuran derivative as a
quantitative measure of the inhibition. The fractional decrease in the initial rate of hydrolysis
typically shows a sigmoidal profile on a semi-log plot, which is then fitted by a dose – response
equation 1 (see experimental section 4.4.2) to derive IC50, HS, Y0 and YM parameters for each
potential inhibitor.
Figure 18 shows the semi-log inhibition curves observed for selected benzofuran
monomers and dimers from the library shown in Figure 17 (See Chapter 3). Of the 28 potential
inhibitors studied in this work, only 11 molecules exhibited reasonable inhibition of human αthrombin at pH 7.4 and 25 °C. These included the sulfated monomer 5i and dimers 12a – 12f, 13,
and 17 – 19 (Tables 7 and 8). Within this group, inhibitors 12b, 12c, and 12f were the only
molecules exhibiting IC50 less than 50 µM. The t-butyl derivative 12c was found to be the most
potent thrombin inhibitor with an IC50 of 7.3 µM under physiologically relevant conditions.
The range of inhibition efficacy was found to vary considerably with the structure of the
inhibitor. For example, the sulfated dimer 12e displayed essentially complete inhibition of
thrombin (95%, Table 8), while dimer 15 with two carboxylic acid groups inhibited to the extent
of only 14% (Table 8). Nearly 85% of the inhibitors displayed 60% or more thrombin inhibition
suggesting good overall efficacy for sulfated benzofurans.
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Fractional Residual
Thrombin Activity

1
0.8
5e
5i
12a
12c
15
19

0.6
0.4
0.2
-6.5

-5.5

-4.5

-3.5

-2.5

-1.5

log [Inhibitor]0 (M)
Figure 18. Direct inhibition of thrombin by designed sulfated benzofuran monomers and dimers.
The inhibition of human thrombin was determined spectrophotometrically through a
Spectrozyme TH hydrolysis assay at pH 7.4 and 25 °C. Solid lines represent sigmoidal fits to the
data to obtain IC50, YM, and YO (equation 1), as described in the experimental section (4.4.2).

Comparison of the two series of benzofuran molecules shows that dimers tend to inhibit
thrombin several-fold better than monomers. Of the 15 sulfated monomers studied in this work
and 17 sulfated and unsulfated monomers studied earlier,218 only 5i inhibited thrombin with
measurable potency (~500 µM, Table 7). By contrast, most sulfated dimers displayed thrombin
inhibition (Table 8). This suggested that larger scaffolds may exhibit higher potency. This also
rationalizes the nanomolar potency observed for sulfated LMWL inhibition of thrombin.213
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Table 7. Inhibition of Human α-Thrombin by Sulfated Benzofuran Monomers
R

R’

log IC50 (M)

IC50 (µM)

∆Y

OCH2CH3
OCH3
OC(CH3)3
OCH2 CH2OCH3

CH3
CH3
CH3
CH3

ndb

>2500c

0.60

5g
5h

OCH2CH3
OCH2CH3
OCH2CH3

-1.9±0.3
nd
nd
-3.3±0.2
nd

13650±10400
>16000c
>25,000c
520±280
>3000

0.75
-

5i
5j

CH2CH3
CH(CH3)2
CH2OCH3
Morpholine-4-carbonyl
Benzoyl-p-methoxy

>3000c
>3000c
>2000c
20560±8500

5f

OCH2CH3
OCH2CH3

nd
nd
nd
-1.7±0.2d

5a
5b
5c
5d
5e

OCH2CH=CH2
N-morpholino
N-piperidino

CH3
CH3

0.54
-

nd
>2000c
nd
>2000c
9b
CH3
e
c
nd
>7000
10 CH2CH3
CH3
a
Thrombin inhibition was measured in spectrophotometric assay through initial rate of
Spectrozyme TH hydrolysis as described in Experimental section. bNot determined due to
incomplete and/or poor inhibition. cEstimates on the basis of the highest concentration used in
experiment. dstandard error shown is ±1 S.E. e10 contains a morpholine group at the allylic
position (instead of a –CH3 group).
9a
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Table 8. Inhibition of Human α-Thrombin by Sulfated Benzofuran Dimers

12a
12b
12c
12d
12e
12f
13
14
15
17
18
19

R

R’

log IC50 (M)

IC50 (µM)

∆Y

OCH2CH3
OCH3
OC(CH3)3
OCH2 CH2OCH3
OCH2CH3
OCH2CH3
nac
N-morpholino
OH
nac
nac
nac

CH3
CH3
CH3
CH3
CH2CH3
CH(CH3)2
Na
CH3
CH3
Na
Na
Na

-4.22±0.16b
-4.43±0.12
-5.14±0.18
-3.42±0.13
-3.92±0.05
-4.52±0.19
-3.89±0.20
Incompleted
-3.43±0.37
-3.12±0.35
-3.44±0.06
-4.05±0.26

60±22
37±11
7.3±3.1
375±109
121±14
30±13
129±60
>7100
~374e
~764e
365±57
89±54

0.75
0.68
0.84
0.80
0.95
0.72
0.62
nac
0.14
0.95
0.79
0.70

a

Thrombin inhibition was measured in spectrophotometric assay through initial rate of
Spectrozyme TH hydrolysis as described in Experimental section. bstandard error shown is ±1
S.E. cNot applicable. See complete structures of 13, 14, 15, 17, 18 and 19 in Figure 17. dFull
inhibition profile was not measured. eThe error in IC50 could not be accurately defined because
of insufficient number of data points.

The distinct groups at the 2, 3, 5 and 6- positions on the benzofuran ring result in
interesting structure–activity relationships. The sulfate group at the 5- position was found to be
the key basis for thrombin inhibition, since all unsulfated precursors studied in this work,
monomers as well as dimers, did not inhibit thrombin. Such a high level of dependence on one
sulfate group is striking. It also appears to be unusual because thrombin is known to be
considerably forgiving in recognizing ligands. For example, ligands as different as heparin and
RNA are known to bind in exosite II.224, 225 Similarly, hirudin, which contains a sulfated tyrosine,
as well as de-sulfated hirudin, i.e., desirudin, binds in exosite I with excellent affinities.79, 209, 226
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The stringent requirement for 5-sulfate led to the expectation that multiple sulfate groups
on the benzofuran scaffold may induce higher potency. Yet, dimers 17 and 18, which bear two
sulfate groups (5 and 5’, and 5 and 6- positions, respectively) inhibited thrombin approximately
6–17-fold weaker (Table 8). Furthermore, the IC50 of 15, which contains the 5-sulfate as well as
a carboxylate at each of the 3- positions of the benzofuran rings, also decreases 6.2-fold from its
parent 12a. This implies that any additional anionic group on the benzofuran scaffold is counterproductive, which is contrary to what one would predict on the basis of the thrombin – heparin
system.212, 224, 226
Comparison of the IC50s of 12a, 12b and 12c shows that as lipophilicity of the 3-ester
increases, the inhibition potency improves 8.2-fold (Table 8). Likewise, change in substitution
from ethyl to isopropyl at the 6- position, as in 12e and 12f, also increases the potency nearly 4fold. This implies that hydrophobicity of the scaffold plays an important role in thrombin
recognition. In support of this, increase in hydrophilicity of groups markedly decreases potency.
For example, the 3-methoxyethyl ester containing 12d is a 6.2-fold weaker inhibitor of thrombin
than the 3-ethyl containing 12a (Table 8). More importantly, introduction of an N-morpholinyl
ring (dimer 14) increased IC50 to >2000 µM, which represents a more than 270-fold loss of
affinity from a comparable t-butyl ester containing dimer 2c.
While the above discussion suggests fairly stringent structural requirements on the
benzofuran scaffold, two interesting results highlight the possible variances. Dimer 13 containing
a morpholine ring at the 2-allylic position displays IC50 of 129 µM, which is only 2.2-fold higher
than that of 12a. This suggests that introduction of a hydrophilic and sterically bulkier group at
the terminus opposite the 5-sulfate is not detrimental. Likewise, dimer 19 displays no change in
IC50 from its comparable parent 12a (Table 8). Dimer 19 contains a 2-CH2O-6 inter-monomeric
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linkage as compared to a 2-CH2O-5 linkage present in dimer 12a. An essentially identical
inhibition potency of 19 as compared to 12a indicates that a change as drastic as a ring flip, or
regioisomerism, is well tolerated.

4.2.2 Mechanism of Thrombin Inhibition By Sulfated Benzofuran Dimer 12a
To elucidate the nature of thrombin inhibition by the designed sulfated benzofurans, the
kinetics of Spectrozyme TH hydrolysis by thrombin at pH 7.4 in the presence and absence of 12a
was studied. Spectrozyme TH has been routinely used as a chromogenic substrate of thrombin.213
The initial rate of amidolysis as a function of the substrate concentration displayed a hyperbolic
profile, as expected (Figure 19), from which the Michaelis constant (KM) and maximal velocity
of the reaction (VMAX) were derived. The KM and VMAX for Spectrozyme TH in the absence of
12a was found to be 18.9 µM and 100 mAUmin-1µM-1, respectively. In the presence of 1.5, 3.0,
10.5 and 30 µM 12a, the KM of substrate was found to be 12.6 ± 4.7, 15.5 ± 5.5, 15.9 ± 7.4, and
15.5 ± 3.7 µM. In contrast, the VMAX was measured to be 97 ± 13, 107 ± 14, 73 ± 13 and 66 ± 6
mAUmin-1µM-1 in these experiments. This corresponds to ~34% decrease in maximal velocity of
reaction upon approximately 50% saturation of the enzyme. This suggests that the presence of
12a does not significantly affect the binding of the chromogenic substrate to the active site of the
enzyme, while significantly reducing its catalytic efficiency.
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Initial Rate of
Hydrolysis (mAU/min)

100
80
60
40

0 uM
3.0 uM
10.5 uM
30 uM

20
0
0

20

40

60

80

100

[Spectrozyme TH]0 (µM)
Figure 19. Michaelis-Menten kinetics of Spectrozyme TH hydrolysis by human thrombin in the
presence of dimer 12a. The initial rate of hydrolysis at various substrate concentrations was
measured spectrophotometrically in pH 7.4 buffer as described in ‘Experimental Procedures’.
The concentrations of 12a chosen for study include 0 (), 3.0 (), 10.5 (▲), and 30 µM ().
Solid lines represent non-linear regressional fits to the data by the standard Michaelis-Menten
equation to yield KM and VMAX.

The above Michaelis–Menten kinetics result indicates a non-competitive, allosteric
mechanism of thrombin inhibition by 12a and, by analogy, other sulfated benzofuran molecules.
The reduction in catalytic efficiency by these novel inhibitors is primarily brought about by the
slow conversion of the thrombin–Spectrozyme TH Michaelis complex, which may arise from the
intrinsic change in the rate of chemical reaction or by a change in the structure of the catalytic
triad induced by the allosteric inhibitors.
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4.2.3 Prolongation of Plasma Clotting Time by Sulfated Benzofurans
Two plasma clotting assays are typically used to assess the anticoagulant potential of
new coagulation inhibitors. These are the prothrombin and activated partial thromboplastin time
assays (PT and APTT, respectively), which attempt to measure the effect of an inhibitor on the
extrinsic and intrinsic flux of coagulation. The concentrations of the inhibitors required to double
the PT and APTT were measured, as described earlier for sulfated LMWLs.215,

216

The

prolongation of plasma clotting time as a function of the concentration of the sulfated
benzofurans followed a pattern typical of other well-studied anticoagulants (Figure 20), except
for the range of active concentrations. A 2-fold increase in PT required 850 – 2100 µM
concentration of 5i, 12a or 12b (Table 9). In a similar manner, the doubling of APTT required
355 – 1250 µM of 5i, 12a, 12c, or 12e (Table 9). Most other monomers or dimers were found to
be not effective. These results suggest that the designed small, sulfated benzofurans are about
100 – 250-fold less potent in human plasma than the oligomeric sulfated LMWLs from which
they were designed.216 This is not too unexpected considering that thrombin inhibition by the
smaller synthetic molecules is nearly 400-fold weaker than that of the parent oligomers. Yet,
interesting similarities and differences are discernible. For example, dimers are better
anticoagulants in plasma than monomers. Within the group of dimers 12a, 12c and 12e, which
inhibit thrombin well, are also the best in terms of prolonging APTT. Interestingly, 12b, which is
comparable to 12a in thrombin inhibition, does not affect APTT at all (Table 9) and the reason
for this behavior is not clear. Overall, the plasma studies suggest the feasibility of designing
sulfated benzofurans that will function as anticoagulants in vivo.
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Table 9.

Effect of Designed Sulfated Benzofurans on Human Plasma Clotting Time
APPT

PT

(µM)

(µM)

5i
5g

1,250
>1,200

1,200
neb

5c
12a
12b
12c

>2,000
740
>1,000
355

ne
2,100
850
ne

12d
12e
14

>1,000
530
>1,000

ne
ne
ndc

15

>1,000

ne

a

PT and APTT values were deduced in in vitro human plasma experiments where the clot
initiator is either thromboplastin or ellagic acid, respectively. See Methods for details. b no effect.
c
not determined.
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Clotting Time (sec)

A)
90
70
12c

50

12a
5i

30
0

0.4

0.8

1.2

1.6

[Sulfated Benzofuran]0 (mM)
Clotting Time (sec)

80

B)
60
40
12a

20

5i
12b

0
0

0.5

1

1.5

2

2.5

3

[Sulfated Benzofuran]0 (mM)
Figure 20. Prolongation of clotting time as a function of concentration of sulfated benzofuran
monomers and dimers in either activated partial thromboplastin time assay (A) or prothrombin
time assay (B). Solid lines are trend lines, and not non-linear regressional fits. Error bars in the
range of symbol size have been omitted. APTT and PT assays were performed as described in
the experimental section.
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4.2.4 Complementary Biochemical Studies (Studies performed by Dr. Aiye Liang and Ms.
May H. Abdel Aziz)
1) To test whether dimers bind in exosite I, competition studies with the hirugen analog,
[5F]-Hir[54-65](SO3-), were performed. The presence of [5F]-Hir[54-65](SO3-) did not
significantly affect the thrombin inhibition profiles indicating that the dimer does not
appear to bind in the anion-binding exosite I of thrombin.
2) To test whether dimers bind in exosite II, competition studies with three different exosite
II binding ligands; porcine unfractionated, heparin, H8, and γ’fibrinogen peptide were
performed. A distinct shift in the profiles is observed as the concentration of the
γ’fibrinogen peptide increases, suggesting full competition between the two ligands for
thrombin binding. This indicates that the dimer and γ’fibrinogen peptide compete for
exosite II of thrombin. However, no change in inhibition profile was observed with
increasing concentration of heparin octasaccharide H8 and a slight change in inhibition
profile was observed with heparin. This indicates that the dimer and H8 do not compete
with each other, whereas partial competition is observed with UFH.
3) To identify the basic residues that might play an important role in dimer recognition, we
studied the inhibition of five thrombin mutants containing single and triple replacements
of Arg/Lys to Ala. The dose – response profiles for three of the four single point mutants
(Arg175Ala, Lys169Ala, and Lys235Ala) and one triple mutant (Arg93, 97,101Ala)
studied in this work were essentially identical to the recombinant wild type enzyme. In
striking contrast, the Arg173Ala mutant displayed a 22-fold increase in IC50 compared to
the wild type enzyme, suggesting its importance for thrombin binding and inhibition by
12a and related sulfated benzofuran derivatives.
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4.2.5 Molecular Docking Identifies a Single Plausible Binding Geometry for 12a on
Thrombin
To identify a plausible binding geometry of sulfated benzofuran dimers on thrombin for
structure-based design, we employed a molecular docking and scoring approach. We have
previously utilized a similar approach using the automated docking routine GOLD to understand
how highly sulfated oligosaccharides recognize proteins.227, 228 This approach was also exploited
to study the recognition of antithrombin by sulfated LMWLs,229 which are the parent molecules
for the sulfated benzofuran dimers being studied here. Hence, we chose to employ a GOLDbased identification of plausible binding sites and geometries of 12a on human thrombin.
The GOLD-based docking and scoring approach utilizes a genetic algorithm (GA) to
iteratively derive the best binding geometry for each ligand in a pre-defined binding site. Our
recent work on the recognition of sulfated LMWLs binding to thrombin mutants revealed that
hydrophobic patches in the vicinity of Arg93 may be involved.230 Considering this, we
hypothesized that hydrophobic region(s) near Arg173, which has been implicated by the
Arg173Ala thrombin mutant studies presented here, would be important for recognition of 12a
and its related sulfated benzofurans. Several GA docking runs were thus performed to assess
how well 12a could be recognized by the binding site regions surrounding Arg173. Each docking
run was performed using a constraint that encouraged the guanidine group of Arg173 to
hydrogen bond with the sulfate group of SBD. Only one particular binding site was consistently
found to provide a surface complementary to 12a in which the ligand is bound in an extended,
flat conformation. This binding domain was located between Arg173 and the active site of
human thrombin, exhibits a high degree of shape complementarity with the ligand and consists
of hydrophobic areas suitable for recognizing the benzofuran rings and their substituents. To
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more rigorously test whether low occupancy, alternate binding site(s) are possible, a ‘diversedocking’ experiment was performed in which GOLD was forced to identify solutions with
alternative binding sites of 12a that differ by at least 1.5 Å from the binding mode described
above. With this directive, GOLD identified binding sites vastly different from that shown in
Figure 21 but with no complementarity to 12a. This was also reflected in very poor GOLD
scores for these alternative geometries. Additionally, the reproducibility of these geometries was
poor, suggesting that the algorithm was not able to converge on a plausible binding pose.
On the basis of these initial docking results as well as the FibP and Arg173Ala thrombin
studies described above, we concluded that the class of sulfated benzofuran dimers being studied
here do recognize this highly complementary domain. To test this prediction further, the library
of sulfated benzofuran dimers studied earlier was docked onto human thrombin.231 Three crystal
structures of human thrombin (PDB ID = 3EQ0, 1H8D and 2UUF)232,

233

with resolution

between 1.5 and 2.5 Å were used to test the consistency of binding of the entire library. Each
thrombin crystal structure was bound by both an active site inhibitor and a hirudin peptide in
exosite II. All of the residues within reach of an Arg173-associated SBD were completely
resolved in these three thrombin structures. Overall, the three structures were similar in terms of
the resolution of residues in exosite II (backbone RMSD = 0.2 Å; Figure 22).
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Figure 21. Connolly surface of thrombin (PDB ID = 3EQ0), showing the location of several
electropositive basic residues, including those contributing to exosite II and the γ‘-fibrinogen
peptide binding site (purple patches). The putative binding site and mode of the lead sulfated
benzofuran dimer 12a is rendered as a yellow surface and shows the high degree of shape
complementarity with its putative binding site. The thrombin light chain (yellow ribbon) and
hirudin peptide denoting the location of exosite-I (red ribbon) are also shown. B) The same 3D
image rotated by 90°, further highlighting the high degree of shape complementarity between the
ligand dimer and its proposed binding site. The active site is displayed with a hydropathic
potential map (blue = hydrophilic, green = amphipathic, brown = hydrophobic) with the
nucleophilic serine S195 shown as a red patch. The S1 and S4 substrate specificity pockets are
indicated; the hydrophobic S4 pocket is occluded because it is occupied by the ethyl group of the
3’-ethyl ester of 12a.
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Figure 22. GOLD
OLD binding site definitions for 3EQ0, 1H8D and 2UUF (22 Å radius about R173)
highlighting the conformational similarity among the three proteins. The thrombin heavy chain is
shown as a colored ribbon (red = helix, blue = sheet/strand, yellow = coil) and the
t residues are
rendered as capped sticks (white carbon atoms, 3EQ0; orange carbon atoms, 1H8D; green carbon
atoms, 2UUF). The inter-heavy
heavy chain backbone RMSD among the three proteins is 0.2 Å.

For the inhibitors studied as a part of the docking library, the binding site between
Arg173 and the active site was found to satisfy known thrombin inhibition characteristics. In
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addition, the GOLDScores of the compounds in the library showed a modest correlation with
their inhibitory activity; compounds with significant, minimal and no inhibitory activity were
effectively distinguished (Tables 10 and Figure 23). The docking pose of 12a onto 3EQ0
thrombin could be used explain interactions at an atomic level. For example, in this pose the 4sulfate group of 12a forms a bidentate hydrogen-bond with Arg173, which supports the
observation that all molecules devoid of 4-sulfate group are completely devoid of thrombin
inhibition activity.231 This consistency was expected due to the inclusion of the Arg173
hydrogen-bond docking constraint. In the proposed binding mode, the Arg173 side chain is in
fact surrounded by atoms of the first monomer: the sulfate group forms a double hydrogen-bond
salt bridge with the guanidinium group, the 3-ethyl ester group is in a sterically unhindered
region adjacent to the guanidinium group and may engage in pi-stacking interactions with it, and
the benzofuran core is closely associated with the alkyl portion of the Arg173 side chain.

Table 10. Comparison of GOLD scores obtained from docking studies and IC50 obtained from
experimental data.
Inhibitor
12a
12b
12c
12d
12e
12f
13
14
15

GoldScore
64.37
62.92
64.01
59.94
64.60
64.37
63.16
56.70
59.43
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IC50 (µM)
60±22
37±11
7.3±3.1
375±109
121±14
30±13
129±60
>7100
~374

4.5

r 2 = 0.76
4.0

3.5

pIC50

3.0

2.5

2.0

1.5

1.0

0.5
56

58

60

62

64

66

GoldScore

Figure 23. Scatter Plot of GOLDScore vs. pIC50 Values for Docked SBDs.
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Figure 24. Expanded view of the interaction of 12a with it putative binding site. The ligand is
rendered as a ball-and-stick figure and binding site residues rendered as capped sticks. All
binding site side chains within 5 Å of 12a are displayed. Hydrogen bonds between Arg173 and
the ligand sulfate group are shown as green dotted lines.

Additionally, the 3’-ethyl ester group on the second monomeric unit binds in a shallow
hydrophobic pocket lined by Asn98, Ile174, Ile176 and Trp215 (i.e., the S4 substrate specificity
pocket). Interaction of the 3’-ester group here is consistent with the higher potency of inhibitors
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12a, 12b, and 12c (see Table 11 for structures). As the hydrophobic character of groups at the 3’position increases, the potency possibly also increases because of more favorable interactions in
the hydrophobic S4 pocket. In contrast, inhibitors 12d, 14 and 15, which contains larger and/or
polar groups at this position have poorer thrombin inhibition potential.231

Table 11. Structure of sulfated benzofuran dimers 12a ̶ f and 13 ̶ 15 found to potently inhibit
human thrombin.

R’

R

R”

12a

-CH3

-OC2H5

-H

12b

-CH3

-OCH3

-H

12c

-CH3

-OC(CH3)3

-H

12d

-CH3

-OC2H4OCH3

-H

12e

-C2H5

-OC2H5

-H

12f

-CH(CH3)2

-OC2H5

-H

13

-CH3

-OC2H5

N-morpholino

14

-CH3

N-morpholino

-H

15

-CH3

-OH

-H

The 6-methoxy group of 12a is suggested to bind in a region lined by the amide
backbones of Arg175, Glu97A, and Ile174, whereas the 6’-methoxy group binds in region
formed largely by Asp217 and Lys224 side chains. Both these pockets appear to possess a
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combination of hydrophobic and polar properties and are significantly sterically unhindered,
which implies they can accommodate larger groups. In fact, the inhibition potency increases as
we move from 12a to 12b to 12c, which display increasing homologation at these positions.
The 2’-allylic position is located in an amphiphilic region near Trp215 between the S1
and S4 substrate binding pockets and is oriented toward S1. The model indicates that this region
is moderately sterically constrained, which helps us understand why inhibitor 13 containing a 2’morpholino ring substituent is essentially inactive. The larger and much more polar morpholine
ring at 2’-region is likely to prevent the SBD from binding in this pocket resulting in loss of
activity.
A key aspect of this binding geometry is that the benzofuran scaffold appears to be an
effective core structure because it places its substituents into stereoelectronically favorable
pockets on thrombin. It remains to be seen whether or not other planar hydrophobic scaffolds can
improve inhibitor potency. Thus, at present it is difficult to discount the value of benzofuran
rings to inhibition potency.

4.2.6 Screening Against Other Serine Proteases
The library of sulfated benzofuran monomers and dimers was screened against the panel
of coagulation proteases. It includes factors VIIa, IXa, Xa, XIa and XIIa, which are involved in
either the intrinsic or extrinsic pathways. The assay is based on hydrolysis of a chromogenic
substrate by the protease, the rate of which is decreased in the presence of inhibitor. Screening
was performed at single concentration of inhibitors using substrate hydrolysis assay in 96 wellplates. This assay is based on the decrease in the initial rate of substrate hydrolysis in the
presence of inhibitor. The decrease in initial rate of hydrolysis typically provides the fractional
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residual activity of enzyme. The details of experimental conditions are provided in the
Experimental Section (4.4.6).
Tables 12 and 13 show the percentage residual activity of all proteases at a final
concentration of 365 µM of each inhibitor. Seven representative monomers were selected to
cover a range of substitutions from hydrophobic to polar characteristics as well as the number of
sulfate groups. None of these monomers inhibited the factors VIIa, IXa, Xa and XII more than
20% at the concentration of 365 µM. This was expected as monomers showed very poor potency
for thrombin except 5i (IC50 ~ 500 µM). The inhibitor 5i was not able to inhibit any protease
except factor XIa greater than 20% at the given concentration. 5i completely inhibited factor XIa
at given concentration, showing its higher potency (Figure 25).
Similarly, seven representative molecules were selected from the library of dimers. None
of the dimers inhibited factors VIIa, IXa and XIIa greater than 30% at given concentration
showing selectivity of the designed benzofuran dimer derivatives against these proteases (Figure
26). The molecules 12a, 12e and 20 inhibited factor Xa activity more than 40%. It is
hypothesized that these molecules have the potential to inhibit factor Xa that moderates potency.
It has been observed from data on thrombin inhibition that a library of dimers was only able to
inhibit thrombin 60% or less. Beside factor Xa, 12e and 21 were also able to completely inhibit
factor XIa at the given concentration. The results are again consistent with the library of
monomers and dimers, which showed inhibition potential for both thrombin and factor XIa.
Thus, it can be concluded that sulfated benzofuran derivatives bind at a site that have high
homology in thrombin and factor XIa.
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Table 12. Residual activity of various proteases obtained by screening the library of monomers
Factor IXa

Factor Xa

Factor VIIa

Factor XIa

Factor XIIa

5c

92±2.7

73±3.9

102±4.2

92±3

100±2

5f

90±1.3

94±1.6

105±5.6

85±4

102±6

5g

104±7

101±5

96±4

96±3.5

104±4

5i

104±5.5

113±16

56±3.2

7±4.1

102±3.3

9a

127±9.9

104±7.8

97±3.2

100±3

105±6

9b

117±22

112±10

100±2.5

106±6

100±4

5j

121±9

106±8

75±3.5

65±3

90±2.5

Table -13. Residual activity of various proteases obtained by screening the library of monomers
Factor IXa

Factor Xa

Factor VIIa

Factor XIa

Factor XIIa

12a

81±3

61±2

100±3.5

88±2

100±3

12e

89±3

59±4

101±6

6±2

103±6

14

82±3.5

100±4

90±2

89±2

91±1

12d

96±6

114±17

83±3

77±1.6

94±5

15

91±4

101±3

91±2

85±4

94±5

20

82±3

57±3.5

87±1

103±6

96±5

21

83±2

108±10

85±2

51±3

104±5
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Figure 25.. Bar graph showing the % residual activity of given proteases at single concentration
of each inhibitor
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Figure 26. Bar graph showing the % residual activity of given proteases at single concentration
of each inhibitor
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4.3 Discussion
The range of thrombin inhibition potency and efficacy discovered for sulfated
benzofurans suggests that the designed sulfated benzofuran scaffold may be an excellent lead in
developing anticoagulants radically different from those studied to-date. The β-5 inter-monomer
linkage is only one of the many units present in sulfated LMWLs,213,

216

which implies that

computational structure-based design may be necessary to identify the most appropriate ‘small’
structure from the large number of potential molecules. One such strategy, e.g., combinatorial
virtual library screening, has been put forward for highly sulfated molecules228 and also been
found useful for sulfated lignins binding to antithrombin.234
This work presents small synthetic sulfated aromatic structures as novel allosteric
modulators of thrombin function. Allosteric exosite II-based modulators of thrombin are of
special interest because they afford the possibility of controlled inhibition of this key protease
that takes part in a number of physiological processes.79 Excess inhibition could, in principle, be
reversed by highly sulfated small molecules, e.g., sucrose octasulfate, that are also expected to
bind in this region without inducing significant reduction in thrombin’s catalytic activity.
Allosteric exosite II-mediated inhibitors with nanomolar potency, other than sulfated LMWLs,213
have not been designed as yet and thus, sulfated benzofurans represent first molecules in a new
class of thrombin modulators.
Although the potency of our first allosteric inhibitors is not high, it is not a major concern
because rational design of these molecules from the parent polymers invoked a rather drastic
reduction in molecular weight. Whereas sulfated LMWLs are oligomeric chains with an average
molecular weight of 5000, sulfated benzofurans range from 500 to 1000.215 Thus, a relatively
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easy approach to higher potency would be to prepare appropriate tri- and tetramers of sulfated
benzofurans.
This work suggests that SBDs utilize a hydrophobic cavity, which overlaps with the S4
binding pocket (see Figure 21). Although designed as mimetics of heparin, SBDs do not engage
the traditional exosite II ligand residues including Arg101, Arg126, Lys235, Lys236 and Lys240.
SBDs recognize Arg173, a heparin-binding residue. Yet, the predicted binding mode and
orientation of 12a (see Figure 21 and 24) is likely to be dramatically different from that of
polymeric heparin with its chain oriented along the highly electropositive surface.224 In fact, 12a
binds in a region different from that predicted for sulfated LMWLs, which appear to bind in a
linear hydrophobic segment present in exosite II on either sides of residues Arg93 and
Arg101.235 The competition of 12a with FibP coupled with the known structure of FibP –
thrombin complex bodes well for designing peptidomimetics based on the FibP sequence that
recognizes the new binding site.236 These peptidomimetics are likely to possess structures
different from our SBDs.
Molecule 12a does not compete with the chromogenic substrate and yet reduces the rate
of substrate hydrolysis231 suggesting that the new binding site is energetically coupled to the
active site. The affinity of 12a for thrombin at pH 7.4 and 25 °C is approximately 6 µM, which
implies a reasonably high affinity interaction. In fact, other than the antithrombin-binding
heparin pentasaccharide, which binds with an affinity of ~50 nM,237 no small, sulfated molecule
is known to bind with such high affinity. A recent study of a group of synthetic heparin
octasaccharides that target herpes virus glycoproteins with ~20 µM affinity further support this
observation. The reason for the very high affinity of antithrombin-binding heparin
pentasaccharide is marvelous engineering by nature over millions of years. Thus, the ~6 µM
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affinity of 12a, which is ~1000-fold higher than that of its monomer precursor,238 is a good lead.
In fact, the putative binding site presents excellent opportunities advancing the design. For
example, Lys224 and Arg221A are within 5 to 8 Å of the carboxylic acid ester. Likewise, several
hydrophobic residues are also available for targeting.
Molecule 12a reduces thrombin’s catalytic activity approximately 50% in comparison to
known inhibitors that target the active site and exosite I.20, 197 This implies that 12a does not
completely inhibit the procoagulant signal. Whereas this could be traditionally considered as a
defect of design, considering the problems of over-anticoagulation induced by thrombin
inhibitors, the less than perfect reduction in catalytic activity of thrombin may serve to foster the
fine balance between procoagulant and anticoagulant signals. More importantly, detailed
inhibition profiles reveal that some SBDs exhibit efficacies of greater than 50%, while only
between 10 and 20% for others.231 This implies that the SBD binding site may be a ‘tunable’
binding site and appropriate molecules may be designed with variable efficacies to treat varying
levels of procoagulant tendencies.
Finally, this work also highlights the opportunity of exploring allosteric modulators of
other coagulation enzymes, e.g., factors Xa, IXa and XIa, through sulfated lignin scaffolds.
Considering the wealth of structural diversity accessible with the lignin scaffold, it may be
possible to design allosteric inhibitors that target these enzymes in a highly specific manner.

4.4 Experimental Section
4.4.1 Enzyme and Chemicals for Biological Experiments
Human α-thrombin, factors Xa, XIa, IXa, VIIa and recombinant tissue factor were
purchased from Haematologic Technologies (Essex Junction, VT). Factor XIIa was purchased
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from Enzyme Research Laboratories (South Bend, IN). Stock solutions of thrombin were
prepared in 20 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl. The
chromogenic substrates Spectrozyme TH, Spectrozyme FXa, Spectrozyme FXIIa, Spectrozyme
FIXa (299), Spectrozyme VIIa, and Spectrozyme CTY were obtained from American
Diagnostica (Greenwich, CT). Citrated human plasma for coagulation time assays was purchased
from Valley Biomedical (Winchester, VA). Thromboplastin and ellagic acid were obtained from
Fisher Diagnostics (Middletown, VA).

4.4.2 Inhibition of Thrombin
Direct inhibition of thrombin by sulfated benzofuran derivatives was measured through a
chromogenic substrate hydrolysis assay.213, 214 The buffer used in these experiments was 20 mM
Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 0.1% polyethylene
glycol (PEG) 8000. Benzofuran derivatives (2 to 30 µL) at concentrations ranging from 4 µg/mL
to 5 mg/mL were diluted with the appropriate volume of assay buffer in PEG 20,000-coated
acrylic cuvettes at 25 °C. To this solution was added 5 µL of thrombin solution to give
approximately 5 nM initial thrombin concentration. After 10 min of incubation, 20 µL of 1 mM
Spectrozyme TH was rapidly added and the residual thrombin activity was measured from the
initial rate of increase in absorbance at 405 nm. Relative residual thrombin activity at each
concentration of the inhibitor was calculated from the ratio of thrombin activity in the presence
and absence of inhibitor. Logistic equation 1 was used to fit the dose-dependence of residual
proteinase activity to obtain the IC50 and the efficacy ∆Y (= YM – Y0) of inhibition.
 =  +

 
(     )×
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Equation 1

In this equation, Y is the ratio of residual thrombin activity in the presence of inhibitor to
that in its absence (fractional residual activity), YM and YO are the maximum and minimum
possible values of the fractional residual proteinase activity, IC50 is the concentration of the
inhibitor that results in 50% inhibition of enzyme activity, and HS is the Hill Slope, which was
set constant at 1. A current version of SigmaPlot (SPSS, Inc. Chicago, IL) was used to perform
non-linear curve fitting in which YM, YO and IC50 were allowed to float.

4.4.3 Michaelis-Menten Kinetics of Spectrozyme TH Hydrolysis
The initial rate of Spectrozyme TH hydrolysis by 5 – 10 nM thrombin was monitored
from the linear increase in absorbance at 405 nm corresponding to less than 10% consumption of
the substrate, as described earlier.213, 214 The initial rate was measured as a function of various
concentrations of the substrate (10 to 600 µM) in the presence of fixed concentration of dimer
12a (0–30 µM) in 20 mM Tris-HCl buffer, pH 7.4, at 37 °C. The data were fitted by MichaelisMenten equation 2 to determine KM and VMAX.

 =

 ×

Equation 2

 

4.4.4 Prothrombin Time and Activated Partial Thromboplastin Time
Clotting time was measured in a standard 1-stage recalcification assay with a BBL
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD), as described previously.215, 216 For PT
assays, thromboplastin was reconstituted according to manufacturer’s directions and warmed to
37 °C. A 10 µL sample of the sulfated benzofuran, to give the desired concentration, was brought
up to 100 µL with citrated human plasma, incubated for 30 s at 37 ºC followed by addition of 200
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µL pre-warmed thromboplastin. Clotting time in the absence of an anticoagulant was determined
using 10 µL deionized water. For the APTT assay, 10 µL inhibitor was mixed with 90 µL
citrated human plasma and 100 µL of pre-warmed APTT reagent (0.2% ellagic acid). After
incubation for 4 minutes, clotting was initiated by adding 100 µL of 25 mM CaCl2 (37 ºC) and
time to clot was noted. Each clotting assay was performed in duplicate. The data were fit to a
quadratic trendline, which was used to determine the concentration of the inhibitor necessary to
double the clotting time, 2×APTT or 2×PT.

4.4.5 Molecular Modeling Studies
Molecular docking studies to identify potential binding poses require an accurate 3D
crystal structure of thrombin with high resolution and well-defined side chains. The crystal
structure of thrombin bound to its allosteric exosite I ligand hirugen at 1.53 Å resolution was
obtained from the Protein Data Bank (PDB ID = 3EQ0), as well as two additional thrombin
structures (PDB IDs = 1H8D and 2UUF).29,30 All the residues in region of Arg173 were
manually inspected to insure that the side chains were completely resolved. Each of the acidic
and basic residues was modeled in its most predominant ionization state at physiological pH (i.e.,
anionic Asp and Glu; cationic Arg and Lys). The inorganic salts and water molecules were
deleted from the crystal structure, and hydrogen atoms were added using SYBYL 8.1 (Tripos
International, St. Louis, MO). To prepare the structure for docking and scoring protocol, the
newly-added hydrogen atoms were energy-minimized using the Tripos Force Field (Gasteiger–
Hückel charges; termination criterion of 0.05 kcal/(mol×Å) or 1 × 105 iterations; distancedependent dielectric constant ε = 4.0).
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Substituted benzofuran-based dimers 12a–f and 13–15, each studied previously, 24 were
prepared in SYBYL for virtual library screening. Using in-house SYBYL Programming
Language (SPL) scripts, compounds contained in the resulting virtual library were postprocessed to (1) assign appropriate atom types to the sulfate groups (sulfur atom = S.o2; terminal
oxygen atoms = O.co2); (2) assign an initial set of 3D coordinates using the CONCORD module
within SYBYL; (3) add missing hydrogen atoms and (4) energy-minimize the resulting
structures using the Tripos Force Field as described for the protein (vide supra).
Docking of the synthesized inhibitors onto the defined binding site of the thrombin was
performed using GOLD 4.1 (Cambridge Crystallographic Data Centre, Cambridge, UK). The
binding site was defined to include all atoms within 22 Å around the Arg173 Cα atom. Default
parameters were employed during the GOLD docking runs with the following exceptions: a
protein hydrogen bonding constraint was added such that the score was reduced by 10.0
GoldScore units if the ligand did not form an H-bond with the guanidinium group of Arg173.
Amide bonds were allowed to flip. The number of GA runs was increased to 30 in order to more
accurately screen all possible binding geometries, and early termination was disabled. The
docking was driven by the GOLDScore fitness function and the docked solutions were ranked
based on the unmodified GOLDScore obtained. To assess the reproducibility of the docked
poses, the docking runs were performed in triplicate.

4.4.6 Screening for other proteases
Screening of library for Factor VIIa inhibition - Direct inhibition of factor VIIa by the library
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4,
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containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000 and 0.02%
Tween 80. Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 75 µL
volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this solution was
added 10 µL of factor VIIa solution to give approximately 80 nM initial factor VIIa
concentration and 5 µL of tissue factor solution to give 800 nM. After 10 min of incubation, 5 µL
of 20 mM Spectrozyme factor VIIa was rapidly added and the residual factor VIIa activity was
measured from the initial rate of increase in absorbance at 405 nm. The plate was read using a
microplate reader (FlexStation III, Molecular Devices). Relative residual factor VIIa activity was
calculated from the ratio of thrombin activity in the presence and absence of inhibitor. The
percent residual activity was calculated using the equation 3:
% Residual Activity = [(slope of blank – slope of well with inhibitor)/slope of blank] x 100
A cut off of 40% was selected, and those compounds which showed a % residual activity lower
than 40% were selected for full inhibition profile.

Screening of library for Factor IXa inhibition - Direct inhibition of factor IXa by the library
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000, 0.02% Tween
80 and 33% v/v ethylene glycol. Benzofuran derivatives (5 µL) at concentrations 20 mM were
diluted with 80 µL volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To
this solution was added 5 µL of factor IXa solution to give approximately 1780 nM initial factor
IXa concentration. After 10 min of incubation, 10 µL of 8.5 mM Spectrozyme factor IXa was
128

rapidly added and the residual factor IXa activity was measured from the initial rate of increase
in absorbance at 405 nm. The plate was read using a microplate reader (FlexStation III,
Molecular Devices). Relative residual factor IXa activity was calculated from the ratio of
thrombin activity in the presence and absence of inhibitor. The percent residual activity was
calculated using the equation 3.
Screening of library for Factor Xa inhibition - Direct inhibition of Factor Xa by the library of
sulfated benzofuran derivatives was measured through a one-point chromogenic substrate
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000 and 0.02%
Tween 80. Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 185 µL
volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this solution was
added 5 µL of factor Xa solution to give approximately 43.5 nM initial factor Xa concentration.
After 10 min of incubation, 5 µL of 5 mM Spectrozyme factor Xa was rapidly added and the
residual factor Xa activity was measured from the initial rate of increase in absorbance at 405
nm. The plate was read using a microplate reader (FlexStation III, Molecular Devices). Relative
residual factor Xa activity was calculated from the ratio of thrombin activity in the presence and
absence of inhibitor. The percent residual activity was calculated using the equation 3.
Screening of library for Factor XIa inhibition - Direct inhibition of factor XIa by the library
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl, 0.1% polyethylene glycol (PEG) 8000 and 0.02% Tween 80.
Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 85 µL volume of assay
buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To this solution was added 5 µL of
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factor XIa solution to give approximately 15.3 nM initial factor XIa concentration. After 10 min
of incubation, 5 µL of 6.6 mM Spectrozyme factor XIa was rapidly added and the residual factor
XIa activity was measured from the initial rate of increase in absorbance at 405 nm. The plate
was read using a microplate reader (FlexStation III, Molecular Devices). Relative residual factor
XIa activity was calculated from the ratio of thrombin activity in the presence and absence of
inhibitor. The percent residual activity was calculated using the equation 3.
Screening of library for Factor XIIa inhibition - Direct inhibition of factor XIIa by the library
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl, 0.1% polyethylene glycol (PEG) 8000 and 0.02% Tween 80.
Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 185 µL volume of
assay buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To this solution was added 5 µL
of factor XIIa solution to give approximately 200 nM initial factor XIIa concentration. After 10
min of incubation, 5 µL of 5 mM Spectrozyme factor XIIa was rapidly added and the residual
factor XIIa activity was measured from the initial rate of increase in absorbance at 405 nm. The
plate was read using a microplate reader (FlexStation III, Molecular Devices). Relative residual
factor XIIa activity was calculated from the ratio of thrombin activity in the presence and
absence of inhibitor. The percent residual activity was calculated using the equation 3.
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Chapter 5 Synthesis and Biochemical Evaluation of 2nd Generation Sulfated Benzofurans

5.1 Introduction
The previous chapters describe the successful design and synthesis of small molecules
that display an antithrombotic effect through an allosteric mechanism.23, 12, 18 Those were the first
reported small molecules that reduced the catalytic efficiency of thrombin by binding to an
allosteric site. In order to improve the potency of benzofuran dimeric units, we designed a library
of 2nd generation compounds. From the SAR studies of the sulfated benzofuran monomers and
dimers, we found that substitution at the 2’-allylic position of the sulfated benzofuran dimer does
not have a detrimental effect on potency.231 This led us to design a second generation library
containing three linked benzofuran units as the backbone scaffold and various substitutions at the
first benzofuran unit to improve the potency and solubility of the compounds. In this work, we
report the synthesis, biological activity, mechanistic and blood plasma studies of a library of
eleven sulfated benzofuran trimers and tetramer. Based on substrate hydrolysis assay and
through Michaelis-Menten kinetic studies, we can state that these molecules are potent small
synthetic allosteric inhibitors of thrombin. The strong competition with heparin suggests that
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these molecules bind at exosite II. Finally, plasma studies showed that these molecules are potent
anticoagulants in whole human plasma.
5.2 Results and Discussion
5.2.1 Design and Synthesis of the 2nd Generation Sulfated Benzofuran Scaffold
Previously, we reported that the sulfated low molecular weight lignins (LMWLs) are
potent allosteric inhibitors of thrombin and are structurally very different from heparin with less
anionic charge and a more hydrophobic scaffold.239 Similar to heparin, LMWLs are constituted
of a mixture of different structures arising from varying inter-residue linkages and degrees of
sulfations. It is well known that the β-5 linkage is the most abundant linkage present in natural
lignins.200, 202 Based on this assumption and its synthetic feasibility, the benzofuran scaffold was
designed. In preliminary work, we synthesized a diverse library of sulfated benzofuran
monomers and dimers to study the effects of various substitutions on their potency of thrombin
inhibition.231 Among the members of this library, a few structures were found to inhibit thrombin
with moderate potency in the range of 5-50 µM. A mechanistic study divulged that these
molecules inhibit the catalytic efficiency of thrombin in an allosteric fashion, similar to the
parent LMWLs. SAR studies revealed very interesting findings and guided the design 2nd
generation compounds. It had been known that one sulfate group at the 5- position is optimal for
potency. In addition, any increase in the number of anionic charges, either from sulfate or
carboxylate, is detrimental. The presence of hydrophobic groups at the 3-ester and 6-hydroxy
positions is favorable. The most striking feature in the SAR that leads to the design of 2nd
generation compounds was tolerance of steric group at the 2’-allylic position of sulfated
benzofuran dimer.231 Along with this, a 1000-fold improvement in potency on moving from
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monomers to dimers led us to add an additional substituted benzofuran unit to the existing
dimeric scaffold.
Incorporating the above, a pilot 2nd generation library of ten sulfated benzofuran trimers
was designed and synthesized. In this library, the terminal two benzofuran units were kept the
same and variations were made at 3, 4 and 5- positions of the first benzofuran units. The
variation at the 3-carboxylate ester position included both hydrophilic and bulky hydrophobic
groups, while the position and number of anionic group and hydrophobic groups at 6- position
were also varied.

5.2.2 Chemistry
Syntheses of β-5-like trimeric units were described in Figure 27-30. Figure 27 described
the synthesis of various reactive handles T4a ̶ T4h starting from the readily available catechol.
The first step leads to formation of 5, 6-dihydroxy-benzofuran-3-carboxylic acid esters using
conditions published previously.231 The highly functionalized benzofuran unit T1a ̶ T1e was
synthesized in one step using an oxidative-Michael addition reaction. The selective monoalkylation of the 6-hydroxy group of compounds T1a ̶ T1e was achieved under basic condition
to afford T2a ̶ T2g in 60% yield. This reaction also resulted in formation of another regio-isomer
T2h in minor amounts (< 10 %), causing an unfortunate difficulty in purification. The separation
can be achieved by careful purification using flash chromatography. Subsequently, protection of
the 5-hydroxy group was achieved by t-butyltrimethylsilyl chloride in the presence of imadazole,
this led to formation of T3a ̶ T3h in very high yield. The bromination of the allylic position in
the presence of N-bromosuccinimide leads to the synthesis of reactive handles T4a ̶ T4h.
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Figure 27. Description of synthesis of a library reactive handles T4a ̶ T4h for synthesis of
library of sulfated benzofuran trimers. Reactions: a) Alkyl aceto-acetate, NaIO4, DIPEA, ethanol:
water (3:1); b) Cs2CO3, alkyl or acyl halide, anh. DMF; c) TBDMSCl, Imidazole, DMF; d) NBS,
CCl4.
As shown in Figure 28, synthesis of compound T5a ̶ T5b was afforded by nucleophilic
displacement of the allylic bromide of T4a by a free phenolic group at the 5- position of T2a and
T2e under basic condition. The coupling reaction was low yielding <50% due to steric
interference around both nucleophilic (allylic bromide) and electrophilic (phenolic group)
positions. The required handle T6a ̶ T6b was achieved by removal of the protecting silyl group
from 5- position using potassium fluoride and a catalytic amount of glacial acetic acid.
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Figure 28. Description of synthesis of reactive handles T6a ̶ T6b for synthesis of library of
sulfated benzofuran trimers. Reactions: e) Cs2CO3, T2a & T2e; DMF; f) KF, CH3COOH, DMF.

Figure 29 describes the synthesis of the nine desired sulfated trimeric units T9a ̶ T9h and
T14. The coupling of the two reactive handles T4a ̶ T4h and T6a ̶ T6b were achieved using
microwave radiation to afford trimeric units T7a ̶ T7h. Unlike the coupling reactions for dimeric
unit T5a ̶ T5b, coupling for trimers failed at room temperature due to solubility and steric issues.
Microwave-based coupling reaction afforded the desired compounds in a reaction time of 80
minutes with 50% yield. The compounds T8a ̶ T8h were obtained by removal of the protecting
silyl group similar to condition used above (synthesis of T6a ̶ T6b, Figure 27). The selective
hydrolysis of the allyl ester of T8e is achieved by a catalytic amount of Pd(PPh3)3 in the presence
of base to give T13 in good yield. The targeted compounds T9a ̶ T9h and T14 were accessed by
addition of a sulfate group using the microwave-based conditions previously developed in our
laboratory.222 The cation exchange from triethylamine to sodium was performed using weak
cation exchange resin and purified using flash chromatography. In Figure 30, intermediate T8a
and T4a were coupled together under basic conditions using the microwave method described
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above in synthesis of T7a ̶ T7h. This followed by removal of the protecting group and sulfation
afforded the desired compound T12.

Figure 29. Description of synthesis of library of sulfated benzofuran trimers T9a ̶ T9h and T14.
Reactions: g) Cs2CO3, 2; DMF; h) KF, CH3COOH, DMF; i) Et3N:SO3, CH3CN: DMF (4:1),
MW; j) Pd(PPh3)3, PPh3, pyrrolidine.
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Figure 30..Description of synthesis of sulfated benzofuran tetramer T12. Reactions: k) Cs2CO3,
T2a; DMF; L) KF, CH3COOH, DMF; M) Et3N:SO3, CH3CN: DMF (4:1).
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5.2.3 Substrate Hydrolysis Assay
The inhibition potencies of sulfated benzofuran trimers and tetramer for thrombin were
measured using the Spectrozyme TH hydrolysis-based assay.202 This assay measures the decrease
in the initial rate of substrate hydrolysis in the presence of the inhibitors as a quantitative
measure of the inhibition. The fractional decrease in the initial rate of hydrolysis typically gives a
sigmoidal curve on a semi-log plot, which is then fitted by a dose - response equation 4 (see
Experimental Section 5.4.3) to calculate IC50, HS and ∆Y parameters for each potential inhibitor.
The semi-log inhibition profile observed for sulfated benzofuran trimers are shown in
Figure 31. From the library of 11 inhibitors, ten molecules demonstrated potent inhibition of
human α-thrombin at pH 7.4 and 25 °C. These include sulfated trimers T9a ̶ T9h, T14 and the
sulfated tetramer T12 (Tables 14). The inhibitor T9a showed the most potent inhibition with an
IC50 of 670 nM under physiologically relevant conditions. The range of inhibition efficacy (45 to
95 %, Table 14) was found to vary considerably with the structure of the inhibitor. Nearly all of
the inhibitors studied inhibited thrombin to more than 50% suggesting reasonably good overall
efficacy in this series of sulfated benzofurans.
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Table 14. Inhibition of human thrombin by sulfated benzofuran trimers
R’

R

log IC50 (M)

IC50 (µM)

∆Y

T9a

OCH2CH3

CH3

-3.17 ± 0.02

0.67 ± 0.04

44.1

T9b

OCH3

CH3

-2.59 ± 0.12

2.5 ± 0.2

54.9

T9c

OC(CH3)3

CH3

-0.77 ± 0.03

149.24 ± 0.04

92.8

T9d

OCH2 CH2OCH3

CH3

-1.05 ± 0.01

88.49 ± 0.01

67.8

T9f

OCH2CH3

CH2CH3

-2.29± 0.01

5.1 ± 0.1

41.4

T9g

OCH2CH3

CH(CH3)2

-0.48± 0.01

324 ± 0.1

83.8

T9e

OCH2CHCH2

CH3

-1.12 ± 0.04

75.64 ± 0.02

64.3

T9h

na

na

-0.79 ± 0.3

162 ± 1

88.6

T12

na

na

-0.97 ± 0.25

107 ± 1

50.88

T13

na

na

T14

OH

CH3

>500
-0.84 ± 0.03

143 ± 0.04

47.72

Spectrozyme TH was used as the substrates and the residual enzyme activity in the presence of
the trimer was assessed by measuring the initial rate of substrate hydrolysis at 405 nm. Equation
3 was used to fit the dose dependence of the residual enzyme activity to obtain log IC50, Y0, and
YM values.
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Figure 31. Direct inhibition of thrombin by designed sulfated benzofuran trimers and tetramer.
The inhibition of human thrombin was determined spectrophotometrically through a
Spectrozyme TH hydrolysis assay at pH 7.4 and 25 °C.

Comparison of the IC50 of T9b, T9c, T9d and T9e shows that as the size of the 3-ester
3
increases, the inhibition potency decrease
decreases by 30 to 60-fold (Table 14).
). For example, T9c
containing the highly hydrophobic and bulky t-butyl is 60-fold
fold less potent than T9b containing
the small methyl group. Whereas, in the cases of T9d and T9e, having methoxy methyl and allyl
group, respectively, IC50 dropped only 30
30-fold. Although the potency of inhibition is decreased
on steric crowding, polar groups are tolerated well than hydrophobic groups of the same size.
The exceptionally high potency displayed by
byT9a having an ethyl ester at the 33 position is not
well understood. This may be due to a stringent requirement of an ethyl ester at 33 position
suggesting a highly conserved
onserved binding region here.
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Similarly for T9f and T9g potency decreased 65-fold by changing the substitution from
ethyl to isopropyl at the 6- position. These imply that Hydrophobicity, as well as the size of the
substitution at the 6- position, plays an important role. Increasing the anionic charge, as seen in
T14, decreases the potency by 220-fold. This suggests that the terminal benzofuran unit binds in
a hydrophobic pocket that cannot tolerate the highly charged carboxylate group. This is a
significant finding about the nature of this binding pocket. The trimer unit was found to be
optimal for activity. Increasing the oligomeric chain to the tetramer as in T12 decreased activity
by 150-fold.
Comparing the effect of the sulfate group with the carboxylate group, it was found that
the carboxylate group is not polar enough to solubilize the aromatic trimer scaffold. The
molecule T13 was found to precipitate at a higher concentration, thus causing problems in
determination of the full inhibition profile. Thus, we can conclude that carboxylate group cannot
successfully replace the sulfate group in this series for direct thrombin inhibition.

5.2.4 Biochemical Studies
1) Michaelis-Menten studies show no change in KM, while there are significant changes in
VMax with increasing concentration of inhibitor. This suggests that the presence of the
trimer does not affect the binding of the chromogenic substrate to the active site of the
enzyme, but significantly reduces its catalytic efficiency. This indicates an
uncompetitive, allosteric mechanism of thrombin inhibition by the trimer.
2) To test whether trimers binds in exosite I, competition studies with the hirugen analog,
[5F]-Hir[54-65](SO3-), were performed. The presence of [5F]-Hir[54-65](SO3-) did not
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significantly affect the thrombin inhibition profiles indicating that the trimer does not
appear to bind in the anion-binding exosite I of thrombin.
3) To test whether trimers binds in exosite II, competition studies with three different
exosite II binding ligands; porcine unfractionated heparin, H8, and γ’Fibrinogen peptide
were performed. A distinct shift in these profiles is observed as the concentration of the
UFH increases, suggesting competition between the two ligands for thrombin binding.
This indicates that the trimer and full-length heparin compete for exosite II of thrombin.
However, there was no change in inhibition profile observed with increasing
concentration of heparin octasaccharide H8 and γ’Fibrinogen peptide. This indicates that
the trimer and H8 do not compete with each other, although both are exosite II ligands.

5.2.5 Prolongation of Plasma Clotting Time by T9a
Typically, two plasma clotting assays are performed to evaluate the anticoagulant
potency in plasma for new coagulation inhibitors. Prothrombin time (PT) and activated partial
thromboplastin time (APTT) assays are used to measure the effect of an inhibitor on the extrinsic
and intrinsic flux of coagulation, respectively. The concentrations of the inhibitors required to
double the PT and APTT were measured and reported as described earlier (Chapter 4) for our
first generation compounds (see Table 15).
A 2-fold increase in PT required 568 µM concentration of T9a. In a similar manner, the
doubling of APTT required 139 µM of T9a. The higher potency for the APTT assay as
compared to the PT assay suggests a more profound effect on intrinsic pathway. These results
also suggest that the 2nd generation library of sulfated trimeric benzofurans is 10-fold more
potent in human plasma than 1st generation compounds. These results were expected and prove
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the validity of our design. The 2nd generation compounds are only 10 times less potent than our
LMWLs, from which the benzofuran scaffold was designed. To further evaluate the mechanism
of anticoagulation of these inhibitors in plasma, we performed plasma studies on various factordeficient human plasmas. When the APTT test was performed on factors IX and XI-deficient
human plasma, we measured that concentrations required to double the APTT time were 135 µM
and 120 µM respectively (see Table 15). There was no significant change in 2ˣAPPT time
compared to normal human plasma suggesting a less significant role factors IX and XI with
respect to the anticoagulation effect of these inhibitors. Similarly, 2ˣPT value for factor VII
deficient plasma was 518 µM, which is not significantly different from normal human plasma.
Thus, we can conclude that our designed inhibitors are not inhibiting factors IX, XI and VII in
human whole plasma. Overall, the plasma studies suggest the feasibility of designing sulfated
benzofurans that will function as anticoagulants in vivo.
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Figure 32 Prolongation of clotting time as a function of concentration of sulfated benzofuran
trimer and tetramer in either activated partial thromboplastin time assay (top) or prothrombin
time assay (bottom). Solid lines are trend lines, and not non-linear regressional fits.
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Table 15. The PT and APTT assay results for T9a in normal as well as factor deficient plasma
APTT Assay

2ˣPT (µM)

2ˣAPTT

Normal Plasma

568

139

Factor XI Deficient Plasma

NA

135

Factor IX Deficient Plasma

NA

120

Factor VII deficient Plasma

518

NA

PT and APTT values were deduced in in vitro human plasma experiments where the clot initiator
is either thromboplastin or ellagic acid, respectively.

5.2.6 Screening against Other Serine Proteases
The library of sulfated benzofuran trimers was screened against the panel of coagulation
proteases including factors VIIa, IXa, Xa, XIa and XIIa, all of which are either involved in
intrinsic or extrinsic pathways of the coagulation cascade. These assays are based on the rate of
hydrolysis of a chromogenic substrate by the protease, which decreases in the presence of an
inhibitor. Screening was performed at a single concentration of inhibitors using a substrate
hydrolysis assay in 96-well plates. The decrease in initial rate of hydrolysis provided the
fractional residual activity of enzyme. The details of experimental conditions are provided in the
Experimental Section (5.4.6).
Table 16 shows the residual activity of all proteases at a final concentration of 365 µM of
each inhibitor. The library of trimers contains molecules with varying substitutions ranging from
hydrophobic to polar as well multiple anionic groups. None of these trimers inhibited factor XIIa
more than 20% at this concentration. In the screening against factor VIIa, molecules T9b and
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T9e inhibited factor VIIa activity more than 70%, this showing potential for potent inhibition.
These two molecules were selected for further inhibition study. Similarly, several trimers showed
higher potential for inhibition of factor IXa. Molecules T9a, T9b, T9e, T9f, T12 and T15
inhibited factor IXa activity greater than 80% at the given concentration. These inhibitors were
selected for detailed inhibition profile and thus have potential for the design into better inhibitors
of factor IXa.

Table 16. Residual activity of proteases (in %) at single concentration (365 µM) of each
inhibitor
Factor VIIa

Factor IXa

Factor Xa

Factor XIa

Factor XIIa

T9a

72±3

1±1.5

84±2

2±3

103±5

T9b

26±3.5

3±3

38±3

3±5

86±3

T9c

92±3.5

103±6

31±2

11±1

92±3

T9e

37±3

16±2

69±2

1±1.5

93±3

T9f

98±4

31±2

73±3

5±7

98±6

T9g

101±3

82±3

85±3

39±2.5

98±3

T9h

104±7

96±6

76±2

6±2

96±4

T12

100±6

11±6

66±3

3±2.5

86±2

T14

74.±1

103±8

102±4

11±5

47±1.5

T15

100±4

17±1

70±3

4±3

99±3.5

In screening against factor Xa, with the exception of inhibitors T9b and T9c, the majority
of trimers showed minimal activity against factor Xa. Although the inhibitory abilities of T9b
and T9c are just 40%, which were much less as compared to inhibition by other proteases, these
molecules were selected for detailed inhibition profiles. As expected from the results of
inhibition by monomers and dimers, the library of trimers showed potent inhibition against factor
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XIa. The trimers inhibited the factor XIa activity greater than 80% at the given concentration.
co
The entire library of trimers was selected for detailed inhibition profile.
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Figure 33. Bar
ar graph showing the % residual activity of given proteases at single concentration
of each inhibitor

5.2.7 Factor VIIa Inhibition Potential of Designed Sulfated Benzofuran Trimers
The full Inhibitionn profile of factor VIIa by sulfated benzofuran trimers was measured
with the Spectrozyme TH
H hydrolysis assay, as described in
n Experimental Section (5.4.3).
(5.4.3) This
assay analyzes the decrease in the initial rate of substrate hydrolysis in the presence of the
sulfated benzofuran with respect to the initial rate of substrate hydrolysis in absence of the
inhibitor, to provide a measure of % inhibition of the enzyme.
me. The fractional decrease in initial
rate of hydrolysis typically shows a sigmoidal profile on a semi
semi-log
log plot, which is then fitted by a
dose – response to derive IC50, HS
HS, Y0 and YM parameters for each potential inhibitor.
Figure 34 shows the semi
semi-log inhibition curves obtained from selected sulfated trimer
compounds.. The selected trimer molecules exhibited reasonable inhibitio
inhibition
n of human factor VIIa
at pH 7.4 and 37 OC. Out of the library of 10 trimers, only T9b and T9e exhibited moderate
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inhibition potency for factor VIIa. T9e is the most potent with an IC50 of 82.5 ± 0.1 µM, while
T9b exhibited an IC50 of 239 ± 1 µM under physiologically relevant conditions. Although T9b
displayed lower potency compared to T9e, it showed a better inhibition efficacy (85%, Table 17)
than T9e (45%, Table 17). Although this study is too small to predict SAR, these molecules can
still serve as potential leads to design inhibitors for factor VIIa.

100

% Residual Activity

80

60

40

20

T9e
T9b

0
-4.5

-4.0

-3.5

-3.0

Log [Inhibitor]0 (M)

Figure 34. Direct inhibition of factor VII by inhibitors T9e and T9b. The inhibition of human
factor VIIa was determined spectrophotometrically through a Spectrozyme factor VIIa
hydrolysis assay at pH 7.4 and 37 °C. Solid lines represent sigmoidal fits to the data to obtain
IC50, YM, and YO, as described in the experimental section.
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Table 17. Inhibition of sulfated benzofuran trimers
Log IC50

IC50 (µM)

∆Y

T9b

-3.62 ± 0.01

239 ± 0.02

83.6

T9e

-4.08 ± 0.01

82.4 ± 0.02

45.3

5.2.8 Factor IXa Inhibition Potential of Designed Sulfated Benzofuran Trimers
Figure 35 shows the semi-log inhibition curves observed obtained from the selected
sulfated trimers. The selected trimer molecules exhibited reasonable inhibition of human factor
VIIa at pH 7.4 and 37 OC. Out of the library of 10 trimers, five trimers exhibited moderate
inhibition potency for factor VIIa. T9f is most potent with an IC50 of 9.2 µM and displayed
complete inhibition efficacy (95%, Table 18). The other trimers T9c, T9d, T12 and T15
displayed potencies of 25.7 µM, 22.3 µM, 65.5 µM and 23.8 µM, respectively. These trimers
displayed inhibition efficacy of 80-90% (Table 18). However, a clear trend of SAR is not
observed from this small library of molecules. However, more hydrophobic scaffolds displayed
higher potency and efficacy for inhibition of factor IXa. The most potent inhibitor T9f has a
hydrophobic isopropyl group at the 6- position. Similarly, T9c, T9d and T15 with hydrophobic
substitutions at the 6- and 3- positions displayed similar potency. The presence of a terminal
carboxylate group in T15 is well tolerated. Increasing the chain length with additional
benzofuran units (T12) reduces the inhibition potency by 2-fold. Thus, it can be concluded that
the trimer is optimal with hydrophobic substitutions at the first unit.
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Figure 35. Direct inhibition of factor IXa by inhibitors T9c, T9d, T9f, T12 and T15. The
inhibition of human factor IXa was determined spectrophotometrically through a Spectrozyme
factor IXa hydrolysis assay at pH 7.4 and 37 °C. Solid lines represent sigmoidal fits to the data to
obtain IC50, YM, and YO, as described in the Experimental Section (5.4.8).

Table 18. Inhibition of human factor IXa by sulfated benzofuran trimer
Log IC50

IC50 (µM)

∆Y

T9c

-4.59 ± 0.02

25.7 ± 0.04

81.3

T9d

-4.65 ± 0.01

22.2 ± 0.01

67

T9f

-5.03 ± 0.01

9.2 ± 0.02

95.8

T12

-4.18 ± 0.01

65.5 ± 0.01

82.2

T15

-4.62 ± 0.01

23.7 ± 0.02

81.3

5.2.9 Factor Xa Inhibition Potential of Designed Sulfated Benzofuran Trimers
Figure 36 shows the semi-log inhibition curves obtained from selected sulfated trimers. The
selected trimer molecules exhibited reasonable inhibition of human factor Xa at pH 7.4 and 37
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C. Out of a library of 10 trimers, only T9b and T9d exhibited moderate inhibition potency. T9b

is the most potent with an IC50 of 61 µM and T9d displayed a potency of 103 µM (Table 19).
These molecules displayed inhibition efficacy of 80-100%. Although this study is too small to
predict any SAR, these molecules can serve as potential lead to design inhibitors for factor Xa.
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Figure 36. Direct inhibition of factor Xa by inhibitors T9b, and T9d. The inhibition of human
factor Xa was determined spectrophotometrically through a Spectrozyme factor Xa hydrolysis
assay at pH 7.4 and 37 °C. Solid lines represent sigmoidal fits to the data to obtain IC50, YM, and
YO, as described in the Experimental Section (5.4.7).
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Table 19 Inhibiton of human factor Xa by sulfated benzofuran trimers
Log IC50

IC50 (µM)

∆Y

T9b

-4.21 ± 0.02

61.1 ± 0.03

68.9

T9d

-3.98 ± 0.04

103.0 ± 0.05

99

5.3 Significance
This work presents a library of small homogenous sulfated aromatic scaffolds as novel
inhibitors of thrombin with an allosteric mode of action. These are the first known small
aromatic molecules as allosteric inhibitors of thrombin with nanomolar potency. The allosteric
inhibition of thrombin offers advantages of controlled inhibition and ease of design of antidote.
Finally, the successful design of allosteric inhibitors of thrombin opens a path for
designing allosteric inhibitors for other upstream proteases of the coagulation cascade. The
recognization of the heparin binding site by these aromatic inhibitors may extend the inhibition
activity for other proteases that are known to bind heparin. By exploring the other structural
features of lignins, it may be possible find scaffolds inhibiting other proteases in highly specific
manners.
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5.4 Experimental Procedures
5.4.1 Chemicals, Reagents and Analytical Chemistry
Reagents, chemicals and solvents were purchased either from Sigma-Aldrich
(Milwaukee, WI) or Fisher (Pittsburgh, PA) and were used as received. Reagent solutions and
chemicals were handled under inert nitrogen atmosphere using syringe techniques for liquid and
dried spatula for solids. All glassware was dried in the oven overnight before use. All organic
layers obtained during work-up were dried using anhydrous sodium sulfate. Reaction progress
was monitored using analytical thin layer chromatography (TLC) using UNIPLATETM silica gel
GHLF 250 µm pre-coated plates (ANALTECH, Newark, DE) and detected by UV (254 nm).
Column chromatography was performed using Teledyne ISCO (Lincoln, NE) Combiflash RF
system and disposable normal silica cartridges of 30 – 50 µm particle size, 230 – 400 mesh size
and 60 Å pore size. Sodium exchange chromatography was performed using SP Sephadex C-25
sodium cation exchange resin from GE Healthcare Life Sciences (Piscataway, NJ).
Approximately 100 mg of each sulfated sample was loaded onto 10 g of the cation exchanger in
a 10 × 460 mm column and eluted with water at 0.5 mL/min. Microwave-based sulfation and
coupling reactions were performed using a CEM-Discover synthesizer (Matthews, NC) in sealed
reaction vessels (7 mL) at 50 W. Temperature of the reaction was maintained at the desired
setting using cooled nitrogen (45 psi) flow.
1

H and

13

C NMR spectra were recorded at either 300 or 400 MHz (Varian Mercury or

Bruker UltrashieldTMPlus) in appropriate deuterated solvents including CDCl3, DMSO-d6, or
D2O. All signals are reported in ppm with the internal chloroform, DMSO, and D2O signals at
7.26, 2.50, 2.05, and 4.79, respectively, as standards. The data is reported as chemical shifts
(ppm) and splitting pattern is described as (s = singlet, d = doublet, t = triplet, m = multiplet)
with coupling constant(s) (Hz), and integration. Mass spectrometry was performed on all
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synthesized molecules using a Micromass ZMD4000 single quadrupole mass spectrometer with
ESI ionization probe operating in negative ion mode (Waters Corp., Milford, MA). The samples,
dissolved in acetonitrile containing formic acid (5% v/v), were infused at 10 µL/min. The source
block temperature and the probe temperature were typically held at 100 and 120 °C, respectively,
while corona and cone voltages were selected through manual optimization. The desolvation
nitrogen flow was 500 L/hour. Mass spectra were acquired in the mass range from 110 to 1000
Daltons at 400 amu/sec.
Chromogenic substrate Spectrozyme TH (H-D-hexahydrotyrosol-Ala-Arg-p-nitroanilide)
was purchased from American Diagnostica (Greenwich, CT). Unfractionated porcine heparin
was purchased from Sigma (St. Louis, MO). Heparin octasaccharide H8 was purchased from VLabs (Covington, LA). All other chemicals were analytical reagent grade from either Sigma
Chemicals (St. Louis, MO) or Fisher (Pittsburgh, PA) and used as such.

5.4.2 Synthesis Protocols
Synthesis of 5, 6-dihydroxy-2-methylbenzofuran-3-carboxylate esters (T1a ̶ T1e).

To a solution of catechol (20 mmol) in 75 mL of ethanol were added ester of acetoacetate (20
mmol) and N, N-Diisopropylethylamine (40 mmol). The reaction mixture was stirred for 5 min.
To this mixture was added sodium iodate (20 mmol) and the solution stirred vigorously for 5 min
and then 25 mL of water was added. The reaction mixture was stirred for 10 hours at room
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temperature and quenched with 400 mL of ethyl acetate and extracted with 150 mL of brine and
30 mL of 0.5 N HCl. The organic layer was dried over magnesium sulfate and concentrated. The
product was purified by passing through a plug of silica (1 inch in height) using 2% methanol in
methylene chloride. The product was concentrated and dried under vacuum to provide a yield of
40%.
T1a: 1H NMR (Acetone-d6, 300 MHz) δ 1.36 (t, J =3 Hz, 3H), 2.63 (s, 3H), 4.31 (q, J =6 Hz,
2H), 6.95 (s, 1H), 7.37 (s, 1H). 13C NMR (CDCl3) δ 14.79, 14.96, 60.54, 98.53, 106.62, 108.83,
117.56, 144.09, 144.92, 147.79, 161.79, 164.48.
T1b: 1H NMR (CDCl3, 300 MHz) δ 2.65 (s, 3H), 3.97 (s, 3H), 6.99 (s, 1H), 7.43 (s, 1H).
T1c: 1H NMR (CDCl3, 300 MHz) δ 1.60 (s, 9H), 2.63 (s, 3H), 6.96 (s, 1H), 7.39 (s, 1H).
T1d: 1H NMR (CDCl3, 300 MHz) 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t, J=12 Hz, 2H), 4.46 (t, J=12
Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H).
T1e: 1H NMR (CDCl3, 300 MHz) 2.71 (s, 3H), 4.85 (d, 2H), 5.22 (d, 1H), 5.36 (d, 2H), 6.00 (m,
1H), 6.91 (s, 1H), 7.46 (s, 1H).

Synthesis of 5-hydroxy-6-alkoxy-2-methylbenzofuran-3-carboxylate esters (T2a ̶T2h)

To a solution of T1a ̶ T1e (1.44 mmol) in DMF (12 mL) were added cesium carbonate (0.72
mmol) and acyl or alkyl halide (1.44 mmol) and stirred for 15 hours under an N2 atmosphere.
The reaction was quenched by adding 0.5 N HCl and extracted with ethyl acetate. The organic
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extract was dried over magnesium sulfate, concentrated and purified on silica gel (0-25% ethyl
acetate in hexanes) to give product in 53% yield.
T2a: 1H NMR (CDCl3, 300 MHz) δ 1.46 (t, J=6 Hz, 3H), 2.75 (s, 3H), 3.96 (s, 3H), 4.39 (q, J=6
Hz, 2H), 5.58 (s, 1H), 6.95 (s, 1H), 7.37 (s, 1H). 13C NMR (CDCl3) δ 14.60, 14.66, 56.54, 60.43,
94.33, 106.04, 109.23, 119.19, 143.37, 145.18, 147.86, 162.87, 164.88.
T2b: 1H NMR (CDCl3, 300 MHz) δ 2.71 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 6.95 (s, 1H), 7.44 (s,
1H).
T2c: 1H NMR (CDCl3, 300 MHz) δ 1.60 (s, 9H), 2.63 (s, 3H), 3.92 (s, 3H), 6.92 (s, 1H), 7.39 (s,
1H).
T2d: 1H NMR (CDCl3, 300 MHz) δ 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t, J=12 Hz, 2H), 3.82 (s,
3H), 4.46 (t, J=12 Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H).
T2e: 1H NMR (CDCl3, 300 MHz) δ 2.71 (s, 3H), 3.83 (s, 3H), 4.85 (d, 2H), 5.22 (d, 1H), 5.36
(d, 2H), 6.00 (m, 1H), 6.91 (s, 1H), 7.46 (s, 1H).
T2f: 1H NMR (CDCl3, 400 MHz) δ 1.45 (s, 6H), 2.70 (s, 3H), 4.13 (d, 2H), 4.36 (d, 2H), 6.93 (s,
1H), 7.43 (s, 1H).

13

C NMR (CDCl3) δ 14.34, 14.43, 14.76, 31.42, 36.45, 60.15, 65.02, 76.69,

77.00, 77.32, 94.97, 105.73, 109.04, 118.95, 143.34, 144.13, 147.63, 162.50, 162.58, 164.63.
T2g: 1H NMR (CDCl3, 300 MHz) δ 1.40 (d, J=1.5 Hz, 6H), 1.43 (t, J=1.8 Hz, 3H), 2.71 (s, 3H),
4.38 (t, J=1.8 Hz, 2H), 4.58 (m, 1H), 6.96 (s, 1H), 7.44 (s, 1H).
T2h: 1H NMR (CDCl3, 300 MHz) δ 1.46 (t, J=6 Hz, 3H), 2.75 (s, 3H), 3.96 (s, 3H), 4.39 (q, J=6
Hz, 2H), 5.58 (s, 1H), 7.01 (s, 1H), 7.31 (s, 1H).
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Synthesis of 5-((t-butyldimethylsilyl)oxy)-6-alkoxy-2-methylbenzofuran-3-carboxylate ester
(T3a ̶ T3h).

To a solution of T2a ̶ T2f (3.63 mmol) in DMF (30 mL) were added imidazole (18.15 mmol) and
TBDMSCl (21.83 mmol) and the mixture was stirred. After 16 hours the reaction mixture was
quenched with water and extracted with diethyl ether. The organic layer was dried over
magnesium sulfate, concentrated and purified by flash chromatography on silica gel (0-15%
EtOAc in hexanes) to obtain product in yield of 85-90 %.
T3a: 1H NMR (CDCl3, 300 MHz) δ 0.17 ( s, 6H), 1.01 (s, 9H), 1.46 (t, J=6 Hz, 3H), 2.69 (s,
3H), 3.87 (s, 3H), 4.39 (q, J=6 Hz, 2H), 7.05 (s, 1H) and 7.41 (s, 1H). 13C NMR (CDCl3) δ 4.5,
14.47, 18.73, 22.25, 25.96, 55.99, 61.00, 95.23, 111.31, 112.77, 118.07, 143.56, 149.97, 151.43,
157.60, 163.69.
T3b: 1H NMR (CDCl3, 300 MHz) δ 1.16 (s, 6H), 1.02 (s, 9H), 2.70 (s, 3H), 3.83 (s, 3H), 3.91 (s,
3H), 6.93 (s, 1H), 7.37 (s, 1H).
T3c: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.03 (s, 9H), 1.62 (s, 9H), 2.69 (s, 3H), 3.83 (s,
3H), 6.92 (s, 1H), 7.36 (s, 1H).
T3d: 1H NMR (CDCl3, 300 MHz) δ 0.13 (s, 6H), 1.01 (s, 9H), 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t,
J=12 Hz, 2H), 3.82 (s, 3H), 4.46 (t, J=12 Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H).
T3f:1H NMR (CDCl3, 400 MHz) δ 0.11(s, 6H), 1.04 (s, 9H), 1.46 (s, 6H), 2.71 (s, 3H), 4.03 (d,
2H), 4.35 (d, 2H), 6.93 (s, 1H), 7.40 (s, 1H).
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T3g: 1H NMR (CDCl3, 400 MHz) δ 0.19 (s, 6H), 1.04 (s, 9H), 1.37 (d, 6H), 1.42 (t, 3H), 2.71 (s,
3H), 4.40 (d, 2H), 6.94 (s, 1H), 7.40 (s, 1H).
T3h: 1HNMR (CDCl3, 300 MHz) δ 0.17 ( s, 6H), 1.01 (s, 9H), 1.46 (t, J=6 Hz, 3H), 2.69 (s,
3H), 3.87 (s, 3H), 4.39 (q, J=6 Hz,, 2H), 7.08 (s, 1H) 7.35 (s, 1H).

Synthesis
of
2-(bromomethyl)-5-((tert-butyldimethylsilyl)oxy)-6-alkoxybenzofuran-3carboxylate ester (T4a ̶ T4h).

To a solution of T3a ̶ T3f (1 mmol) in THF (20 mL) was added NBS (1 mmol) and the solution
was refluxed at 65 oC under a halogen lamp for 1 hour. The reaction mixture was cooled and
quenched with water and extracted with hexanes. The organic layer was concentrated and
product was obtained in 90-95 % yield.
T4a: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 1.46 (t, J=6 Hz, 3H), 3.87 (s, 3H),
4.39 (q, J=6 Hz, 2H), 4.93 (s, 2H), 7.05 (s, 1H), 7.41 (s, 1H).
T4b: 1H NMR (CDCl3, 300 MHz) δ 1.17 (s, 6H), 1.02 (s, 9H), 3.83 (s, 3H), 3.91 (s, 3H), 4.91 (s,
2H), 6.93 (s, 1H), 7.37 (s, 1H).
T4c: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.01 (s, 9H), 1.65 (s, 9H), 3.85 (s, 3H), 4.93 (s,
2H), 6.96 (s, 1H), 7.40 (s, 1H).
T4d: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 3.45 (s, 3H), 3.76 (t, J=12 Hz,
2H), 3.86 (s, 3H), 4.50 (t, J=12 Hz, 2H), 4.96 (s, 2H), 6.98 (s, 1H), 7.45 (s, 1H).
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T4f: 1H NMR (CDCl3, 400 MHz) δ 0.11(s, 6H), 1.04 (s, 9H,), 1.46 (s, 6H,), 4.03 (d, 2H,), 4.35
(d, 2H), 4.96 (s, 2H), 6.93(s, 1H), 7.40(s, 1H).
T4g: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 1.38 (d, 6H), 1.43 (t, 3H), 4.48 (d,
2H), 4.57 (s, 2H), 6.97 (s, 1H), 7.41 (s, 1H).
T4h: 1HNMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 1.46 (t, J=6 Hz, 3H), 3.87 (s, 3H),
4.39 (q, J=6 Hz, 2H), 4.93 (s, 2H), 7.08 (s, 1H) 7.35 (s, 1H).

Synthesis of ethyl 5-((tert-butyldimethylsilyl)oxy)-2-(((3-(ethoxycarbonyl)-6-methoxy-2methylbenzofuran-5-yl)oxy)methyl)-6-methoxybenzofuran-3-carboxylate (T5a ̶ T5b).
H3 CO
H 3CO

O

Br

H3 CO

Cs2CO 3

O

O

O
OR"

TBDMSO

O

TBDMSO
OC 2H 5

OC 2H 5

O

O
5a: R" = -C 2 H5
5b: R" = -CH2CHCH2

To a solution of T2a or T2e (0.3 mmol) and T4a (0.4 mmol) in ethyl acetate (4 mL) were added
cesium carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred
under nitrogen for 15 hours at room temperature. The reaction was quenched with methylene
chloride and extracted with brine. The organic layer was dried over magnesium sulfate and
concentrated. Purification was done by using flash chromatography on silica gel using (0-20) %
ethyl acetate in hexanes. The product was obtained in 60-65 % yield.
T5a: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 1.46 (m, 6H), 2.71 (s, 3H), 3.87
(s, 3H), 3.91 (s, 3H), 4.39 (m, 4H), 5.60 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.42 (s, 1H), 7.55 (s,
1H).

13

C NMR (CDCl3) δ 4.55, 14.41, 14.73, 14.68, 18.92, 25.57, 55.77, 56.62, 60.62, 61.93,
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64.47, 95.27, 98.31, 103.47, 109.31, 112.55, 112.73, 117.90, 119.98, 143.29, 146.34, 147.95,
148.08, 151.20, 150.69, 157.66, 162.67, 164.17, 164.83.
T5b: 1H NMR (CDCl3, 400 MHz) δ 0.15 (s, 6H), 1.00 (s, 9H), 1.37 (t, J=10.2 Hz, 3H), 2.70 (s,
3H), 3.82 (s, 3H), 3.85 (s, 3H), 4.35 (q, J=10.2 Hz, 2H), 4.80 (d, J=5.6 Hz, 2H), 5.20 (m, 1H),
5.38 (m, 1H), 5.57 (s, 2H), 5.99 (m, 1H), 6.97 (s, 1H), 6.98 (s, 1H), 7.24 (s, 1H), 7.44 (s, 1H),
7.59 (s, 1H).

13

C NMR (CDCl3) δ 4.72, 14.20, 14.46, 18.49, 25.75, 55.77, 56.31, 60.52, 63.93,

64.78, 95.32, 107.68, 108.93, 11.88, 118.33, 132.39, 143.07, 145.83, 148.91, 149.09, 149.94,
150.70, 157.79, 162.62, 163.67.

Synthesis of ethyl 5-(hydroxy)-2-(((3-(ethoxycarbonyl)-6-methoxy-2-methylbenzofuran-5yl)oxy)methyl)-6-methoxybenzofuran-3-carboxylate (T6a ̶T6b).

To a solution of T5a – T5b (0.3 mmol) in DMF (3 mL) were added KF (4 mmol) and acetic acid
(10 µL). The reaction mixture was stirred for 5 hours. The reaction was quenched by methylene
chloride and extracted with brine solution. The aqueous layer was again extracted with fresh
methylene chloride. The organic layer was combined and dried over magnesium sulfate and
concentrated in vacuum. The solid was precipitated using methanol to obtain product in 90%
yield.
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T6a: 1H NMR (CDCl3, 300 MHz) δ 1.46 (m, 6H), 2.71 (s, 3H), 3.80 (s, 3H), 3.85 (s, 3H), 4.39
(m, 4H), 5.35 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.42 (s, 1H), 7.55 (s, 1H). 13C NMR (CDCl3) δ
14.41, 14.73, 14.68, 25.57, 55.77, 56.62, 60.62, 61.93, 64.47, 95.27, 98.31, 103.47, 109.31,
112.55, 112.73, 117.90, 119.98, 143.29, 146.34, 147.95, 148.08, 151.20, 150.69, 157.66, 162.67,
164.17, 164.83.
T6b: 1H NMR (CDCl3, 400 MHz) δ 1.39 (t, J=10.2 Hz, 3H), 2.71 (s, 3H), 3.87 (s, 3H), 3.3 (s,
3H), 4.36 (q, J=10.2 Hz, 2H), 4.80 (d, J=5.6 Hz, 2H), 5.23 (m, 1H), 5.38 (m, 1H), 5.60 (s, 2H),
5.99 (m, 1H), 6.98 (s, 1H), 7.02 (s, 1H), 7.50 (s, 1H), 7.59 (s, 1H).

13

C NMR (CDCl3) δ 14.15,

14.37, 56.26, 60.64, 64.02, 84.81, 64.91, 94.63, 95.37, 105.85, 106.05, 107.84, 118.09, 118.28,
132.25, 143.70, 145.69, 146.51, 147.68, 148.80, 148.88, 149.11, 157.92, 162.72, 162.81, 163.82.

Synthesis of T7a ̶ T7h
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R

R’

R”

T7a

-C2H5

- CH3

-H

T7b

- CH3

- CH3

-H

T7c

-C(CH3)3

- CH3

-H

T7d

-C2H4OCH3

- CH3

-H

T7e

-C2H5

-CH3

-CH2CHCH2

T7f

-C2H5

- C2H5

-H

T7g

-C2H5

- CH(CH3)2

-H

T7h

-C2H5

-CH3

-H

To a solution of T6a-T6b (0.3 mmol) and T4a ̶ T4h (0.4 mmol) in ethyl acetate (3 mL) were
added cesium carbonate (0.3 mmol) and anhydrous DMF (0.5 mL) in a microwave tube (10 mL).
The reaction mixture was stirred under microwave radiation at 90 °C for 80 minutes. The
reaction was quenched with methylene chloride and extracted with brine. The organic layer was
dried over magnesium sulfate and concentrated. Purification was by using flash chromatography
on silica gel using 20-60) % ethyl acetate in hexanes. The product was obtained in 50 % yield
(see Appendix, Page 318-325 for NMR spectra).
T7a: 1H NMR (CDCl3, 400 MHz) δ 0.16 (s, 6H), 1.02 (s, 9H), 1.37 (m, 9H), 2.71 (s, 3H), 3.83
(s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 4.35 (m, 6H), 5.59 (s, 2H), 5.60 (s, 2H), 6.98 (s, 1H), 7.00 (s,
1H), 7.05 (s, 1H), 7.45 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H).
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13

C NMR (CDCl3) δ 4.73, 14.20,

14.23, 14.28, 14.36, 14.39, 25.74, 55.76, 56.25, 56.29, 60.11, 60.56, 60.70, 63.77, 64.02, 95.28,
95.53, 106.05, 107.59, 107.82, 109.10, 111.93, 112.04, 112.52, 117.72, 117.86, 118.39, 143.08,
145.66, 146.07, 148.86, 149.10, 149.84, 149.94, 150.14, 150.72, 157.68, 157.89, 162.37, 163.49,
163.68, 164.40.
T7b: 1H NMR (CDCl3, 400 MHz) δ 0.16 (s, 6H), 1.02 (s, 9H), 1.35 (m, 6H), 2.70 (s, 3H), 3.83
(s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 3.91 (s, 3H), 4.34 (s, 4H), 5.58 (s, 2H), 5.59 (s, 2H), 6.98 (s,
1H), 7.00 (s, 1H), 7.05 (s, 1H), 7.43 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H).

13

C NMR (CDCl3, 400

MHz) δ 4.72, 14.23, 14.37, 14.39, 18.49, 25.76, 51.63, 55.71, 56.26, 56.31, 60.11, 60.57, 63.86,
64.06, 95.23, 95.32, 95.56, 107.74, 107.89, 109.12, 111.78, 112.03, 112.44, 117.77, 117.86,
118.42, 143.15, 145.68, 146.05, 148.89, 149.12, 149.88, 149.95, 150.75, 157.67, 157.91, 162.38,
163.49, 163.78, 164.40.
T7c: 1H NMR (CDCl3, 400 MHz) δ 0.16 (s, 6H), 1.02 (s, 9H), 1.35 (m, 6H), 1.58 (s, 9H), 2.70
(s, 3H), 3.83 (s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 4.33 (m, 4H), 5.57 (s, 2H), 5.59 (s, 2H), 6.97 (s,
1H), 6.99 (s, 1H), 7.05 (s, 1H), 7.42 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H).

13

C NMR (CDCl3, 400

MHz) δ 4.74, 14.25, 14.37, 14.39, 18.47, 25.75, 28.33, 55.74, 56.24, 56.31, 60.12, 60.56, 63.91,
64.05, 81.41, 95.23, 95.32, 95.53, 107.64, 107.90, 109.12, 112.05, 112.66, 113.14, 117.75,
118.08, 118.42, 142.91, 145.68, 146.23, 148.89, 149.12, 149.87, 150.14, 150.59, 157.34, 157.88,
162.38, 162.51, 162.86, 163.50, 164.40.
T7d: 1H NMR (CDCl3, 400 MHz) δ 0.16 (s, 6H), 1.02 (s, 9H), 1.33 (m, 6H), 2.70 (s, 3H), 3.37 (s,
3H), 3.71 (m, 2H), 3.83 (s, 3H), 3.85 (s, 3H), 3.87 (s, 3H), 4.34 (m, 4H), 4.45 (m, 2H), 5.58 (s,
2H), 5.61 (s, 2H), 6.97 (s, 1H), 6.99 (s, 1H), 7.05 (s, 1H), 7.46 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H).
13

C NMR (CDCl3, 400 MHz) δ 4.7, 14.25, 14.28, 14.38, 18.49, 25.76, 55.70, 56.27,56.32, 58.94,
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60.12, 60.57, 63.51, 63.75, 64.07, 70.40, 95.28, 95.33, 95.56, 107.47, 107.90, 109.12, 111.77,
112.50, 112.60, 117.75, 117.83, 118.43, 143.16, 145.69, 146.13, 148.90, 149.12, 149.82, 149.97,
150.32, 157.89, 157.97, 162.38, 163.49, 163.60, 164.40.
T7e: 1H NMR (CDCl3, 400 MHz) δ 0.02 (s, 6H), 1.02 (s, 9H), 1.37 (m, 6H), 2.72 (s, 3H), 3.84 (s,
3H), 3.86 (m, 2H), 3.88 (s, 3H), 4.26 (m, 4H), 4.62 (m, 2H), 5.22 (s, 1H), 5.25 (s, 1H), 5.58 (s,
2H), 5.62 (s, 2H), 6.01 (m, 1H), 6.98 (s, 1H), 7.00 (s, 1H), 7.05 (s, 1H), 7.45 (s, 1H), 7.60 (s,
1H), 7.64 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 4.72, 14.20, 14.24, 14.47, 18.49, 25.75, 55.76,
56.26, 56.31, 60.56, 63.79, 64.00, 64.78, 95.30, 95.33, 95.56, 107.64, 107.76, 108.92, 111.94,
112.08, 112.53, 117.75, 117.89, 118.11, 118.33, 132.37, 143.09, 145.76, 146.09, 148.91, 149.11,
149.86, 149.95, 150.16, 150.73, 157.70, 157.82, 162.63, 163.47.
T7f: 1H NMR (CDCl3, 400 MHz) δ -0.17 (s, 6H), 1.03 (s, 9H), 1.34 (m, 12H), 2.71 (s, 3H), 3.86
(s, 3H), 3.87 (s, 3H), 4.18 (m, 2H), 4.35 (m, 6H), 5.58 (s, 3H), 5.60 (s, 3H), 6.98 (s, 1H), 6.99 (s,
1H), 7.05 (s, 1H), 7.45 (s, 1H), 7.58 (s, 1H), 7.64 (s, 1H).

13

C NMR (CDCl3) δ 4.71, 14.21,

14.23, 14.27, 14.29, 14.36, 14.38, 25.71, 55.77, 56.27, 56.30, 60.14, 60.56, 60.72, 63.77, 64.12,
95.30, 95.52, 95.99, 106.05, 107.61, 107.82, 109.13, 111.83, 112.10, 112.52, 117.62, 117.84,
118.44, 143.08, 145.61, 146.17, 148.76, 149.11, 149.83, 149.94, 150.14, 150.72, 157.68, 157.89,
162.33, 163.43, 163. 65,164.42.
T7g: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 1.35 (m, 15H), 2.70 (s, 3H), 3.85
(s, 3H), 3.87 (s, 3H), 4.35 (m, 6H), 4.58 (m, 1H), 5.58 (s, 3H), 5.60 (s, 3H), 6.97 (s, 1H), 6.99 (s,
1H), 7.05 (s, 1H), 7.43 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 4.74,
14.24, 14.27, 14.28, 14.30, 14.36, 14.35, 25.71, 55.75, 56.27, 56.31, 60.14, 60.58, 60.72, 63.74,
64.12, 95.31, 95.55, 95.91, 106.05, 107.61, 107.85, 109.13, 111.83, 112.13, 112.52, 117.64,
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117.84, 118.44, 143.12, 145.61, 146.11, 148.76, 149.19, 149.73, 149.94, 150.24, 150.72, 157.58,
157.89, 162.33, 163.43, 163.67, 164.48.
T7h:1H NMR (CDCl3, 400 MHz) δ 0.16 (s, 6H), 1.00 (s, 9H), 1.35 (m, 9H), 2.70 (s, 3H), 3.86 (s,
3H), 3.87 (s, 9H), 4.35 (m, 6H), 5.58 (s, 4H), 6.97 (s, 1H), 7.03 (s, 1H), 7.05 (s, 1H), 7.44 (s,
1H), 7.57 (s, 1H), 7.64 (s, 1H).

13

C NMR (CDCl3, 400 MHz) δ 4.72, 14.26, 14.37 (2C), 18.49,

25.70, 28.26, 55.88, 56.26, 56.31, 60.11, 60.57, 60.59, 60.66, 64.07, 95.33, 95.57, 103.47,
103.61, 103.85, 103.95, 107.91, 107.95, 109.12, 111.99, 112.03, 117.78, 118.43, 119.08, 144.71,
145.69, 146.10, 148.90, 149.13, 149.58, 149.95, 150.23, 157.70, 157.93, 162.38, 163.70, 164.40.

Synthesis of T8a ̶ T8g

To a solution of T7a ̶ T7g (0.3 mmol) in DMF (3 mL) were added KF (4 mmol) and acetic acid
(10 µL). The reaction mixture was stirred for 5 hours. The reaction was quenched by methylene
chloride and extracted with brine solution. The aqueous layer was again extracted with
methylene chloride. The organic layer was combined and dried over magnesium sulfate and
concentrated in vacuum. The solid was precipitated using methanol to obtain product in 90%
yield (see Appendix, Page 326-332 for NMR spectra).
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T8a: 1H NMR (CDCl3, 400 MHz) δ 1.35 (m, 9H), 2.72 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 3.93
(s, 3H), 4.35 (m, 6H), 5.58 (s, 2H), 5.62 (s, 2H), 6.97 (s, 1H), 7.02 (s, 1H), 7.15 (s, 1H), 7.39 (s,
1H), 7.51 (s, 1H), 7.59 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 14.22, 14.31, 14.36, 14.39, 56.24,
56.31, 60.11, 60.56, 60.64, 63.83, 64.06, 94.49, 95.33, 95.58, 106.07, 107.71, 107.90,
109.12,112.02, 117.76, 118.35, 118.42, 143.59, 145.68, 146.04, 146.09, 148.72, 148.88, 149.12,
149.75, 150.46, 157.93, 158.12, 162.39, 163.37, 163.68, 164.43.
T8b: 1H NMR (CDCl3, 400 MHz) δ 1.34 (m, 6H), 2.70 (s, 3H), 3.85 (s, 3H), 3.88 (s, 3H), 3.92
(s, 3H), 3.93 (s, 3H), 4.34 (m, 4H), 5.58 (s, 2H), 5.61 (s, 2H), 6.97 (s, 1H), 7.01 (s, 1H), 7.05 (s,
1H), 7.49 (s, 1H), 7.56 (s, 1H), 7.62 (s, 1H).

13

C NMR (CDCl3, 400 MHz) δ 14.21, 14.36, 14.39,

51.63, 56.28, 56.31, 60.11, 60.57, 63.80, 64.06, 94.49, 95.33, 95.58, 106.05, 107.76, 107.90,
109.11, 111.85, 112.02, 117.77, 118.27, 118.43, 143.66, 145.68, 145.98, 146.16, 148.82, 148.89,
149.12, 149.86, 150.17, 157.93, 158.05, 162.39, 162.69, 163.47, 164.08, 164.40.
T8c: 1H NMR (CDCl3, 400 MHz) δ 1.34 (m, 6H), 1.57 (s, 9H), 2.70 (s, 3H), 3.85 (s, 3H), 3.86
(s, 3H), 3.92 (s, 3H), 4.34 (m, 4H), 5.58 (s, 2H), 5.59 9s, 2H), 6.97 (s, 1H), 7.00 (s, 1H), 7.05 (s,
1H), 7.46 (s, 1H), 7.58 (s, 1H), 7.61 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 14.23, 14.36, 14.38,
28.33, 56.25, 56.28, 56.32, 60.12, 60.56, 64.00, 64.05, 81.58, 94.43, 95.34, 95.56, 106.08,
107.79, 107.91, 109.12, 112.04, 113.19, 117.77, 118.43, 118.61, 143.49, 145.68, 146.00, 146.16,
148.71, 148.90, 149.12, 149.89, 150.16, 157.48, 157.90, 162.38, 162.66, 162.85, 163.47.
T8d: 1H NMR (CDCl3, 400 MHz) δ 1.33 (m, 6H), 2.70 (s, 3H), 3.37 9s, 3H), 3.70 (m, 3H), 3.85
(s, 3H), 3.87 (s, 3H), 3.92 (s, 3H), 4.34 (m, 4H), 4.47 (m, 2H), 5.58 (s, 2H), 5.61 (s, 2H), 6.97 (s,
1H), 7.01 (s, 1H), 7.05 (s, 1H), 7.50 (s, 1H), 7.56 (s, 1H), 7.62 (s, 1H).

13

C NMR (CDCl3, 400

MHz) δ 14.22, 14.37, 28.25, 35.48, 56.29, 58.93, 60.12, 60.58, 63.47, 63.81, 64.08, 70.38, 70.46,
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94.43, 95.34, 95.56, 106.07, 107.54, 107.93, 109.12, 111.82, 112.04, 117.78, 118.34, 118.44,
143.70, 145.70, 146.09, 146.19, 148.84, 148.91, 149.13, 149.81, 150.13, 157.91, 158.17, 162.38,
162.64, 163.46, 164.40.
T8e: 1H NMR (CDCl3, 400 MHz) δ 1.31 (t, J=6.8 Hz, 3H), 1.39 (t, J=6.8 Hz, 3H), 2.71 (s, 3H),
3.87 (s, 3H), 3.88 (s, 3H), 3.92 (s, 3H), 4.37 (m, 4H), 4.79 (d, J=5.6 Hz, 2H), 5.22 (m, 2H), 5.33
(m, 2H), 5.57 (s, 2H), 5.62 (s, 2H), 6.00 (m, 1H), 6.97 (s, 1H), 7.01 (s, 1H), 7.04 (s, 1H), 7.49 (s,
1H), 7.59 (s, 1H), 7.62 (s, 1H).

13

C NMR (CDCl3) δ 14.20, 14.24, 14.47, 25.75, 55.76, 56.26,

56.31, 60.56, 63.79, 64.00, 64.78, 95.30, 95.33, 95.56, 107.64, 107.76, 108.92, 11.94, 112.08,
112.53, 116.05, 117.79, 119.11, 119.93, 131.35, 143.09, 145.76, 146.09, 148.59, 149.01, 149.53,
148.75, 151.06, 151.71, 157.38, 167.92, 163.61, 164.07.
T8f: 1H NMR (CDCl3, 400 MHz) δ 1.35 (m, 12H), 2.71 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 4.17
(m, 2H), 4.35 (m, 6H), 5.58 (s, 3H), 5.62 (s, 3H), 6.98 (s, 1H), 7.00 (s, 1H), 7.05 (s, 1H), 7.50 (s,
1H), 7.57 (s, 1H), 7.62 (s, 1H). ). 13C NMR (CDCl3) δ 14.20, 14.24, 14.29, 14.31, 14.36, 14.38,
55.78, 56.29, 56.32, 60.15, 60.57, 60.74, 63.77, 64.19, 95.34, 95.52, 95.89, 106.15, 107.61,
107.85, 109.13, 111.73, 112.10, 112.42, 117.65, 117.84, 118.44, 143.08, 145.65, 146.17, 148.76,
149.21, 149.83, 149.94, 150.14, 150.72, 157.68, 157.85, 162.33, 163.47, 163.65, 164.42.
T8g: 1H NMR (CDCl3, 400 MHz) δ 1.37 (m, 15H), 2.70 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 4.36
(m, 6H), 4.58 (m, 1H), 5.58 (s, 3H), 5.62 (s, 3H), 6.97 (s, 1H), 7.02 (s, 1H), 7.05 (s, 1H), 7.49 (s,
1H), 7.57 (s, 1H), 7.63 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 14.21, 14.25, 14.27, 14.34, 14.36,
14.38, 55.79, 56.25, 56.40, 60.12, 60.56, 60.62, 63.77, 64.12, 95.40, 95.52, 95.79, 106.15,
107.51, 107.72, 109.43, 111.63, 112.10, 112.52, 117.52, 117.83, 118.44, 143.08, 145.51, 146.17,
148.66, 149.11, 149.53, 149.64, 150.24, 150.72, 157.88, 157.92, 162.33, 163.33, 163.65, 164.32.
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T8h: 1H NMR (CDCl3, 400 MHz) δ 1.35 (m, 9H), 2.72 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 3.93
(s, 3H), 4.35 (m, 6H), 5.58 (s, 2H), 5.62 (s, 2H), 6.97 (s, 1H), 7.02 (s, 1H), 7.15 (s, 1H), 7.39 (s,
1H), 7.51 (s, 1H), 7.59 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 14.22, 14.31, 14.36, 14.39, 56.24,
56.31, 60.11, 60.56, 60.64, 63.83, 64.06,

94.49, 95.33, 95.58, 106.07, 107.71, 107.90,

109.12,112.02, 117.76, 118.35, 118.42, 143.59, 145.68, 146.04, 146.09, 148.72, 148.88, 149.12,
149.75, 150.46, 157.93, 158.12, 162.39, 163.37, 163.68, 164.43.

Synthesis of T13

To a solution of T8e (0.19 mmol) in methylene chloride (1.5 mL) were added Pd(PPh3)4 (0.009
mmol) and PPh3 (0.018 mmol). The reaction mixture was stirred for 10 minutes in ice bath to
bring temperature down. To this mixture was added pyrrolidine (0.21 mmol) and it was stirred
for 30 minutes. The reaction was quenched by methylene chloride and extracted with brine
solution. The aqueous layer was again extracted with methylene chloride. The organic layer was
combined and dried over magnesium sulfate and concentrated in vacuum. The solid obtained was
washed with hexane several times to remove excess of PPh3 and purified by flash
chromatography using ethyl acetate and hexanes (40% to 80%) as the solvent system (see
Appendix, Page 331 for NMR spectra).
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T13: 1H NMR (DMSO-d6, 400 MHz) δ 1.25 (t, J=7.2 Hz, 3H), 1.30 (t, J=7.2 Hz, 3H), 2.66 (s,
3H), 3.78 (s, 3H), 3.82 (s, 6H), 4.29 (m, 4H), 5.50 (s, 2H), 5.52 (s, 2H), 7.26 (s, 1H), 7.30 (s,
1H), 7.32 (s, 1H), 7.41 (s, 1H), 7.48 (s, 2H).

13

C NMR (DMSO-d6, 400 MHz) δ 13.85, 13.96,

54.85, 55.95, 55.99, 56.04, 60.38, 60.50, 62.62, 62.74, 95.67, 95.95, 96.17, 105.93, 106.24,
108.95, 111.22, 111.43, 116.59, 116.99, 117.95, 144.82, 145.06, 145.63, 147.89, 147.97, 148.30,
148.36, 149.32, 149.61, 157.17, 157.59, 161.68, 162.58, 162.90, 165.02. MS (-ve) m/z calcd. for
C39H37O15 [(M-H)-)] 717.37, found 717.26 (M-H)-.

Synthesis of T9a ̶ T9g and T14

To a solution of T8a ̶ T8g (0.07 mmol) in acetonitrile: DMF (4:1, 0.45 mL) in a microwave tube
were added triethylamine (10 equiv) and trimethylamine-sulfur trioxide complex (15 equiv). The
reaction mixture was exposed to microwaves (50 W) for 40 min at 100 °C followed by vacuum
concentration to remove all solvent. The solid so obtained was directly loaded on a Sephadex C25 cation exchange resin and eluted with water. Fractions containing the sulfated product were
lyophilized to obtain a solid residue, which was further purified on flash chromatography using
0-20% methanol in methylene chloride (see Appendix, Page 334-342 for NMR spectra and page
344-348 for Mass Spectra).
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T9a: 1H NMR (DMSO-d6, 400 MHz) δ 1.24 (m, 12H), 2.65 (s, 3H), 3.77 (s, 6H), 3.80 (s, 3H),
4.26 (m, 6H), 5.49 (s, 2H), 5.53 (s, 2H), 7.30 (s, 1H), 7.32 (s, 1H), 7.36 (s, 1H), 7.41 (s, 1H),
7.46 (s, 1H), 8.03 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.84, 14.01, 14.16, 14.29, 56.04,
56.11, 60.23, 60.59, 60.74, 63.73, 64.16,

94.56, 95.44, 95.58, 106.17, 107.71, 107.94,

109.12,112.12, 117.44, 118.35, 118.22, 143.59, 145.68, 146.04, 146.09, 148.72, 148.88, 149.12,
149.75, 150.46, 156.93, 157.12, 161.39, 162.37, 162.68, 163.43. MS (-ve) m/z calcd. for
C39H37O18S [(M-Na)-)] 825.17, found 825.23 (M-Na)-.
T9b: 1H NMR (DMSO-d6, 400 MHz) δ 1.25 (m, 6H), 2.68 (s, 3H), 3.80 (s, 6H), 3.84 (s, 3H),
3.86 (s, 3H), 4.27 (m, 4H), 5.52 (s, 2H), 5.56 (s, 2H), 7.32 (s, 1H), 7.34 (s, 1H), 7.40 (s, 1H),
7.43 (s, 1H), 7.49 (s, 1H), 8.00 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.85, 14.00, 48.56,
51.76, 56.04, 56.09, 59.92, 60.47, 62.80, 62.97, 95.97, 96.06, 96.23, 106.53, 106.73, 108.26,
111.35, 111.39, 113.15, 116.28, 116.60, 117.31, 140.86, 145.10, 145.54, 148.51, 148.62, 149.39,
149.65, 150.21, 150.85, 157.63, 157.82, 162.07, 162.62, 163.18, 163.34. MS (-ve) m/z calcd. for
C38H35O18S [(M-Na)-)] 811.15, found 811.43 (M-Na)-.
T9c: 1H NMR (DMSO-d6, 400 MHz) δ 1.25 (m, 6H), 1.50 (s, 9H), 2.68 (s, 3H), 3.80(s, 3H),
3.81 (s, 3H), 3.82 (s, 3H), 4.27 (m, 4H), 5.51 (s, 2H), 5.53 (s, 2H), 7.31 (s, 1H), 7.32 (s, 1H),
7.40 (s, 1H), 7.43 (s, 1H), 7.48 (s, 1H), 8.11 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.87,
14.01, 14.04, 27.76, 56.01, 56.04, 56.07, 59.70, 59.92, 60.46, 62.93, 63.07, 95.60, 96.06, 96.23,
106.75, 106.84, 108.29, 111.38, 112.69, 113.08, 116.64, 116.74, 117.33, 140.86, 145.10, 145.70,
148.51, 148.64, 149.45, 149.74, 149.96, 150.52, 156.98, 157.83, 161.92, 162.05, 162.61, 163.34.
HRMS (-ve) m/z calcd. for C41H41O18S [(M-Na)-)] 853.20, found 853.46 (M-Na)-.
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T9d: 1H NMR (DMS0-d6, 400 MHz) δ 1.24 (m, 6H), 2.65 (s, 3H), 3.21 (s, 3H), 3.76 (m, 3H),
3.83 (s, 3H), 3.86 (s, 3H), 3.96 (s, 2H), 4.24 (m, 4H), 4.57 (m, 2H), 5.51 (s, 2H), 5.59 (s, 2H),
7.31 (s, 1H), 7.34 (s, 1H), 7.38 (s, 1H), 7.40 (s, 1H), 7.44 (s, 1H), 8.05 (s, 1H).

13

C NMR

(DMSO-d6, 400 MHz) δ 13.57, 14.17, 28.15, 35.41, 57.29, 58.83, 60.22, 60.51, 63.27, 63.61,
64.18, 70.48, 70.56, 94.73, 95.44, 95.66, 106.17, 107.54, 107.93, 109.12, 111.82, 112.04, 117.78,
118.34, 118.44, 143.70, 145.70, 146.09, 146.19, 148.84, 148.91, 149.13, 149.81, 151.13, 157.61,
158.11, 162.28, 162.44, 163.36, 164.10. MS (-ve) m/z calcd. for C39H37O19S [(M-Na)-)] 841.16
found 841.42 (M-Na)-.
T9e: 1H NMR (DMSO-d6, 400 MHz) δ 1.29 (m, 6H), 2.68 (s, 3H), 3.76 (s, 3H), 3.79 (s, 3H),
3.84 (s, 3H), 4.30 (m, 4H), 5.46 (s, 2H), 5.55 (s, 2H), 7.30 (s, 1H), 7.34 (s, 1H), 7.48 (s, 1H),
7.50 (s, 1H), 7.57 (s, 1H), 8.05 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.52, 13.89, 13.92,
14.05, 48.56, 52.81, 56.03, 56.05, 60.48, 60.53, 62.85, 63.22, 95.77, 96.06, 96.26, 96.36, 106.42,
107.37, 108.75, 111.42, 111.55, 113.19, 116.44, 116.63, 117.64, 140.85, 145.24, 145.63, 148.37,
148.62, 148.77, 149.40, 149.66, 150.17, 150.77, 157.45, 157.56, 157.67, 159.52, 162.24, 162.60,
162.68. MS (-ve) m/z calcd. for C40H37O18S [(M-Na)-)] 837.16, found 837.42 (M-Na)-.
T9f: 1H NMR (DMSO-d6, 400 MHz) δ 1.25 (m, 12H), 2.66 (s, 3H), 3.81 (s, 3H), 3.89 (s, 3H),
4.12 (m, 2H), 4.25 (m, 6H), 5.51 (s, 3H), 5.58 (s, 3H), 7.30 (s, 1H), 7.32 (s, 1H), 7.35 (s, 1H),
7.39 (s, 1H), 7.42 (s, 1H), 8.02 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.86, 14.04, 14.19,
14.23, 14.31, 14.34, 56.78, 56.99, 57.32, 60.35, 60.59, 60.84, 63.47, 64.59, 95.84, 95.92, 96.19,
106.55, 107.41, 107.84, 109.43, 111.763, 112.13, 113.42, 117.65, 117.84, 118.44, 143.08,
145.65, 146.17, 148.56, 149.01, 149.73, 149.84, 150.74, 151.72, 156.68, 156.85, 161.33, 163.27,
163. 45,164.22. MS (-ve) m/z calcd. for C40H339O18S [(M-Na)-)] 839.18, found 839.41 (M-Na)-.
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T9g: 1H NMR (DMSO-d6, 400 MHz) δ 1.27 (m, 15H), 2.64 (s, 3H), 3.81 (s, 3H), 3.87 (s, 3H),
4.26 (m, 6H), 4.42 (m, 1H), 5.52 (s, 3H), 5.59 (s, 3H), 7.30 (s, 1H), 7.32 (s, 1H), 7.37 (s, 1H),
7.39 (s, 1H), 7.43 (s, 1H), 8.00 (s, 1H). 13C NMR (DMS0-d6, 400 MHz) δ 13.88, 14.15, 14.26,
14.31, 14.33, 14.37, 56.79, 57.25, 57.40, 60.62, 60.76, 60.68, 63.57, 64.33, 95.63, 95.72, 95.89,
107.15, 107.58, 107.92, 109.83, 112.63, 112.90, 113.52, 117.52, 117.83, 118.44, 143.08, 145.51,
146.17, 148.66, 149.11, 149.53, 149.64, 150.24, 151.72, 158.88, 158.92, 162.63, 163.13, 163.
45,164.12. MS (-ve) m/z calcd. for C41H41O18S [(M-Na)-)] 853.20, found 853.47 (M-Na)-.
T9h: 1H NMR (DMSO-d6, 400 MHz) δ 1.25 (m, 9H), 2.64 (s, 3H), 3.82 (s, 3H), 3.87 (s, 3H),
3.91 (s, 3H), 4.25 (m, 6H), 5.51 (s, 2H), 5.58 (s, 2H), 7.31 (s, 1H), 7.34 (s, 1H), 7.35 (s, 1H),
7.41 (s, 1H), 7.46 (s, 1H), 8.02 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.82, 14.11, 14.26,
14.31, 56.84, 56.91, 60.41, 60.76, 60.94, 63.63, 64.16, 94.79, 95.93, 96.18, 106.27, 107.74,
107.98, 109.52,112.02, 117.76, 118.35, 118.42, 141.59, 144.68, 144.84, 145.09, 148.12, 148.48,
149.02, 149.75, 150.36, 157.63, 157.92, 162.49, 163.07, 163.48, 164.13. MS (-ve) m/z calcd. for
C39H37O18S [(M-Na)-)] 825.17, found 825.29 (M-Na)-.
T14: 1H NMR (DMSO-d6, 400 MHz) δ 1.29 (m, 6H), 2.68 (s, 3H), 3.76 (s, 3H), 3.79 (s, 3H),
3.84 (s, 3H), 4.30 (m, 4H), 5.46 (s, 2H), 5.55 (s, 2H), 7.30 (s, 1H), 7.34 (s, 1H), 7.48 (s, 1H),
7.50 (s, 1H), 7.57 (s, 1H), 8.05 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.52, 13.89, 13.92,
14.05, 48.56, 52.81, 56.03, 56.05, 60.48, 60.53, 62.85, 63.22, 95.77, 96.06, 96.26, 96.36, 106.42,
107.37, 108.75, 111.42, 111.55, 113.19, 116.44, 116.63, 117.64, 140.85, 145.24, 145.63, 148.37,
148.62, 148.77, 149.40, 149.66, 150.17, 150.77, 157.45, 157.56, 157.67, 159.52, 162.24, 162.60,
162.68. MS (-ve) m/z calcd. for C37H33O18S [(M-Na)-)] 793.13, found 793.27 (M-Na)-.
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Synthesis of T10
H3CO
H3 CO
H3CO
H3CO

T8a + T4a

O

O

O

O

O
O

O

OC2H5

OC2 H5
O

O
OC2 H5
O

TBDMSO
OC2H5
O

To a solution of T8a (0.3 mmol) and T4a (0.4 mmol) in ethyl acetate (3 mL) were added cesium
carbonate (0.3 mmol) and anhydrous DMF (0.5 mL) in a microwave tube (10 mL). The reaction
mixture was stirred under microwave radiation at 90 °C for 80 minutes. The reaction was
quenched with methylene chloride and extracted with brine. The organic layer was dried over
magnesium sulfate and concentrated. Purification was done by using flash chromatography on
silica gel using 30-70% ethyl acetate in hexanes. The product was obtained in 50 % yield (see
Appendix, Page 341 for NMR spectra).
1

H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 1.35 (m, 12H), 2.71 (s, 3H), 3.83 (s,

3H), 3.86 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 4.35 (m, 8H), 5.58 (s, 2H), 5.60 (s, 2H), 5.61 (s,
2H), 6.98 (s, 1H), 7.00 (s, 1H), 7.05 (s, 2H), 7.45 (s, 1H), 7.58 (s, 1H), 7.63 (s, 1H), 7.64 (s, 1H).
13

C NMR (CDCl3, 400 MHz) δ 4.71, 14.08 (2C), 14.20, 14.24, 14.37, 18.48, 25.75, 55.77, 56.27

(2C), 56.23, 60.10, 60.55 (2C), 60.58, 63.86, 63.91, 64.09, 95.32 (2C), 95.36, 95.59, 107.77,
107.97, 109.13, 111.93, 112.03, 112.13, 112.53, 117.72, 117.80, 117.91, 118.45, 143.12, 145.72,
146.10, 146.15, 148.93, 149.14, 149.90, 149.95 (2C), 150.19 (2C), 150.74, 157.71 (2C), 157.75,
157.95, 162.37, 163.47, 163.67, 164.38.
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Synthesis of T11

To a solution of T10 (0.3 mmol) in DMF (3 mL) were added KF (4 mmol) and acetic acid (10
µL). The reaction mixture was stirred for 5 hours. The reaction was quenched by methylene
chloride and extracted with brine solution. The aqueous layer was again extracted with
methylene chloride. The organic layer was combined and dried over magnesium sulfate and
concentrated in vacuum. The solid was precipitated using methanol to obtain product in 90%
yield (see Appendix, Page 342 for NMR spectra).
1

H NMR (CDCl3, 400 MHz) δ 1.35 (m, 12H), 2.70 (s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 3.88 (s,

3H), 3.93 (s, 3H), 4.35 (m, 8H), 5.58 (s, 2H), 5.59 (s, 2H), 5.62 (s, 2H), 6.98 (s, 1H), 7.02 (s,
1H), 7.05 (s, 2H), 7.49 (s, 1H), 7.57 (s, 1H), 7.62 (s, 2H). 13C NMR (CDCl3, 400 MHz) δ 14.22,
14.29 (2C), 14.36, 14.39, 56.28 (4C), 60.12, 60.57, 60.60 (2C), 60.64, 63.81 (2C), 64.03, 94.48
(2C), 95.32, 95.56, 106.07 (2C), 107.66, 107.71, 107.84, 109.10, 112.00, 112.12, 117.68, 117.75,
118.30, 118.41, 143.63 (2C), 145.67, 146.05, 146.16, 148.81 (2C), 148.87, 149.11, 149.87,
150.16 (2C), 157.72, 157.91, 157.97 (2C), 162.38, 162.73, 163.46, 163.67.
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Synthesis of T12

To a solution of T11 (0.05 mmol) in acetonitrile: DMF (4:1, 0.45 mL) in a microwave tube were
added triethylamine (10 equiv) and trimethylamine-sulfur trioxide complex (15 equiv). The
reaction mixture was exposed to microwaves (50 W) for 40 min at 100 °C followed by vacuum
concentration to remove all solvent. The solid so obtained was directly loaded on a Sephadex C25 cation exchange resin and eluted with water. Fractions containing the sulfated product were
lyophilized to obtain a solid residue, which was further purified on flash chromatography using
0-20% methanol in methylene chloride (see Appendix, Page 343 for NMR spectra).
1

H NMR (DMSO-d6, 400 MHz) δ 1.30 (m, 12H), 2.66 (s, 3H), 3.79 (s, 6H), 3.81 (s, 3H), 3.82 (s,

3H), 4.28 (m, 8H), 5.51 (s, 2H), 5.53 (s, 2H), 5.55 (s, 2H), 7.31 (s, 1H), 7.33 (s, 1H), 7.37 (s,
2H), 7.42 (s, 2H), 7.49 (s, 1H), 8.05 (s, 1H).

13

C NMR (DMSO-d6, 400 MHz) δ 13.79, 13.87,

14.00, 14.01, 56.02 (4C), 56.08, 59.90, 60.60 (2C), 60.45, 62.89 (2C), 95.72 (2C), 96.07, 96.25,
106.57 (2C), 106.67, 107.71, 107.84, 109.10, 112.00, 112.12, 117.68, 117.75, 118.30, 118.41,
143.63 (2C), 145.67, 146.05, 146.16, 148.81 (2C), 148.87, 149.11, 149.87, 150.16 (2C), 157.42
175

162.08, 162.62, 162.68, 163.34. MS (-ve) m/z calcd. forC52H49O23S [(M-Na)-)] 1073.44, found
1073.67 (M-Na)-.

5.4.3 Substrate Hydrolysis Assay
Thrombin activity in the presence of inhibitors was studied using a chromogenic substrate
hydrolysis assay in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2
and 0.1 % polyethylene glycol (PEG) 8000 in PEG 20,000-coated acrylic cuvettes. Spectrozyme
TH was used as substrate and the residual thrombin activity was quantified by measuring the
initial rate of hydrolysis from the linear increase in absorbance at 405 nm as a function of time.
Briefly, a solution of 10 µL of the inhibitors to form final concentrations ranging from 4.5 – 900
µM, was diluted with 970 µL of buffer and 5 µL of 1 µM thrombin (5 nM) and incubated. This
was followed by addition of 15 µL of 2 mM Spectrozyme TH (30 µM) and the initial rate was
quickly measured. Logistic equation 4 was used to fit the dose dependence of residual thrombin
activity to obtain IC50.
 =  +

 
(     )×

Equation 4

In this equation, Y is the ratio of residual thrombin activity in the presence of the inhibitor to that
in its absence; YM and Y0 are the maximum and minimum possible values of the fractional
residual thrombin activity, respectively; and IC50 is the concentration of inhibitors that results in
50% inhibition of enzyme activity. Sigmaplot 8.0 (SPSS, Inc. Chicago, IL) was used to perform
non-linear curve fitting in which YM, YO, and IC50 were allowed optimized.
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5.4.4 Michaelis-Menten Kinetics of Substrate Hydrolysis by Thrombin in Presence of T9a
The initial rate of Spectrozyme TH hydrolysis by 5 nM thrombin was monitored from the
linear increase in absorbance at 405 nm corresponding to less than 10% consumption of the
substrate. The initial rate was measured as a function of various concentrations of the substrate (2
– 80 µM) in the presence of fixed concentrations of 9a (0–3.6 µM), from one or three different
stock solutions, incubated with thrombin either overnight at 25°C or for two hours at 37°C in 20
mM Tris-HCl buffer, pH 7.4, to ensure the prevention of aggregation at both conditions. The
data was fitted by the standard Michaelis-Menten equation to determine KM and VMAX.

5.4.5 Plasma Studies (Prothrombin Time and Activated Partial Thromboplastin Time)
For both PT and APTT assays, standard 1-stage recalcification assay with a BBL
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD) was used to measure the clotting time.
For the APTT assay, 90 µL citrated human plasma, 10 µL inhibitor (or vehicle for blank test),
and 100 µL of pre-warmed APTT reagent (0.2% ellagic acid) were mixed and incubated for 4
minutes. The clotting was initiated by adding 100 µL of 25 mM CaCl2 (37 OC) and the time to
clot was recorded. For Prothrombin (PT) assays, a 10 µL sample of the inhibitor (or vehicle for
blank test), and 90 µL of citrated human plasma were mixed and incubated for 30 seconds at 37
O

C followed by addition of 200 µL pre-warmed thromboplastin (Reconstituted as per directions

provided by manufacturer). Each clotting assay was performed in duplicate. The data were fit to
a quadratic trend line, which was used to determine the concentration of the inhibitor necessary
to double the clotting time, 2×APTT or 2×PT.
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5.4.6 Screening Protocols
Screening of library for Factor VIIa inhibition ̶ Direct inhibition of factor VIIa by the library
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000 and 0.02%
Tween 80. Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 75 µL
volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this solution was
added 10 µL of FVIIa solution to give approximately 80 nM initial FVIIa concentration and 5 µL
of tissue factor solution to give 800 nM. After 10 min of incubation, 5 µL of 20 mM
Spectrozyme factor VIIa was rapidly added and the residual factor VIIa activity was measured
from the initial rate of increase in absorbance at 405 nm. The plate was read using a microplate
reader (FlexStation III, Molecular Devices). Relative residual factor VIIa activity was calculated
from the ratio of thrombin activity in the presence and absence of inhibitor. The percent residual
activity was calculated using the equation 5.
% Residual Activity = [(slope of blank – slope of well with inhibitor)/slope of blank] x 100
A cut off of 40% was selected, and those compounds which showed a % residual activity lower
than 40% were selected for full inhibition profile.

Screening of library for Factor IXa inhibition ̶ Direct inhibition of factor IXa by the library of
sulfated benzofuran derivatives was measured through a one-point chromogenic substrate
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000, 0.02% Tween
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80 and 33% v/v ethylene glycol. Benzofuran derivatives (5 µL) at concentrations 20 mM were
diluted with 80 µL volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To
this solution was added 5 µL of factor IXa solution to give approximately 1780 nM initial factor
IXa concentration. After 10 min of incubation, 10 µL of 8.5 mM Spectrozyme factor IXa was
rapidly added and the residual factor IXa activity was measured from the initial rate of increase
in absorbance at 405 nm. The plate was read using a microplate reader (FlexStation III,
Molecular Devices). Relative residual factor IXa activity was calculated from the ratio of
thrombin activity in the presence and absence of inhibitor. The percent residual activity was
calculated using the equation 5.
Screening of library for Factor Xa inhibition ̶ Direct inhibition of Factor Xa by the library of
sulfated benzofuran derivatives was measured through a one-point chromogenic substrate
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000 and 0.02%
Tween 80. Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 185 µL
volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this solution was
added 5 µL of factor Xa solution to give approximately 43.5 nM initial factor Xa concentration.
After 10 min of incubation, 5 µL of 5 mM Spectrozyme factor Xa was rapidly added and the
residual factor Xa activity was measured from the initial rate of increase in absorbance at 405
nm. The plate was read using a microplate reader (FlexStation III, Molecular Devices). Relative
residual factor Xa activity was calculated from the ratio of thrombin activity in the presence and
absence of inhibitor. The percent residual activity was calculated using the equation 5.
Screening of library for Factor XIa inhibition ̶ Direct inhibition of factor XIa by the library of
sulfated benzofuran derivatives was measured through a one-point chromogenic substrate
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hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl, 0.1% polyethylene glycol (PEG) 8000 and 0.02% Tween 80.
Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 85 µL volume of assay
buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To this solution was added 5 µL of
factor XIa solution to give approximately 15.3 nM initial factor XIa concentration. After 10 min
of incubation, 5 µL of 6.6 mM Spectrozyme factor XIa was rapidly added and the residual factor
XIa activity was measured from the initial rate of increase in absorbance at 405 nm. The plate
was read using a microplate reader (FlexStation III, Molecular Devices). Relative residual factor
XIa activity was calculated from the ratio of thrombin activity in the presence and absence of
inhibitor. The percent residual activity was calculated using the equation 5.
Screening of library for Factor XIIa inhibition ̶ Direct inhibition of factor XIIa by the library
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4,
containing 100 mM NaCl, 0.1% polyethylene glycol (PEG) 8000 and 0.02% Tween 80.
Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 185 µL volume of
assay buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To this solution was added 5 µL
of factor XIIa solution to give approximately 200 nM initial factor XIIa concentration. After 10
min of incubation, 5 µL of 5 mM Spectrozyme factor XIIa was rapidly added and the residual
factor XIIa activity was measured from the initial rate of increase in absorbance at 405 nm. The
plate was read using a microplate reader (FlexStation III, Molecular Devices). Relative residual
factor XIIa activity was calculated from the ratio of thrombin activity in the presence and
absence of inhibitor. The percent residual activity was calculated using the equation 5.
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5.4.7 Inhibition of Factor VIIa
Direct inhibition of factor VIIa by the sulfated benzofuran trimer was measured through a
chromogenic substrate hydrolysis assay. The buffer used in these experiments was 20 mM TrisHCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG)
8000 and 0.02% Tween 80. Benzofuran derivatives (5 µL) at various concentrations were diluted
with 75 µL volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this
solution was added 10 µL of factor VIIa solution to give approximately 80 nM initial factor VIIa
concentration and 5 µL of tissue factor solution to give 800 nM. After 10 min of incubation, 5 µL
of 20 mM Spectrozyme factor VIIa was rapidly added and the residual factor VIIa activity was
measured from the initial rate of increase in absorbance at 405 nm. The plate was read using a
microplate reader (FlexStation III, Molecular Devices). Relative residual VIIa activity was
calculated from the ratio of thrombin activity in the presence and absence of inhibitor. Equation
6 was used to fit the dose-dependence of residual proteinase activity to obtain the IC50 and the
efficacy ∆Y (= YM – Y0) of inhibition.
 =  +

 
(     )×

Equation 6

In this equation, Y is the ratio of residual thrombin activity in the presence of inhibitor to
that in its absence (fractional residual activity), YM and YO are the maximum and minimum
possible values of the fractional residual proteinase activity, IC50 is the concentration of the
inhibitor that results in 50% inhibition of enzyme activity, and HS is the Hill Slope, which was
set constant at 1. A current version of SigmaPlot (SPSS, Inc. Chicago, IL) was used to perform
non-linear curve fitting in which YM, YO and IC50 were optimized.
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5. 4.8 Inhibition of Factor IXa
Direct inhibition of factor IXa by sulfated benzofuran trimer was measured through a
chromogenic substrate hydrolysis assay. The buffer used in these experiments was 20 mM TrisHCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG)
8000, 0.02% Tween 80 and 33% v/v ethylene glycol. Benzofuran derivatives (5 µL) at
concentrations 20 mM were diluted with 80 µL volume of assay buffer in flat bottom 96 wellplates (BD Falcon) at 25 °C. To this solution was added 5 µL of factor IXa solution to give
approximately 1780 nM initial factor IXa concentration. After 10 min of incubation, 10 µL of 8.5
mM Spectrozyme factor IXa was rapidly added and the residual factor IXa activity was
measured from the initial rate of increase in absorbance at 405 nm. The plate was read using a
microplate reader (FlexStation III, Molecular Devices). Relative residual factor IXa activity was
calculated as described in Experimental Section 5.4.7.

5.4.9 Inhibition of Factor Xa
Direct inhibition of factor Xa by sulfated benzofuran trimer was measured through a
chromogenic substrate hydrolysis assay. The buffer used in these experiments was 20 mM TrisHCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG)
8000 and 0.02% Tween 80. Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted
with 185 µL volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this
solution was added 5 µL of factor Xa solution to give approximately 43.5 nM initial factor Xa
concentration. After 10 min of incubation, 5 µL of 5 mM Spectrozyme Xa was rapidly added and
the residual factor Xa activity was measured from the initial rate of increase in absorbance at 405
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nm. The plate was read using a microplate reader (FlexStation III, Molecular Devices). Relative
residual factor Xa activity was calculated as described in Experimental Section 5.4.7.
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Chapter 6 Identification of Novel Allosteric Inhibitor by Exploring a Larger Chemical
Space

6.1 Introduction
High throughput screening (HTS) and virtual screening (VS) are two most widely used
techniques to discover new lead molecules.240 In the last few decades, there has been an
enormous growth in the availability of databases of molecules, which in turn has led to increased
screening costs and a reduction in hit rate making the HTS approach less appealing.241
Computational methods such as VS may offer a time saving and cost saving solution for this
problem.242 VS has been validated for performance in several studies for identifying hits.243 The
increasing requirement for improvement in the drug discovery process has sparked the path away
from traditional HTS to high speed and cost efficient VS methods.244 The main goal of VS is to
come up with novel chemical structures with unique pharmacological profiles. Hence, VS can be
called as rational alternative to traditional HTS.240
VS can be classified into two categories: structure-based and ligand-based methods.
Structure-based docking is used when the structure of the target is known. The success of this
method is compromised, however, by the inability of available scoring functions to identify the
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most appropriate binding mode.243 In addition, it is very time consuming and may not consider
the flexibility of the binding site.245 In contrast to structure-based methods, ligand-based methods
focus on specific key interactions responsible for protein-ligand binding to generate lead
candidates. The major disadvantage is its inability to consider the shape of the binding site.
Thus, both of these methods face major drawbacks in terms of predictability. In order to
overcome drawbacks associated with both methods, a combination approach may be used. 246
The aim of this study is to utilize a combination of both ligand-based and docking-based
VS approaches to identify new scaffolds in the design of potential allosteric inhibitors of
thrombin. Virtual screening was performed based on the pharmacophore query developed from
the SAR results of a library of sulfated benzofuran dimers (see Chapter 4). The hits generated
from VS were further validated by docking to a crystal structure of thrombin to identify
molecules having high predicted affinity and specificity for the binding site. Three molecules
selected from these VS and docking studies were purchased and tested for thrombin inhibition.

6.2 Results and Discussion
6.2.1 Pharmacophore Generation
A pharmacophore was generated based on the results obtained from SAR studies of
sulfated benzofuran dimers synthesized previously (Chapter 4),231 as shown in Figure 37. Based
on this SAR, it was found that the potency of sulfated monomers improved 1000-fold on addition
of one benzofuran unit. Thus, it can be concluded that at least two benzofuran (or aromatic) units
are necessary for higher potency. The average distances between these two aromatic regions
from their aromatic centroids were measured and found out to be 8.13 ± 0.5 Å. Additionally,
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there was a requirement that a hydrophobic group be present at the 3- position on each unit. The
average distance to these groups was measured to be 7.35±1 Å from the aromatic centroid. The
most stringent requirement was the presence of negative charge (sulfate group) at the first
aromatic unit. There are few molecules present in commercial libraries that contain negative
charge in the form of sulfate group. To make the search successful, the sulfate group was
replaced with a hydroxyl group, which can be later added both in silico and by synthesis to place
negative charge in the specified region. Based on these features, the query for virtual screening
was designed using the tools present in the UNITY search program.

6.2.2 Virtual Screening
The virtual search was performed on the ZINC database (Shoichet Laboratory, UCSF,
CA) containing around 1 million compounds. It was performed using the UNITY search tool
present in SYBYL 8.1. To narrow down the drug like molecules, Lipinski’s rule of five was
applied. The following constraints for Lipinski’s rule were applied; Maximum weight – 500,
maximum donor – 5, maximum acceptor – 10, maximum LogP – 4.15. One deviation from the
rule was allowed. The minimum gradient for tweak was set to 0.001. In order to get maximum
hits, rings were made flexible and no limit was placed on rotatable bonds. Using the 3D
pharmacophore query, a flexible 3D search was performed on the entire ZINC database. Based
on similarity in topological and electronic features, 4560 hits were obtained. These hits were preprocessed to add sulfate group using a script that identifies the free phenolic group and performs
an in silico sulfation. The modified database was used for molecular docking studies.
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A

B
Figure 37. A) Represent atom of the common scaffold for the library of sulfated benzofuran
dimers. B) 3D pharmacophore query used for virtual screening of ZINC database to identify the
new scaffold with similar electronic and topological features. The query defines the important
regions required for defining the activity of inhibitors like aromatic units, hydrophobic centers
and the presence of an electron donating center.

6.2.3 Docking Studies
The docking studies were performed using a two-step method with the GOLD docking
suite, shown in Figure 38. The aim of the first step is to narrow down the large library of hits
obtained from virtual screening by identifying the structures having high affinity for thrombin. In
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this step, an initial single docking experiment was performed with the crystal structure of
thrombin (PDB: 3EQO). The GA run was set to “10” and early termination was set “ON” to save
the CPU time. The molecules were selected based on the GOLDScore. 138 structures were
considered as high affinity based on GOLDScore (> 70). In the second step, docking studies
were performed in triplicate to identify the structures which bind consistently in the same
binding pose over three independent runs. The purpose of three independent runs was to gain
confidence in binding geometry and to identify correct binding poses. In three independent runs,
GA was set to “30” and early terminal was set “OFF” to identify the best binding pose. The
binding poses from three runs were superimposed to calculate the root mean square deviation
(RMSD). The structures having RMSD < 2 were selected. Ten molecules were identified which
met the requirement of both filters. These molecules have high GOLDScore, which correspond
to high affinity for the binding site and consistent binding geometry over three independent runs.
Based on this two-step docking study and commercial availability, three molecules were
purchased. The molecules V1, V2 and V3 was purchased from Spec (RI, USA), ChemBridge
Corporation (CA, USA) and ChemDiv (CA, USA), respectively.
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Figure 38. Graphical representation of docking protocol using the two-step approach to identify
new hits. Figure explains the two filters and cutoff limit to pass both filters. The figure is adapted
from Raghuraman et al. (2006) J. Med. Chem. 49, 3553-3562.

6.2.4 Chemistry
To meet the requirement of pharmacophore query, sulfate groups need to be added. In the
final step, the sulfate group was added on the three purchased compound using the microwavebased sulfation method developed in our laboratory.222 To the solution of unsulfated compound
(typically 50 mg) in acetonitrile: DMF (4:1, 0.45 mL) in a microwave tube were added
triethylamine (10 equiv) and trimethylamine-sulfur trioxide complex (15 equiv). The reaction
mixture was exposed to microwaves (50 W) for 40 min at 100 °C followed by vacuum
concentration to remove all solvent. The solid so obtained was directly loaded on a Sephadex C25 cation exchange resin and eluted with water. Fractions containing the sulfated product were
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lyophilized to obtain a solid residue, which was further purified on reverse-phase gradient HPLC
to remove residual unsulfated contaminants. The final molecules are obtained in good yield (see
Appendix, Page 352-354 for NMR spectra).
V1: 1H NMR (CDCl3, 400 MHz) δ 4.25 (s, 2H), 4.66 (s, 2H), 6.40 (d, J= 8.4 Hz, 1H), 6.64 (d, J=
8.4 Hz, 2H), 6.85 (d, J=8.4 Hz, 1H), 6.90 (m, 2H), 6.95 (m, 4H), 7.04 (m, 2H).
V1S:1HNMR (D2O, 400 MHz) δ 4.78 (s, 2H), 5.15 (s, 2H), 7.18 (d, J=8.8 Hz, 2H), 7.35 (m, 4H),
7.40 (m, 1H), 7.47 (m, 1H), 7.66 (m, 2H), 7.92 (s, 1H).
V2: 1H NMR (CDCl3, 400 MHz) δ 6.18 (m, 4H), 6.96 (m, 6H), 7.46 (m, 3H), 7.92 (m, 1H), 8.08
(s, 1H), 9.32 (s, 1H), 9.66 (s, 1H).
V2S: 1H NMR (D2O, 400 MHz) δ 7.23 (m, 4H), 7.48 (m, 4H), 7.51 (m, 2H), 7.72 (s, 1H), 7.79
(m, 1H), 7.82 (d, J=8 Hz, 1H), 8.05 (s, 1H), 8.16 (m, 1H).
V3: 1H NMR (DMSO-d6, 400 MHz) δ 2.27 (s, 3H), 3.77 (d, J=15 Hz, 1H), 4.93 (d, J=15 Hz,
1H), 5.31 (s, 1H), 6.62 (t, J=2 Hz, 1H), 6.69 (m, 1H), 6.74 (m, 1H), 7.05 (m, 2H), 7.13 (m, 3H),
7.55 (m, 1H), 7.88 (m, 2H), 8.03 (m, 1H).
V3S: 1H NMR (DMSO, 400 MHz) δ 2.18 (s, 3H), 3.84 (d, J=15 Hz, 1H), 4.84 (d, J=15 Hz, 1H),
5.35 (s, 1H), 6.97 (m, 4H), 7.05 (m, 2H), 7.18 (m, 1H), 7.29 (m, 1H), 7.49 (m, 1H), 7.76 (m,
1H), 7.82 (m, 1H), 7.97 (m, 1H).
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Figure 39. Structures of a library of sulfat
sulfated
ed compounds as potential allosteric regulators of
thrombin.These molecules were purchased from Spec, Chembridge and ChemDiv and then
sulfated.). Sulfation protocol is described in chemistry section.

6.2.5 Inhibition of Thrombin by Sulfated Molecules
Inhibition of thrombin by the inhibitors was measured through Spectrozyme TH
hydrolysis assay. The assay is based on the principle that the initial rate of substrate hydrolysis
decreases in the presence of the inhibitor quantitatively.. The fractional decrease in initial rate of
hydrolysis shows a sigmoidal profile on a semi
semi-log
log plot, which is fitted by a dose – response
equation 5 (Experimental Section 6.4.5) to derive IC50, HS, Y0 and YM parameters for each
potential inhibitor. The semi-log
log inhibition curves observed for inhibitors are shown in Figure
40. Three inhibitors studied in this work showed reasonable inhibition of human α-thrombin at
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pH 7.4 and 25 °C. The inhibitors V1S, V2S, and V3S exhibited IC50 65.9 µM, 192.9 µM and
285.6 µM (see Table 20 and Figure 40). The potency for thrombin inhibition for these molecules
is comparable to library of sulfated benzofuran dimers. Thus, these molecules can serve as
additional lead structures for designing allosteric inhibitors of thrombin.

Table 20. Inhibition of Human α-Thrombin by Sulfated molecules

V1S
V2S
V3S

log IC50 (M)

IC50 (µM)

∆Y

-4.18±0.16
-3.71±0.12
-3.54±0.18

65.9±1.1
192±11
285.6±1.1

0.614
0.425
0.890

Thrombin inhibition was measured in spectrophotometric assay through initial rate of
Spectrozyme TH hydrolysis as described in Experimental section. Standard error shown is ±1
S.E.
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Figure 40. Direct inhibition of thrombin by designed V1S, V2S and V3S.. The inhibition of
human thrombin was determined spectrophotometrically through a Spectrozyme TH hydrolysis
assay at pH 7.4 and 25 °C. Solid lines represent sigmoidal fits to the data to obtain IC50, YM, and
YO.

6.2.6 Prolongation of Plasma Clotting Time by Sulfated Compounds
Two types of plasma clotting assays are performed to evaluate the anticoagulant potency
in plasma for new coagulation inhibitors. Prothrombin (PT) and activated partial thromboplastin
time (APTT) assays are used to measure the effect of an inhibitor on the extrinsic and intrinsic
flux of coagulation, respectively. The concentrations of the inhibitors required to double the PT
and APTT were measured and reported, shown in Table 21. A 2-fold increasee in PT required 606
µM concentrations of 1S. In a similar manner, the doubling of APTT required 550 µM of V1S.
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These results suggest that the sulfated compound V1S is significantly potent in human plasma
and hence proves our design and model for allosteric inhibition of thrombin.
To further evaluate the effect of various factors in anticoagulation mechanism by
inhibitor 1S in plasma, we performed plasma studies on various factor deficient human plasma.
The APTT test was performed on factor IX and XI deficient human plasma; it was found that the
concentration required to double the APTT time were 380 µM and 368 µM, respectively (see
Table 21, Figure 41). These results suggest that there was no significant change in APTT time
than normal human plasma; hence factors IX and XI do not play a role in the anticoagulation
effect of these inhibitors. Similarly, the PT test was performed on factor VII deficient plasma
giving 2*PT of 779.24 µM (see Table 21), which is significantly different from the value
obtained in normal human plasma. Thus, we can conclude that our designed inhibitor V1S is
interacting with factor VII in human plasma to show an anticoagulant effect. Overall, the plasma
studies suggest the feasibility of designing small molecules that will function as anticoagulants in
vivo.

Table 21. Effect of Designed Sulfated Benzofurans on Human Plasma Clotting Time.a
Plasma

2*PT (µM)

2*APTT (µM)

Human Plasma

606.8

550

FIX Deficient Plasma

ndb

368.83

FXI Deficient Plasma

ndb

380

FVII Deficient Plasma

779.24

ndb

a

PT and APTT values were deduced in in vitro human plasma experiments where the clot
initiator is either thromboplastin or ellagic acid, respectively. b not determined.
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Figure 41. Prolongation of clotting time as a function of concentration of V1S in either activated
partial thromboplastin time assay (A) or prothrombin time assay (B). Solid lines are trend lines,
and not non-linear regressional fits.
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6.2.7 Screening against Other Serine Proteases
The library of sulfated molecules obtained from virtual screening were screened against
the panel of coagulation proteases including factors VIIa, IXa, Xa, XIa and XIIa, which are
either involved in the intrinsic or extrinsic pathways. The assay is based on hydrolysis of a
chromogenic substrate by the protease, the rate of which is decreased in the presence of inhibitor.
Screening was performed at a single concentration of inhibitors using a substrate hydrolysis
assay in 96 well-plates. This assay is based on the decrease in the initial rate of substrate
hydrolysis in the presence of inhibitor. The decrease in initial rate of hydrolysis typically
provides the fractional residual activity of enzyme.
Table 22 shows the percentage residual activity of all proteases at the final concentration
of 365 µM of each inhibitor. None of these molecules inhibited the factors VIIa, IXa, Xa and XII
by more than 20% at the concentration of 365 µM (see Figure 42). In screening against factor
XIa, molecules V1S and V2S completely inhibited factor XIa activity. These results were
consistent with library of sulfated benzofuran dimers from which they are derived. Similar to
dimers, these molecules showed selectivity against factors VIIa, IXa and XIIa and completely
inhibited factor XIa. Thus, this selectivity filter further validates the computational model for
designing the allosteric inhibitor of thrombin.
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Table 22. Residual enzyme activity for various proteases at 365 µM inhibitor concentration
Factor VIIa

Factor IXa

Factor Xa

Factor XIa

Factor XII

V1S

98±3

91±2

86±3

7±4

100±5

V2S

100±2.5

101±5

91±4

6±8

96±3

V3S

102±4

107±4

97±7

76±4

97±7

120
100
80

1S

60

2S

40

3S

20
0
FVIIa

FIXa

FXa

FXIa

FXII

Figure 42. Bar graph for residual activity for screening against various proteases

6.3 Discussion
Computational structure--based design provides an excellent tool set to identify the most
appropriate ‘small’ molecule structure from a large number of potential molecules.
les. The thrombin
inhibition potency and efficacy discovered for three sulfated molecules designed using
computational tools suggest that these scaffolds may serve as leads in developing new allosteric
inhibitors of thrombin. The moderate potency displayed by these inhibitors validates the
computational
omputational model design; we employed to identify inhibitors that modulate the thrombin
activity by an allosteric mechanism.
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This work presents the combination of ligand-based and docking-based approachs to
identify and design small synthetic sulfated aromatic structures as novel allosteric modulators of
thrombin function. The allosteric inhibitors of thrombin are advantageous in terms of their
controlled inhibition of protease and the ability to reverse excess inhibition. The success of our
computational model for allosteric inhibition of thrombin give us confidence to extend it toward
for developing allosteric inhibitors for other proteases such as factors VIIa, Xa, IXa and XIa.

6.4 Experimental Section
6.4.1 Protein preparation
The docking studies required an accurate 3D structure of thrombin with high resolution.
The crystal structure of thrombin bound to its allosteric exosite I ligand hirugen with resolution
of 1.53 Å was obtained from the protein data bank (ID: 3EQ0). All the heavy atoms in the region
of Arg173 were resolved. The inorganic salts and water molecules were deleted. Hydrogen
atoms were added to the protein using the “Add Hydrogen” function of Sybyl 8.1. The protein
was minimized to adjust the hydrogen position using the minimizing tool in Sybyl 8.1, by using
the Tripos force field to reach the terminating gradient of 0.05 kcal/mol/Å or a maximum of
100000 iterations. The Gasteiger-Huckel type charge was assigned to each atom. The thrombin
binding site was defined to include all the amino acid residues in a radius of 22 Å around the Cα
carbon of Arg173.
6.4.2 Chemical database for virtual screening
A virtual screening of the commercially available database “ZINC” using our pharmacophore
was carried out. The ZINC database contains the structural information of approximately 1
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million molecules. These molecules are supplied by various companies such as Key Organics,
Maybridge, Chemdiv, Otava, Life Chemicals, Specs, Asinex, etc. The compound collection was
obtained as Structure-Data files and stored. The virtual screening was performed using “Unity
Search” available in Sybyl 8.1. The flexible 3D search option was used for screening the
database against the pharmacophore query (Figure 37). To reduce the number of hits obtained
from the search, constraints such as Lipinski rules, were applied.
6.4.3 Docking Protocol
Docking of the potential hits obtained from virtual screening onto the defined binding
site of the thrombin was performed with GOLD 4.1 (Cambridge Crystallographic Data Center,
UK). The binding site is comprised of Arg173 and all the amino acid residues within a radius of
22 Å around it. GOLD is a “soft docking” method that implicitly handles local protein flexibility
by allowing a small degree of interpenetration, or van der Waals overlap, of ligand and protein
atoms. GOLD optimizes the orientation of hydrogen-bond donating atoms on the residues such
as Ser, Thr, Tyr, Lys and Arg as part of the docking process. Except for the automated number of
iterations, the allowed amide bond flip and the prohibited early termination, default parameters
were employed during the GOLD docking runs. Docking was driven by the GOLD scoring
function and molecules were ranked based on the GOLDScore obtained. The protein hydrogen
binding constraints were added for five hydrogen atoms of the guanidine group of Arg173 and
penalty of 10 GOLD score units were assigned.
Docking of the synthesized inhibitors onto the defined binding site of the thrombin were
also performed with GOLD 4.1. Default parameters were employed with the following
exceptions: A protein hydrogen bonding constraint was added such that the score was reduced by
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10.0 GoldScore units if the ligand did not form an H-bond with the guanidinium group of
Arg173. Again, amide bonds were allowed to flip. The number of GA runs was increased to 30
to more accurately screen all possible binding geometries, and early termination was disabled.
The docking was driven by the GOLDScore fitness function and the docked solutions were
ranked based on the unmodified GOLDScore obtained. To assess the reproducibility of the
docked poses, the docking runs were performed in triplicate.

6.4.4 Chemicals, Reagents and Analytical Chemistry
Reagents, chemicals and solvents were purchased either from Sigma-Aldrich
(Milwaukee, WI) or Fisher (Pittsburgh, PA) and were used as received. Reagent solutions and
chemicals were handled under inert nitrogen atmosphere using syringe techniques for liquid and
dried spatula for solids. All glassware was dried in the oven overnight before use. Sodium
exchange chromatography was performed using SP Sephadex C-25 cation exchange resin from
GE Healthcare Life Sciences (Piscataway, NJ). Approximately 100 mg sulfated sample was
loaded onto 10 g of the cation exchanger in a 10 × 460 mm column and eluted with either water
at 0.5 mL/min. Microwave-based sulfation and coupling reactions were performed using a CEMDiscover synthesizer (Matthews, NC) in sealed reaction vessels (7 mL) at 50 W. The temperature
of the reaction was maintained at the desired setting using cooled nitrogen (45 psi) flow.
1

H and

13

C NMR spectra were recorded at either 300 or 400 MHz (Varian Mercury or

Bruker UltrashieldTM Plus) in appropriate deuterated solvents including CDCl3, DMSO-d6, or
D2O. All signals are reported in ppm with the internal chloroform, DMSO, and D2O signals at
7.26, 2.50, 2.05, and 4.79, respectively, as standards. The data is reported as chemical shifts
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(ppm) and splitting pattern is described as (s = singlet, d = doublet, t = triplet, m = multiplet)
with coupling constant(s) (Hz), and integration. Mass spectrometry was performed on all
synthesized molecules using a Micromass ZMD4000 single quadrupole mass spectrometer with
ESI ionization probe operating in negative ion mode (Waters Corp., Milford, MA). The samples,
dissolved in acetonitrile containing formic acid (5% v/v), were infused at 10 µL/min. The source
block temperature and the probe temperature were typically held at 100 and 120 °C, respectively,
while corona and cone voltages were selected through manual optimization. The desolvation
nitrogen flow was 500 L/hour. Mass spectra were acquired in the mass range from 110 to 1000
Daltons at 400 amu/sec. The chromogenic substrate Spectrozyme TH (H-D-hexahydrotyrosolAla-Arg-p-nitroanilide) was purchased from American Diagnostica (Greenwich, CT).
Unfractionated porcine heparin was purchased from Sigma (St. Louis, MO). All other chemicals
were analytical reagent grade from either Sigma Chemicals (St. Louis, MO) or Fisher
(Pittsburgh, PA) and used as such.

6.4.5 Substrate hydrolysis assay
Thrombin activity in the presence of inhibitors was studied using chromogenic substrate
hydrolysis assay in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2
and 0.1% polyethylene glycol (PEG) 8000 in PEG 20,000-coated acrylic cuvettes. Spectrozyme
TH was used as substrate and the residual thrombin activity was quantified by measuring the
initial rate of hydrolysis from the linear increase in absorbance at 405 nm as a function of time.
Briefly, a solution of 10 µL of the inhibitors to form final concentrations ranging from 4.5 – 900
µM, was diluted with 970 µL of buffer and 5 µL of 1µM thrombin (5 nM) and incubated. This
was followed by addition of 15 µL of 2 mM Spectrozyme TH (30 µM) and the initial rate was
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rapidly measured. Equation 6 was used to fit the dose dependence of residual thrombin activity
to obtain IC50.
 =  +

 
(     )×

Equation 6

In this equation Y is the ratio of residual thrombin activity in the presence of the inhibitor
to that in its absence; YM and Y0 are the maximum and minimum possible values of the
fractional residual thrombin activity, respectively; and IC50 is the concentration of inhibitors that
results in 50% inhibition of enzyme activity. Sigmaplot 8.0 (SPSS, Inc. Chicago, IL) was used to
perform non-linear curve fitting in which YM, YO, and IC50 were optimized.
6.4.6 Plasma studies (Prothrombin Time and Activated Partial Thromboplastin Time)
For both PT and APTT assays, standard 1-stage recalcification assay with a BBL
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD) was used to measure the clotting time.
For the APTT assay, 90 µL citrated human plasma, 10 µL inhibitor (or vehicle for blank test),
and 100 µL of pre-warmed APTT reagent (0.2% ellagic acid) were mixed and incubated for 4
minutes. The clotting was initiated by adding 100 µL of 25 mM CaCl2 (37 °C) and the time to
clot was recorded. For prothrombin (PT) assays, 10 µL sample of the inhibitor (or vehicle for
blank test) and 90 µL of citrated human plasma were mixed and incubated for 30 second at 37 °C
followed by addition of 200 µL pre-warmed thromboplastin (reconstituted as per directions
provided by manufacturer). Each clotting assay was performed in duplicate. The data were fit to
a quadratic trend line, which was used to determine the concentration of the inhibitor necessary
to double the clotting time, 2×APTT or 2×PT.
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Chapter 7 Conclusion
Designing allosteric inhibitors offers the opportunity to regulate thrombin for maintaining
balance between its procoagulant and anticoagulant activities. Thus, allosteric inhibitors could
help in overcoming the side effects such as enhanced risk of excessive bleeding and in
eliminating the need for regular laboratory monitoring.

To design novel anticoagulants as

allosteric inhibitors of thrombin based on the β-5 linkage of LMWLs, benzofuran-based sulfated
monomers and oligomers were designed.
A diversified library of monomers and dimers was synthesized and found to exhibit
moderately potent inhibition of thrombin. From this library, 12c was found to be the most potent
allosteric inhibitor designed so far. Interesting structure-activity relationships were observed.
Sulfated dimers were found to be 1000-fold more potent than sulfated monomers. A strict
requirement of a key sulfate group was found, as un-sulfated precursors were found to be
inactive. However, increasing the number of anionic groups was found to be deleterious for
potency. The presence of hydrophobic groups at 3- and 3′-positions improved potency, but
substitution with hydrophilic and bulky groups at these positions led to a decrease in potency.
Similarly, the presence of bulky and hydrophobic groups at 6 and 6′ positions improved the
inhibition potency.
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Michaelis-Menten kinetics study suggested a non-competitive, allosteric mode of
inhibition by these inhibitors. Screening of sulfated monomers and dimers against the panel of
coagulation factors such as factors VIIa, IXa, Xa, XIa and XIIa suggested high selectivity for
thrombin. However, a few dimers were able to inhibit factor XIa also. The in vitro anticoagulant
potency of these inhibitors was translated into higher system, such as human plasma. Based on
competitive and mutagenesis studies, it was found that Arg173 residue played a crucial role in
recognition of these inhibitors. A plausible binding mode was identified using molecular docking
and scoring approaches. The proposed binding mode was able to explain majority of the SAR
findings and GOLDScore correlated well with the experimental IC50 value. Thus, the proposed
binding model offers an excellent opportunity to design new inhibitors with improved inhibition
potency.
In a quest to improve the thrombin inhibition potency, a small library of sulfated
benzofuran trimers and tetramer was synthesized. It was found that extension of oligomeric chain
to trimer improved the potency nearly 10-fold. However, increasing the chain length further to
tetramer was detrimental for potency. This observation suggests that trimer is an optimal
oligomeric chain length for potency. The allosteric mode of inhibition was also retained in higher
oligomers. However, competitive studies suggest that sulfated trimers recognized a site different
from sulfated dimers. The range of thrombin inhibition potency and efficacy discovered for
sulfated benzofurans monomers and higher oligomers suggest that the designed sulfated
benzofuran scaffold may be an excellent lead in developing anticoagulants radically different
from those studied to-date.
Finally, a pharmacophore query was designed based on the SAR results obtained from
the library of sulfated dimers to virtually screen a larger chemical space. The combination of
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both ligand-based and docking-based approach was used to identify new scaffolds as potential
leads for allosteric inhibitors of thrombin. Three molecules were selected to purchase and
sulfated to match the query. It was found that all three sulfated molecules were moderate
inhibitors of thrombin with potency similar to that of the sulfated dimers. The anticoagulant
potency of these new inhibitors translated well into human plasma. Thus, we identified three new
scaffolds, which can serve as starting point to design the new inhibitors for thrombin. Overall,
this work highlights the opportunity of exploring allosteric modulators of thrombin and other
coagulation enzymes, e.g., factors Xa, IXa and XIa, through sulfated lignin scaffolds.
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